CN111741959B - Btk的抑制剂及其突变体 - Google Patents
Btk的抑制剂及其突变体 Download PDFInfo
- Publication number
- CN111741959B CN111741959B CN201980013997.5A CN201980013997A CN111741959B CN 111741959 B CN111741959 B CN 111741959B CN 201980013997 A CN201980013997 A CN 201980013997A CN 111741959 B CN111741959 B CN 111741959B
- Authority
- CN
- China
- Prior art keywords
- methyl
- oxo
- amino
- phenyl
- dihydropyrazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title description 9
- 150000001875 compounds Chemical class 0.000 claims abstract description 154
- 238000000034 method Methods 0.000 claims abstract description 39
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims abstract description 9
- 208000037129 Newborn Diseases Infant Diseases 0.000 claims abstract description 6
- -1 nitro, hydroxy Chemical group 0.000 claims description 332
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 109
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 106
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 54
- 150000003839 salts Chemical class 0.000 claims description 48
- 125000000217 alkyl group Chemical group 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 22
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 229910052805 deuterium Inorganic materials 0.000 claims description 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 238000006467 substitution reaction Methods 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 208000020241 Neonatal disease Diseases 0.000 claims description 6
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims description 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 3
- 125000005865 C2-C10alkynyl group Chemical group 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 230000007815 allergy Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000001613 neoplastic effect Effects 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 239000000243 solution Substances 0.000 description 171
- 239000000203 mixture Substances 0.000 description 126
- 239000007787 solid Substances 0.000 description 114
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 94
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 61
- 230000015572 biosynthetic process Effects 0.000 description 57
- 238000003786 synthesis reaction Methods 0.000 description 56
- 125000003277 amino group Chemical group 0.000 description 54
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 53
- 229910052757 nitrogen Inorganic materials 0.000 description 53
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 49
- 239000003921 oil Substances 0.000 description 45
- 239000012298 atmosphere Substances 0.000 description 43
- 239000012043 crude product Substances 0.000 description 36
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 31
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 26
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 26
- 238000002953 preparative HPLC Methods 0.000 description 25
- 239000000741 silica gel Substances 0.000 description 25
- 229910002027 silica gel Inorganic materials 0.000 description 25
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 description 24
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 description 24
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 238000003556 assay Methods 0.000 description 22
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 22
- 125000003118 aryl group Chemical group 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 21
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000003208 petroleum Substances 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 18
- 102200162764 rs1057519825 Human genes 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 125000004432 carbon atom Chemical group C* 0.000 description 16
- 239000000460 chlorine Substances 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 125000001072 heteroaryl group Chemical group 0.000 description 16
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 15
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 15
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- LNVJQIHAUHVGEV-UHFFFAOYSA-N 3,5-dibromo-1-methylpyrazin-2-one Chemical compound CN1C=C(Br)N=C(Br)C1=O LNVJQIHAUHVGEV-UHFFFAOYSA-N 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- 239000002253 acid Substances 0.000 description 14
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 13
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 13
- 229910000027 potassium carbonate Inorganic materials 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 238000005160 1H NMR spectroscopy Methods 0.000 description 12
- 239000007821 HATU Substances 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 12
- 125000000392 cycloalkenyl group Chemical group 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229940002612 prodrug Drugs 0.000 description 11
- 239000000651 prodrug Substances 0.000 description 11
- 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 11
- 229940124291 BTK inhibitor Drugs 0.000 description 10
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 10
- 125000003342 alkenyl group Chemical group 0.000 description 10
- 125000000304 alkynyl group Chemical group 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000000543 intermediate Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 9
- 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 9
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 230000005764 inhibitory process Effects 0.000 description 9
- 230000002427 irreversible effect Effects 0.000 description 9
- 102200006131 rs34288963 Human genes 0.000 description 9
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 8
- 206010003246 arthritis Diseases 0.000 description 8
- 239000012267 brine Substances 0.000 description 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 8
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 8
- 239000003446 ligand Substances 0.000 description 8
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 238000001959 radiotherapy Methods 0.000 description 8
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 8
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 8
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 238000009739 binding Methods 0.000 description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 7
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 6
- 229920001213 Polysorbate 20 Polymers 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 229940121363 anti-inflammatory agent Drugs 0.000 description 6
- 239000002260 anti-inflammatory agent Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 6
- 239000010452 phosphate Substances 0.000 description 6
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 5
- 206010047115 Vasculitis Diseases 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 5
- 229960001924 melphalan Drugs 0.000 description 5
- 150000007530 organic bases Chemical class 0.000 description 5
- 238000006053 organic reaction Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- CHCCBPDEADMNCI-UHFFFAOYSA-N 3-Methyl-2-cyclopenten-1-one Chemical compound CC1=CC(=O)CC1 CHCCBPDEADMNCI-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 4
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 4
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 4
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 4
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 101150038994 PDGFRA gene Proteins 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- 102100033200 Rho guanine nucleotide exchange factor 7 Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- HFBMWMNUJJDEQZ-UHFFFAOYSA-N acryloyl chloride Chemical compound ClC(=O)C=C HFBMWMNUJJDEQZ-UHFFFAOYSA-N 0.000 description 4
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
- 125000002252 acyl group Chemical group 0.000 description 4
- 230000001363 autoimmune Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 4
- 229960002707 bendamustine Drugs 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- YWGOANMMHJDXMA-UHFFFAOYSA-N benzyl N-(4-fluoro-3-nitrophenyl)carbamate Chemical compound FC1=C(C=C(C=C1)NC(OCC1=CC=CC=C1)=O)[N+](=O)[O-] YWGOANMMHJDXMA-UHFFFAOYSA-N 0.000 description 4
- 238000004820 blood count Methods 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 229960004667 ethyl cellulose Drugs 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 150000002430 hydrocarbons Chemical class 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 150000007524 organic acids Chemical class 0.000 description 4
- 125000004043 oxo group Chemical group O=* 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical class [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229940083542 sodium Drugs 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000012453 solvate Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- HUTNOYOBQPAKIA-UHFFFAOYSA-N 1h-pyrazin-2-one Chemical compound OC1=CN=CC=N1 HUTNOYOBQPAKIA-UHFFFAOYSA-N 0.000 description 3
- OAHDTPWZWVNOGM-UHFFFAOYSA-N 2,4-dibromo-3-methylpyridine Chemical compound CC1=C(Br)C=CN=C1Br OAHDTPWZWVNOGM-UHFFFAOYSA-N 0.000 description 3
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 3
- XIUNFLQSJSCQRM-UHFFFAOYSA-N 7,7-dimethyl-2,3,6,8-tetrahydro-1h-cyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C1=C2C(=O)NCCN2C2=C1CC(C)(C)C2 XIUNFLQSJSCQRM-UHFFFAOYSA-N 0.000 description 3
- 108010006654 Bleomycin Proteins 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 3
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 3
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 3
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 3
- 229920002907 Guar gum Polymers 0.000 description 3
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 3
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 3
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
- 101000628647 Homo sapiens Serine/threonine-protein kinase 24 Proteins 0.000 description 3
- 101000864831 Homo sapiens Serine/threonine-protein kinase Sgk3 Proteins 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 150000001204 N-oxides Chemical class 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
- 206010039710 Scleroderma Diseases 0.000 description 3
- 102100026764 Serine/threonine-protein kinase 24 Human genes 0.000 description 3
- 102100026621 Serine/threonine-protein kinase ICK Human genes 0.000 description 3
- 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 3
- 102100030071 Serine/threonine-protein kinase Sgk3 Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010052779 Transplant rejections Diseases 0.000 description 3
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 229960000548 alemtuzumab Drugs 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000005441 aurora Substances 0.000 description 3
- 229940050390 benzoate Drugs 0.000 description 3
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229960001561 bleomycin Drugs 0.000 description 3
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 229940001468 citrate Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229940050411 fumarate Drugs 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 239000000665 guar gum Substances 0.000 description 3
- 235000010417 guar gum Nutrition 0.000 description 3
- 229960002154 guar gum Drugs 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 3
- 229960003444 immunosuppressant agent Drugs 0.000 description 3
- 239000003018 immunosuppressive agent Substances 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 229960004768 irinotecan Drugs 0.000 description 3
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229960000681 leflunomide Drugs 0.000 description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 3
- 229960004961 mechlorethamine Drugs 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- VGURYVWLCVIMTF-UHFFFAOYSA-N methyl 2-amino-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C=C1N VGURYVWLCVIMTF-UHFFFAOYSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 3
- 229960000801 nelarabine Drugs 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229960003171 plicamycin Drugs 0.000 description 3
- 229920001983 poloxamer Polymers 0.000 description 3
- 229920001993 poloxamer 188 Polymers 0.000 description 3
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 3
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 3
- 229960001860 salicylate Drugs 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 229940095064 tartrate Drugs 0.000 description 3
- 229960001278 teniposide Drugs 0.000 description 3
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- NEWIRJGYIPVUMB-UHFFFAOYSA-N 2-chloro-4,4-dimethylcyclopentene-1-carbaldehyde Chemical compound CC1(C)CC(Cl)=C(C=O)C1 NEWIRJGYIPVUMB-UHFFFAOYSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- ROADCYAOHVSOLQ-UHFFFAOYSA-N 3-oxetanone Chemical compound O=C1COC1 ROADCYAOHVSOLQ-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 2
- GAKCRSSYQHBQAV-UHFFFAOYSA-N 4-(2-methylpiperidin-4-yl)morpholine Chemical compound CC1CC(CCN1)N1CCOCC1 GAKCRSSYQHBQAV-UHFFFAOYSA-N 0.000 description 2
- MRKLOFJXWXDNEO-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-3-nitroaniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1[N+]([O-])=O MRKLOFJXWXDNEO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- PITHQPMZWKZGRZ-UHFFFAOYSA-N 4-bromo-3-nitroaniline Chemical compound NC1=CC=C(Br)C([N+]([O-])=O)=C1 PITHQPMZWKZGRZ-UHFFFAOYSA-N 0.000 description 2
- LLIOADBCFIXIEU-UHFFFAOYSA-N 4-fluoro-3-nitroaniline Chemical compound NC1=CC=C(F)C([N+]([O-])=O)=C1 LLIOADBCFIXIEU-UHFFFAOYSA-N 0.000 description 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- VKNQVUXGCZBYTK-UHFFFAOYSA-N 5-(4-methylpiperazin-1-yl)benzene-1,3-diamine Chemical compound CN1CCN(CC1)C=1C=C(C=C(C=1)N)N VKNQVUXGCZBYTK-UHFFFAOYSA-N 0.000 description 2
- WPHGFMGCYHOMIG-UHFFFAOYSA-N 5-[(4-methylpiperazin-1-yl)methyl]benzene-1,3-diamine Chemical compound CN1CCN(CC1)CC=1C=C(C=C(C=1)N)N WPHGFMGCYHOMIG-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 description 2
- 102100034111 Activin receptor type-1 Human genes 0.000 description 2
- 102100034134 Activin receptor type-1B Human genes 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 208000026872 Addison Disease Diseases 0.000 description 2
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 102000015790 Asparaginase Human genes 0.000 description 2
- 108010024976 Asparaginase Proteins 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- VZVWDODSTJQOSC-UHFFFAOYSA-N BrC1=CN(C(C(=N1)NC1=CC(=C(C=C1)C1CN(CCC1)C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)=O)C Chemical compound BrC1=CN(C(C(=N1)NC1=CC(=C(C=C1)C1CN(CCC1)C(=O)OC(C)(C)C)NC(=O)OC(C)(C)C)=O)C VZVWDODSTJQOSC-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
- 102100022789 Calcium/calmodulin-dependent protein kinase type IV Human genes 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 108010092160 Dactinomycin Proteins 0.000 description 2
- 102100038587 Death-associated protein kinase 1 Human genes 0.000 description 2
- 102100038606 Death-associated protein kinase 3 Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 2
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000024869 Goodpasture syndrome Diseases 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000003893 Histone acetyltransferases Human genes 0.000 description 2
- 108090000246 Histone acetyltransferases Proteins 0.000 description 2
- 102000003964 Histone deacetylase Human genes 0.000 description 2
- 108090000353 Histone deacetylase Proteins 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 description 2
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 description 2
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 description 2
- 101100287682 Homo sapiens CAMK2G gene Proteins 0.000 description 2
- 101100126883 Homo sapiens CAMK4 gene Proteins 0.000 description 2
- 101000956145 Homo sapiens Death-associated protein kinase 1 Proteins 0.000 description 2
- 101000956149 Homo sapiens Death-associated protein kinase 3 Proteins 0.000 description 2
- 101000926535 Homo sapiens Interferon-induced, double-stranded RNA-activated protein kinase Proteins 0.000 description 2
- 101000762967 Homo sapiens Lymphokine-activated killer T-cell-originated protein kinase Proteins 0.000 description 2
- 101001106413 Homo sapiens Macrophage-stimulating protein receptor Proteins 0.000 description 2
- 101001059535 Homo sapiens Megakaryocyte-associated tyrosine-protein kinase Proteins 0.000 description 2
- 101000573441 Homo sapiens Misshapen-like kinase 1 Proteins 0.000 description 2
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 2
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 description 2
- 101001018196 Homo sapiens Mitogen-activated protein kinase kinase kinase 5 Proteins 0.000 description 2
- 101001055085 Homo sapiens Mitogen-activated protein kinase kinase kinase 9 Proteins 0.000 description 2
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 2
- 101001059984 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 4 Proteins 0.000 description 2
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 2
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 description 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 2
- 101000945093 Homo sapiens Ribosomal protein S6 kinase alpha-4 Proteins 0.000 description 2
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 2
- 101000826079 Homo sapiens SRSF protein kinase 3 Proteins 0.000 description 2
- 101000652133 Homo sapiens STE20-like serine/threonine-protein kinase Proteins 0.000 description 2
- 101000648174 Homo sapiens Serine/threonine-protein kinase 10 Proteins 0.000 description 2
- 101000661821 Homo sapiens Serine/threonine-protein kinase 17A Proteins 0.000 description 2
- 101000628693 Homo sapiens Serine/threonine-protein kinase 25 Proteins 0.000 description 2
- 101000880439 Homo sapiens Serine/threonine-protein kinase 3 Proteins 0.000 description 2
- 101000701401 Homo sapiens Serine/threonine-protein kinase 38 Proteins 0.000 description 2
- 101000697608 Homo sapiens Serine/threonine-protein kinase 38-like Proteins 0.000 description 2
- 101000880431 Homo sapiens Serine/threonine-protein kinase 4 Proteins 0.000 description 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 2
- 101000913761 Homo sapiens Serine/threonine-protein kinase ICK Proteins 0.000 description 2
- 101000576904 Homo sapiens Serine/threonine-protein kinase MRCK beta Proteins 0.000 description 2
- 101000576907 Homo sapiens Serine/threonine-protein kinase MRCK gamma Proteins 0.000 description 2
- 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 2
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 2
- 101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 description 2
- 101001098464 Homo sapiens Serine/threonine-protein kinase OSR1 Proteins 0.000 description 2
- 101000983111 Homo sapiens Serine/threonine-protein kinase PAK 6 Proteins 0.000 description 2
- 101000838578 Homo sapiens Serine/threonine-protein kinase TAO2 Proteins 0.000 description 2
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 description 2
- 101000772231 Homo sapiens Testis-specific serine/threonine-protein kinase 1 Proteins 0.000 description 2
- 101000794197 Homo sapiens Testis-specific serine/threonine-protein kinase 3 Proteins 0.000 description 2
- 101000794200 Homo sapiens Testis-specific serine/threonine-protein kinase 6 Proteins 0.000 description 2
- 101000892986 Homo sapiens Tyrosine-protein kinase FRK Proteins 0.000 description 2
- 101001022129 Homo sapiens Tyrosine-protein kinase Fyn Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 2
- 101001117143 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Proteins 0.000 description 2
- 101001046427 Homo sapiens cGMP-dependent protein kinase 2 Proteins 0.000 description 2
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100039137 Insulin receptor-related protein Human genes 0.000 description 2
- 102100034170 Interferon-induced, double-stranded RNA-activated protein kinase Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 2
- 102100026753 Lymphokine-activated killer T-cell-originated protein kinase Human genes 0.000 description 2
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- 102100021435 Macrophage-stimulating protein receptor Human genes 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 102100028905 Megakaryocyte-associated tyrosine-protein kinase Human genes 0.000 description 2
- 102100026287 Misshapen-like kinase 1 Human genes 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 description 2
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 2
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 description 2
- 102100025180 Mitogen-activated protein kinase kinase kinase 12 Human genes 0.000 description 2
- 102100033116 Mitogen-activated protein kinase kinase kinase 20 Human genes 0.000 description 2
- 102100033127 Mitogen-activated protein kinase kinase kinase 5 Human genes 0.000 description 2
- 102100026909 Mitogen-activated protein kinase kinase kinase 9 Human genes 0.000 description 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 2
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 2
- 102100028194 Mitogen-activated protein kinase kinase kinase kinase 4 Human genes 0.000 description 2
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 102100030788 Myosin light chain kinase 2, skeletal/cardiac muscle Human genes 0.000 description 2
- 102100030783 Myosin light chain kinase 3 Human genes 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 102100021733 NUAK family SNF1-like kinase 2 Human genes 0.000 description 2
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010037394 Pulmonary haemorrhage Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 2
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 2
- 102100033644 Ribosomal protein S6 kinase alpha-4 Human genes 0.000 description 2
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100023017 SRSF protein kinase 3 Human genes 0.000 description 2
- 102100030571 STE20-like serine/threonine-protein kinase Human genes 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 102100028900 Serine/threonine-protein kinase 10 Human genes 0.000 description 2
- 102100037955 Serine/threonine-protein kinase 17A Human genes 0.000 description 2
- 102100026737 Serine/threonine-protein kinase 25 Human genes 0.000 description 2
- 102100030514 Serine/threonine-protein kinase 38 Human genes 0.000 description 2
- 102100027898 Serine/threonine-protein kinase 38-like Human genes 0.000 description 2
- 102100037629 Serine/threonine-protein kinase 4 Human genes 0.000 description 2
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 description 2
- 102100025347 Serine/threonine-protein kinase MRCK beta Human genes 0.000 description 2
- 102100025345 Serine/threonine-protein kinase MRCK gamma Human genes 0.000 description 2
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 2
- 102100037143 Serine/threonine-protein kinase OSR1 Human genes 0.000 description 2
- 102100026840 Serine/threonine-protein kinase PAK 6 Human genes 0.000 description 2
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 description 2
- 102100028949 Serine/threonine-protein kinase TAO2 Human genes 0.000 description 2
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 description 2
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 2
- 102100029350 Testis-specific serine/threonine-protein kinase 1 Human genes 0.000 description 2
- 102100030168 Testis-specific serine/threonine-protein kinase 3 Human genes 0.000 description 2
- 102100030141 Testis-specific serine/threonine-protein kinase 6 Human genes 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 102100040959 Tyrosine-protein kinase FRK Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 102100039127 Tyrosine-protein kinase receptor TYRO3 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 102100024150 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial Human genes 0.000 description 2
- 102100034824 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial Human genes 0.000 description 2
- 102100034825 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229950009821 acalabrutinib Drugs 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 150000001350 alkyl halides Chemical class 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 2
- 229960000473 altretamine Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000000340 anti-metabolite Effects 0.000 description 2
- 229940044684 anti-microtubule agent Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940100197 antimetabolite Drugs 0.000 description 2
- 239000002256 antimetabolite Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 229960003272 asparaginase Drugs 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 229960002170 azathioprine Drugs 0.000 description 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 229960002938 bexarotene Drugs 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- 229960002092 busulfan Drugs 0.000 description 2
- 102100022421 cGMP-dependent protein kinase 2 Human genes 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 230000003185 calcium uptake Effects 0.000 description 2
- 229960004117 capecitabine Drugs 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960002436 cladribine Drugs 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 238000010668 complexation reaction Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 229960000640 dactinomycin Drugs 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 229960000975 daunorubicin Drugs 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 201000001981 dermatomyositis Diseases 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 description 2
- 229960002224 eculizumab Drugs 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 229960001904 epirubicin Drugs 0.000 description 2
- QAMYWGZHLCQOOJ-PWIVHLLHSA-N eribulin mesylate Chemical compound CS(O)(=O)=O.C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 QAMYWGZHLCQOOJ-PWIVHLLHSA-N 0.000 description 2
- 229960000439 eribulin mesylate Drugs 0.000 description 2
- 229960001842 estramustine Drugs 0.000 description 2
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 2
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 229960005293 etodolac Drugs 0.000 description 2
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 2
- 229960000752 etoposide phosphate Drugs 0.000 description 2
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 2
- 229960004945 etoricoxib Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 229960005341 fenoprofen calcium Drugs 0.000 description 2
- VHUXSAWXWSTUOD-UHFFFAOYSA-L fenoprofen calcium (anhydrous) Chemical compound [Ca+2].[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1.[O-]C(=O)C(C)C1=CC=CC(OC=2C=CC=CC=2)=C1 VHUXSAWXWSTUOD-UHFFFAOYSA-L 0.000 description 2
- 229960000556 fingolimod Drugs 0.000 description 2
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 2
- 229960000390 fludarabine Drugs 0.000 description 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960002390 flurbiprofen Drugs 0.000 description 2
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 229940049906 glutamate Drugs 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 150000002344 gold compounds Chemical class 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 125000004992 haloalkylamino group Chemical group 0.000 description 2
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- MSYBLBLAMDYKKZ-UHFFFAOYSA-N hydron;pyridine-3-carbonyl chloride;chloride Chemical compound Cl.ClC(=O)C1=CC=CN=C1 MSYBLBLAMDYKKZ-UHFFFAOYSA-N 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 229960000908 idarubicin Drugs 0.000 description 2
- 229960001101 ifosfamide Drugs 0.000 description 2
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108010054372 insulin receptor-related receptor Proteins 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 150000004694 iodide salts Chemical class 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 2
- 229960000991 ketoprofen Drugs 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229960002247 lomustine Drugs 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 229960004270 nabumetone Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-M naproxen(1-) Chemical compound C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-M 0.000 description 2
- 229960001346 nilotinib Drugs 0.000 description 2
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229940049964 oleate Drugs 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-M oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC([O-])=O ZQPPMHVWECSIRJ-KTKRTIGZSA-M 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229960001756 oxaliplatin Drugs 0.000 description 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 2
- 229960002739 oxaprozin Drugs 0.000 description 2
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 2
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 2
- GSWAOPJLTADLTN-UHFFFAOYSA-N oxidanimine Chemical compound [O-][NH3+] GSWAOPJLTADLTN-UHFFFAOYSA-N 0.000 description 2
- 229960001972 panitumumab Drugs 0.000 description 2
- 229950003203 pexelizumab Drugs 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 2
- 229960002702 piroxicam Drugs 0.000 description 2
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- 150000003873 salicylate salts Chemical group 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 150000003871 sulfonates Chemical class 0.000 description 2
- 229960000894 sulindac Drugs 0.000 description 2
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960001967 tacrolimus Drugs 0.000 description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 2
- WAJQZKDVKDTIPI-UHFFFAOYSA-N tert-butyl 4-(4-amino-2-nitrophenyl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2C(=CC(N)=CC=2)[N+]([O-])=O)=C1 WAJQZKDVKDTIPI-UHFFFAOYSA-N 0.000 description 2
- GFLLAMJWQXYKQS-UHFFFAOYSA-N tert-butyl 5-(4-amino-2-nitrophenyl)-3,6-dihydro-2H-pyridine-1-carboxylate Chemical compound NC1=CC(=C(C=C1)C=1CN(CCC=1)C(=O)OC(C)(C)C)[N+](=O)[O-] GFLLAMJWQXYKQS-UHFFFAOYSA-N 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 230000003582 thrombocytopenic effect Effects 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960002044 tolmetin sodium Drugs 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229960003862 vemurafenib Drugs 0.000 description 2
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- BNJMRELGMDUDDB-UHFFFAOYSA-N $l^{1}-sulfanylbenzene Chemical class [S]C1=CC=CC=C1 BNJMRELGMDUDDB-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-ZETCQYMHSA-N (+)-dexrazoxane Chemical compound C([C@H](C)N1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-ZETCQYMHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- RPAJSBKBKSSMLJ-DFWYDOINSA-N (2s)-2-aminopentanedioic acid;hydrochloride Chemical class Cl.OC(=O)[C@@H](N)CCC(O)=O RPAJSBKBKSSMLJ-DFWYDOINSA-N 0.000 description 1
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 1
- LCPKWRSLMCUOOZ-QYCVXMPOSA-N (3r)-n,n-dimethylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.CN(C)[C@@H]1CCNC1 LCPKWRSLMCUOOZ-QYCVXMPOSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- LOVPHSMOAVXQIH-UHFFFAOYSA-N (4-nitrophenyl) hydrogen carbonate Chemical class OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 LOVPHSMOAVXQIH-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- XGQXULJHBWKUJY-LYIKAWCPSA-N (z)-but-2-enedioic acid;n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound OC(=O)\C=C/C(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C XGQXULJHBWKUJY-LYIKAWCPSA-N 0.000 description 1
- WZCQRUWWHSTZEM-UHFFFAOYSA-N 1,3-phenylenediamine Chemical compound NC1=CC=CC(N)=C1 WZCQRUWWHSTZEM-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- WGEKSWPKHRNLHA-UHFFFAOYSA-N 1-(3,5-dinitrophenyl)-4-methylpiperazine Chemical compound CN1CCN(CC1)C1=CC(=CC(=C1)[N+]([O-])=O)[N+]([O-])=O WGEKSWPKHRNLHA-UHFFFAOYSA-N 0.000 description 1
- OLDMYNWXIGPOCI-UHFFFAOYSA-N 1-bromo-3,5-dinitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC([N+]([O-])=O)=C1 OLDMYNWXIGPOCI-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- VUQPJRPDRDVQMN-UHFFFAOYSA-N 1-chlorooctadecane Chemical class CCCCCCCCCCCCCCCCCCCl VUQPJRPDRDVQMN-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- GPWNWKWQOLEVEQ-UHFFFAOYSA-N 2,4-diaminopyrimidine-5-carbaldehyde Chemical compound NC1=NC=C(C=O)C(N)=N1 GPWNWKWQOLEVEQ-UHFFFAOYSA-N 0.000 description 1
- PCMMSLVJMKQWMQ-UHFFFAOYSA-N 2,4-dibromopyridine Chemical compound BrC1=CC=NC(Br)=C1 PCMMSLVJMKQWMQ-UHFFFAOYSA-N 0.000 description 1
- YDYNSAUGVGAOLO-UHFFFAOYSA-N 2,6-dibromobenzaldehyde Chemical compound BrC1=CC=CC(Br)=C1C=O YDYNSAUGVGAOLO-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- JVKUCNQGESRUCL-UHFFFAOYSA-N 2-Hydroxyethyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCCO JVKUCNQGESRUCL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229940013085 2-diethylaminoethanol Drugs 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- JSYAQLZSGHPSJD-UHFFFAOYSA-N 3,3-dimethylcyclopentan-1-one Chemical compound CC1(C)CCC(=O)C1 JSYAQLZSGHPSJD-UHFFFAOYSA-N 0.000 description 1
- ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical compound C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- PCRKXYQAJPDKCF-UHFFFAOYSA-N 4-(2-methyl-1-morpholin-4-ylpropan-2-yl)-3-nitroaniline Chemical compound CC(CN1CCOCC1)(C)C1=C(C=C(N)C=C1)[N+](=O)[O-] PCRKXYQAJPDKCF-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- UEALKTCRMBVTFN-UHFFFAOYSA-N 4-nitroanthranilic acid Chemical compound NC1=CC([N+]([O-])=O)=CC=C1C(O)=O UEALKTCRMBVTFN-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- CDBBOSIQEONGTD-UHFFFAOYSA-N 5-bromo-1-methyl-3-[4-(4-methylpiperazin-1-yl)-3-nitroanilino]pyrazin-2-one Chemical compound BrC=1N=C(C(N(C=1)C)=O)NC1=CC(=C(C=C1)N1CCN(CC1)C)[N+](=O)[O-] CDBBOSIQEONGTD-UHFFFAOYSA-N 0.000 description 1
- OUTMOQVYGNSIMU-UHFFFAOYSA-N 5-bromo-1-methylpyrazin-2-one Chemical compound CN1C=C(Br)N=CC1=O OUTMOQVYGNSIMU-UHFFFAOYSA-N 0.000 description 1
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000005660 Abamectin Substances 0.000 description 1
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 description 1
- 241000349731 Afzelia bipindensis Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001935 American trypanosomiasis Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 101001077245 Aplysia californica Spermatozoon-associated protein kinase Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 101100465059 Arabidopsis thaliana PRK3 gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 239000012664 BCL-2-inhibitor Substances 0.000 description 1
- 102100035080 BDNF/NT-3 growth factors receptor Human genes 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 102100026596 Bcl-2-like protein 1 Human genes 0.000 description 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100021738 Beta-adrenergic receptor kinase 1 Human genes 0.000 description 1
- 102100037281 Beta-adrenergic receptor kinase 2 Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 1
- 102100025422 Bone morphogenetic protein receptor type-2 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- FVCZORVEJJNYLV-UHFFFAOYSA-N C(C1=CC=CC=C1)OC(C(CC)Cl)=O Chemical compound C(C1=CC=CC=C1)OC(C(CC)Cl)=O FVCZORVEJJNYLV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102100033089 Calcium/calmodulin-dependent protein kinase type 1G Human genes 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100023060 Casein kinase I isoform gamma-2 Human genes 0.000 description 1
- 102100040753 Casein kinase II subunit alpha' Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 208000024699 Chagas disease Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000012623 DNA damaging agent Substances 0.000 description 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 101100457345 Danio rerio mapk14a gene Proteins 0.000 description 1
- 101100457347 Danio rerio mapk14b gene Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101100291385 Drosophila melanogaster p38a gene Proteins 0.000 description 1
- 102100029638 Dual serine/threonine and tyrosine protein kinase Human genes 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 description 1
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 1
- 102100040844 Dual specificity protein kinase CLK2 Human genes 0.000 description 1
- 102100040856 Dual specificity protein kinase CLK3 Human genes 0.000 description 1
- 102100040858 Dual specificity protein kinase CLK4 Human genes 0.000 description 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 description 1
- 102100036492 Dual specificity testis-specific protein kinase 1 Human genes 0.000 description 1
- 102100033363 Dual specificity tyrosine-phosphorylation-regulated kinase 1B Human genes 0.000 description 1
- 102100023114 Dual specificity tyrosine-phosphorylation-regulated kinase 3 Human genes 0.000 description 1
- 102100023112 Dual specificity tyrosine-phosphorylation-regulated kinase 4 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150076616 EPHA2 gene Proteins 0.000 description 1
- 101150016325 EPHA3 gene Proteins 0.000 description 1
- 101150097734 EPHB2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 101150078651 Epha4 gene Proteins 0.000 description 1
- 101150025643 Epha5 gene Proteins 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 1
- 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 1
- 102100021604 Ephrin type-A receptor 6 Human genes 0.000 description 1
- 102100021606 Ephrin type-A receptor 7 Human genes 0.000 description 1
- 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 1
- 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
- 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 1
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 description 1
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000402754 Erythranthe moschata Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 102100021808 Eukaryotic elongation factor 2 kinase Human genes 0.000 description 1
- 102100034174 Eukaryotic translation initiation factor 2-alpha kinase 3 Human genes 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 102100035111 Farnesyl pyrophosphate synthase Human genes 0.000 description 1
- 101710125754 Farnesyl pyrophosphate synthase Proteins 0.000 description 1
- 101710089428 Farnesyl pyrophosphate synthase erg20 Proteins 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 102100036990 Fat storage-inducing transmembrane protein 1 Human genes 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 102100023734 G protein-coupled receptor kinase 4 Human genes 0.000 description 1
- 102100023685 G protein-coupled receptor kinase 5 Human genes 0.000 description 1
- 102100023686 G protein-coupled receptor kinase 6 Human genes 0.000 description 1
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031132 Glucose-6-phosphate isomerase Human genes 0.000 description 1
- 108010070600 Glucose-6-phosphate isomerase Proteins 0.000 description 1
- 101710155270 Glycerate 2-kinase Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 101150017137 Haspin gene Proteins 0.000 description 1
- 102100032510 Heat shock protein HSP 90-beta Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 108010016918 Histone-Lysine N-Methyltransferase Proteins 0.000 description 1
- 102000000581 Histone-lysine N-methyltransferase Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 description 1
- 102100032827 Homeodomain-interacting protein kinase 2 Human genes 0.000 description 1
- 102100032826 Homeodomain-interacting protein kinase 3 Human genes 0.000 description 1
- 102100022603 Homeodomain-interacting protein kinase 4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000596896 Homo sapiens BDNF/NT-3 growth factors receptor Proteins 0.000 description 1
- 101000751445 Homo sapiens Beta-adrenergic receptor kinase 1 Proteins 0.000 description 1
- 101000806653 Homo sapiens Beta-adrenergic receptor kinase 2 Proteins 0.000 description 1
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 1
- 101000934635 Homo sapiens Bone morphogenetic protein receptor type-2 Proteins 0.000 description 1
- 101100061529 Homo sapiens CSNK2A2 gene Proteins 0.000 description 1
- 101000944259 Homo sapiens Calcium/calmodulin-dependent protein kinase type 1G Proteins 0.000 description 1
- 101000865739 Homo sapiens Dual serine/threonine and tyrosine protein kinase Proteins 0.000 description 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 1
- 101000749294 Homo sapiens Dual specificity protein kinase CLK1 Proteins 0.000 description 1
- 101000749291 Homo sapiens Dual specificity protein kinase CLK2 Proteins 0.000 description 1
- 101000749304 Homo sapiens Dual specificity protein kinase CLK3 Proteins 0.000 description 1
- 101000749298 Homo sapiens Dual specificity protein kinase CLK4 Proteins 0.000 description 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 description 1
- 101000714159 Homo sapiens Dual specificity testis-specific protein kinase 1 Proteins 0.000 description 1
- 101000926738 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1B Proteins 0.000 description 1
- 101001049991 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 3 Proteins 0.000 description 1
- 101001049983 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 4 Proteins 0.000 description 1
- 101000967216 Homo sapiens Eosinophil cationic protein Proteins 0.000 description 1
- 101000898696 Homo sapiens Ephrin type-A receptor 6 Proteins 0.000 description 1
- 101000898708 Homo sapiens Ephrin type-A receptor 7 Proteins 0.000 description 1
- 101000898676 Homo sapiens Ephrin type-A receptor 8 Proteins 0.000 description 1
- 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
- 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 1
- 101000895759 Homo sapiens Eukaryotic elongation factor 2 kinase Proteins 0.000 description 1
- 101000926530 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 1 Proteins 0.000 description 1
- 101000926508 Homo sapiens Eukaryotic translation initiation factor 2-alpha kinase 3 Proteins 0.000 description 1
- 101000878236 Homo sapiens Fat storage-inducing transmembrane protein 1 Proteins 0.000 description 1
- 101000829481 Homo sapiens G protein-coupled receptor kinase 4 Proteins 0.000 description 1
- 101000829476 Homo sapiens G protein-coupled receptor kinase 5 Proteins 0.000 description 1
- 101000829473 Homo sapiens G protein-coupled receptor kinase 6 Proteins 0.000 description 1
- 101001016856 Homo sapiens Heat shock protein HSP 90-beta Proteins 0.000 description 1
- 101001066435 Homo sapiens Hepatocyte growth factor-like protein Proteins 0.000 description 1
- 101000596894 Homo sapiens High affinity nerve growth factor receptor Proteins 0.000 description 1
- 101001066404 Homo sapiens Homeodomain-interacting protein kinase 1 Proteins 0.000 description 1
- 101001066401 Homo sapiens Homeodomain-interacting protein kinase 2 Proteins 0.000 description 1
- 101001066389 Homo sapiens Homeodomain-interacting protein kinase 3 Proteins 0.000 description 1
- 101001045363 Homo sapiens Homeodomain-interacting protein kinase 4 Proteins 0.000 description 1
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 description 1
- 101001043764 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit alpha Proteins 0.000 description 1
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 1
- 101000599862 Homo sapiens Intercellular adhesion molecule 3 Proteins 0.000 description 1
- 101000852483 Homo sapiens Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- 101000956807 Homo sapiens Leukocyte tyrosine kinase receptor Proteins 0.000 description 1
- 101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101001059429 Homo sapiens MAP/microtubule affinity-regulating kinase 3 Proteins 0.000 description 1
- 101001059427 Homo sapiens MAP/microtubule affinity-regulating kinase 4 Proteins 0.000 description 1
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000628967 Homo sapiens Mitogen-activated protein kinase 11 Proteins 0.000 description 1
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 101000628968 Homo sapiens Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 description 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 description 1
- 101001005605 Homo sapiens Mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 1
- 101001005550 Homo sapiens Mitogen-activated protein kinase kinase kinase 14 Proteins 0.000 description 1
- 101001018145 Homo sapiens Mitogen-activated protein kinase kinase kinase 3 Proteins 0.000 description 1
- 101001055091 Homo sapiens Mitogen-activated protein kinase kinase kinase 8 Proteins 0.000 description 1
- 101001059990 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000584208 Homo sapiens Myosin light chain kinase 2, skeletal/cardiac muscle Proteins 0.000 description 1
- 101000584177 Homo sapiens Myosin light chain kinase 3 Proteins 0.000 description 1
- 101001022780 Homo sapiens Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- 101000970025 Homo sapiens NUAK family SNF1-like kinase 2 Proteins 0.000 description 1
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000598781 Homo sapiens Oxidative stress-responsive serine-rich protein 1 Proteins 0.000 description 1
- 101000613563 Homo sapiens PAS domain-containing serine/threonine-protein kinase Proteins 0.000 description 1
- 101100243116 Homo sapiens PDK1 gene Proteins 0.000 description 1
- 101100463123 Homo sapiens PDK3 gene Proteins 0.000 description 1
- 101100463125 Homo sapiens PDK4 gene Proteins 0.000 description 1
- 101100244966 Homo sapiens PRKX gene Proteins 0.000 description 1
- 101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
- 101000979748 Homo sapiens Protein NDRG1 Proteins 0.000 description 1
- 101000757232 Homo sapiens Protein arginine N-methyltransferase 2 Proteins 0.000 description 1
- 101000613717 Homo sapiens Protein odd-skipped-related 1 Proteins 0.000 description 1
- 101000878540 Homo sapiens Protein-tyrosine kinase 2-beta Proteins 0.000 description 1
- 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
- 101000798007 Homo sapiens RAC-gamma serine/threonine-protein kinase Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101000669917 Homo sapiens Rho-associated protein kinase 1 Proteins 0.000 description 1
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 1
- 101000829506 Homo sapiens Rhodopsin kinase GRK1 Proteins 0.000 description 1
- 101000871032 Homo sapiens Rhodopsin kinase GRK7 Proteins 0.000 description 1
- 101000944921 Homo sapiens Ribosomal protein S6 kinase alpha-2 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 description 1
- 101001051714 Homo sapiens Ribosomal protein S6 kinase beta-2 Proteins 0.000 description 1
- 101000826081 Homo sapiens SRSF protein kinase 1 Proteins 0.000 description 1
- 101000826077 Homo sapiens SRSF protein kinase 2 Proteins 0.000 description 1
- 101000701497 Homo sapiens STE20/SPS1-related proline-alanine-rich protein kinase Proteins 0.000 description 1
- 101000628578 Homo sapiens Serine/threonine-protein kinase 16 Proteins 0.000 description 1
- 101000701393 Homo sapiens Serine/threonine-protein kinase 26 Proteins 0.000 description 1
- 101000697600 Homo sapiens Serine/threonine-protein kinase 32B Proteins 0.000 description 1
- 101000697610 Homo sapiens Serine/threonine-protein kinase 32C Proteins 0.000 description 1
- 101000701396 Homo sapiens Serine/threonine-protein kinase 33 Proteins 0.000 description 1
- 101000771237 Homo sapiens Serine/threonine-protein kinase A-Raf Proteins 0.000 description 1
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 description 1
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 description 1
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 description 1
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 description 1
- 101001047642 Homo sapiens Serine/threonine-protein kinase LATS1 Proteins 0.000 description 1
- 101001047637 Homo sapiens Serine/threonine-protein kinase LATS2 Proteins 0.000 description 1
- 101001059443 Homo sapiens Serine/threonine-protein kinase MARK1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101000691455 Homo sapiens Serine/threonine-protein kinase N3 Proteins 0.000 description 1
- 101001123846 Homo sapiens Serine/threonine-protein kinase Nek1 Proteins 0.000 description 1
- 101001123812 Homo sapiens Serine/threonine-protein kinase Nek11 Proteins 0.000 description 1
- 101000601441 Homo sapiens Serine/threonine-protein kinase Nek2 Proteins 0.000 description 1
- 101000601456 Homo sapiens Serine/threonine-protein kinase Nek3 Proteins 0.000 description 1
- 101000588540 Homo sapiens Serine/threonine-protein kinase Nek6 Proteins 0.000 description 1
- 101000588545 Homo sapiens Serine/threonine-protein kinase Nek7 Proteins 0.000 description 1
- 101000588553 Homo sapiens Serine/threonine-protein kinase Nek9 Proteins 0.000 description 1
- 101000987310 Homo sapiens Serine/threonine-protein kinase PAK 2 Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000987297 Homo sapiens Serine/threonine-protein kinase PAK 4 Proteins 0.000 description 1
- 101000987295 Homo sapiens Serine/threonine-protein kinase PAK 5 Proteins 0.000 description 1
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 1
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 description 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 description 1
- 101000709238 Homo sapiens Serine/threonine-protein kinase SIK1 Proteins 0.000 description 1
- 101000709250 Homo sapiens Serine/threonine-protein kinase SIK2 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101000864806 Homo sapiens Serine/threonine-protein kinase Sgk2 Proteins 0.000 description 1
- 101000838579 Homo sapiens Serine/threonine-protein kinase TAO1 Proteins 0.000 description 1
- 101000665442 Homo sapiens Serine/threonine-protein kinase TBK1 Proteins 0.000 description 1
- 101000607332 Homo sapiens Serine/threonine-protein kinase ULK2 Proteins 0.000 description 1
- 101000607339 Homo sapiens Serine/threonine-protein kinase ULK3 Proteins 0.000 description 1
- 101000649929 Homo sapiens Serine/threonine-protein kinase VRK1 Proteins 0.000 description 1
- 101000649931 Homo sapiens Serine/threonine-protein kinase VRK2 Proteins 0.000 description 1
- 101000770774 Homo sapiens Serine/threonine-protein kinase WNK2 Proteins 0.000 description 1
- 101000742982 Homo sapiens Serine/threonine-protein kinase WNK3 Proteins 0.000 description 1
- 101000623857 Homo sapiens Serine/threonine-protein kinase mTOR Proteins 0.000 description 1
- 101000595531 Homo sapiens Serine/threonine-protein kinase pim-1 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101001001645 Homo sapiens Serine/threonine-protein kinase pim-3 Proteins 0.000 description 1
- 101000799194 Homo sapiens Serine/threonine-protein kinase receptor R3 Proteins 0.000 description 1
- 101000637839 Homo sapiens Serine/threonine-protein kinase tousled-like 1 Proteins 0.000 description 1
- 101000637847 Homo sapiens Serine/threonine-protein kinase tousled-like 2 Proteins 0.000 description 1
- 101000662997 Homo sapiens TRAF2 and NCK-interacting protein kinase Proteins 0.000 description 1
- 101100101258 Homo sapiens TYRO3 gene Proteins 0.000 description 1
- 101000759314 Homo sapiens Tau-tubulin kinase 1 Proteins 0.000 description 1
- 101000759318 Homo sapiens Tau-tubulin kinase 2 Proteins 0.000 description 1
- 101000772239 Homo sapiens Testis-specific serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000823271 Homo sapiens Tyrosine-protein kinase ABL2 Proteins 0.000 description 1
- 101000912503 Homo sapiens Tyrosine-protein kinase Fgr Proteins 0.000 description 1
- 101001009087 Homo sapiens Tyrosine-protein kinase HCK Proteins 0.000 description 1
- 101001050476 Homo sapiens Tyrosine-protein kinase ITK/TSK Proteins 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 1
- 101001054878 Homo sapiens Tyrosine-protein kinase Lyn Proteins 0.000 description 1
- 101000604583 Homo sapiens Tyrosine-protein kinase SYK Proteins 0.000 description 1
- 101000587313 Homo sapiens Tyrosine-protein kinase Srms Proteins 0.000 description 1
- 101000606067 Homo sapiens Tyrosine-protein kinase TXK Proteins 0.000 description 1
- 101000889732 Homo sapiens Tyrosine-protein kinase Tec Proteins 0.000 description 1
- 101000820294 Homo sapiens Tyrosine-protein kinase Yes Proteins 0.000 description 1
- 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
- 101000606129 Homo sapiens Tyrosine-protein kinase receptor TYRO3 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 1
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 1
- 101000734338 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 3, mitochondrial Proteins 0.000 description 1
- 101000734339 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 4, mitochondrial Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 101150057269 IKBKB gene Proteins 0.000 description 1
- 102100027638 Inhibitor of Bruton tyrosine kinase Human genes 0.000 description 1
- 101710139847 Inhibitor of Bruton tyrosine kinase Proteins 0.000 description 1
- 102100021892 Inhibitor of nuclear factor kappa-B kinase subunit alpha Human genes 0.000 description 1
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 description 1
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 1
- 102100037871 Intercellular adhesion molecule 3 Human genes 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100020873 Interleukin-2 Human genes 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 1
- 101000988090 Leishmania donovani Heat shock protein 83 Proteins 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102220577899 Leucine-rich repeat serine/threonine-protein kinase 2_G2019S_mutation Human genes 0.000 description 1
- 102220577984 Leucine-rich repeat serine/threonine-protein kinase 2_I2020T_mutation Human genes 0.000 description 1
- 102220596654 Leucine-rich repeat serine/threonine-protein kinase 2_R1441C_mutation Human genes 0.000 description 1
- 102100038420 Leukocyte tyrosine kinase receptor Human genes 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 238000012897 Levenberg–Marquardt algorithm Methods 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 108010075654 MAP Kinase Kinase Kinase 1 Proteins 0.000 description 1
- 108010075656 MAP Kinase Kinase Kinase 2 Proteins 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- 108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
- 108010041980 MAP-kinase-activated kinase 3 Proteins 0.000 description 1
- 108010041164 MAP-kinase-activated kinase 5 Proteins 0.000 description 1
- 102100028920 MAP/microtubule affinity-regulating kinase 3 Human genes 0.000 description 1
- 102100028913 MAP/microtubule affinity-regulating kinase 4 Human genes 0.000 description 1
- 108700012928 MAPK14 Proteins 0.000 description 1
- 108010066373 MLK-like mitogen-activated protein triple kinase Proteins 0.000 description 1
- 101150078127 MUSK gene Proteins 0.000 description 1
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- MQHWFIOJQSCFNM-UHFFFAOYSA-L Magnesium salicylate Chemical compound [Mg+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O MQHWFIOJQSCFNM-UHFFFAOYSA-L 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150003941 Mapk14 gene Proteins 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical class SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 1
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 102100026930 Mitogen-activated protein kinase 13 Human genes 0.000 description 1
- 102000054819 Mitogen-activated protein kinase 14 Human genes 0.000 description 1
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 description 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 description 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 description 1
- 102100033115 Mitogen-activated protein kinase kinase kinase 1 Human genes 0.000 description 1
- 102100025211 Mitogen-activated protein kinase kinase kinase 14 Human genes 0.000 description 1
- 102100033058 Mitogen-activated protein kinase kinase kinase 2 Human genes 0.000 description 1
- 101710084683 Mitogen-activated protein kinase kinase kinase 20 Proteins 0.000 description 1
- 102100033059 Mitogen-activated protein kinase kinase kinase 3 Human genes 0.000 description 1
- 102100026888 Mitogen-activated protein kinase kinase kinase 7 Human genes 0.000 description 1
- 102100026907 Mitogen-activated protein kinase kinase kinase 8 Human genes 0.000 description 1
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100490437 Mus musculus Acvrl1 gene Proteins 0.000 description 1
- 101100437777 Mus musculus Bmpr1a gene Proteins 0.000 description 1
- 101100452374 Mus musculus Ikbke gene Proteins 0.000 description 1
- 102100038168 Muscle, skeletal receptor tyrosine-protein kinase Human genes 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 101710120693 Myosin light chain kinase 2, skeletal/cardiac muscle Proteins 0.000 description 1
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 description 1
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
- 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
- 229910017917 NH4 Cl Inorganic materials 0.000 description 1
- 102100029166 NT-3 growth factor receptor Human genes 0.000 description 1
- 101150117329 NTRK3 gene Proteins 0.000 description 1
- 101710151812 NUAK family SNF1-like kinase 2 Proteins 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 206010029132 Nephritis haemorrhagic Diseases 0.000 description 1
- 206010072359 Neuromyotonia Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 102000014736 Notch Human genes 0.000 description 1
- 108010070047 Notch Receptors Proteins 0.000 description 1
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 101700056750 PAK1 Proteins 0.000 description 1
- 239000012661 PARP inhibitor Substances 0.000 description 1
- 102100040902 PAS domain-containing serine/threonine-protein kinase Human genes 0.000 description 1
- 101150068407 PRKACB gene Proteins 0.000 description 1
- 101150020891 PRKCA gene Proteins 0.000 description 1
- 101150073266 PRKCD gene Proteins 0.000 description 1
- 101150001670 PRKCG gene Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000005592 Penoxsulam Substances 0.000 description 1
- SYJGKVOENHZYMQ-UHFFFAOYSA-N Penoxsulam Chemical compound N1=C2C(OC)=CN=C(OC)N2N=C1NS(=O)(=O)C1=C(OCC(F)F)C=CC=C1C(F)(F)F SYJGKVOENHZYMQ-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 description 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920002700 Polyoxyl 60 hydrogenated castor oil Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 108010003506 Protein Kinase D2 Proteins 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 1
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 241000720974 Protium Species 0.000 description 1
- 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
- 102100032314 RAC-gamma serine/threonine-protein kinase Human genes 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 108010079933 Receptor-Interacting Protein Serine-Threonine Kinase 2 Proteins 0.000 description 1
- 102100022502 Receptor-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 102100039313 Rho-associated protein kinase 1 Human genes 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 102100023742 Rhodopsin kinase GRK1 Human genes 0.000 description 1
- 102100033090 Rhodopsin kinase GRK7 Human genes 0.000 description 1
- 229940127395 Ribonucleotide Reductase Inhibitors Drugs 0.000 description 1
- 102100033534 Ribosomal protein S6 kinase alpha-2 Human genes 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 description 1
- 102100024917 Ribosomal protein S6 kinase beta-2 Human genes 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 102100023010 SRSF protein kinase 1 Human genes 0.000 description 1
- 102100023015 SRSF protein kinase 2 Human genes 0.000 description 1
- 102100030491 STE20/SPS1-related proline-alanine-rich protein kinase Human genes 0.000 description 1
- 101100384866 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COT1 gene Proteins 0.000 description 1
- 101100390767 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) FIT3 gene Proteins 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 102100026758 Serine/threonine-protein kinase 16 Human genes 0.000 description 1
- 102100030617 Serine/threonine-protein kinase 26 Human genes 0.000 description 1
- 102100037628 Serine/threonine-protein kinase 3 Human genes 0.000 description 1
- 102100028030 Serine/threonine-protein kinase 32B Human genes 0.000 description 1
- 102100027903 Serine/threonine-protein kinase 32C Human genes 0.000 description 1
- 102100030515 Serine/threonine-protein kinase 33 Human genes 0.000 description 1
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 1
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 description 1
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 description 1
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 description 1
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 description 1
- 101710172245 Serine/threonine-protein kinase ICK Proteins 0.000 description 1
- 102100024031 Serine/threonine-protein kinase LATS1 Human genes 0.000 description 1
- 102100024043 Serine/threonine-protein kinase LATS2 Human genes 0.000 description 1
- 102100028921 Serine/threonine-protein kinase MARK1 Human genes 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 102100026219 Serine/threonine-protein kinase N3 Human genes 0.000 description 1
- 102100028751 Serine/threonine-protein kinase Nek1 Human genes 0.000 description 1
- 102100028775 Serine/threonine-protein kinase Nek11 Human genes 0.000 description 1
- 102100037703 Serine/threonine-protein kinase Nek2 Human genes 0.000 description 1
- 102100037706 Serine/threonine-protein kinase Nek3 Human genes 0.000 description 1
- 102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 description 1
- 102100031401 Serine/threonine-protein kinase Nek6 Human genes 0.000 description 1
- 102100031400 Serine/threonine-protein kinase Nek7 Human genes 0.000 description 1
- 102100031398 Serine/threonine-protein kinase Nek9 Human genes 0.000 description 1
- 102100027939 Serine/threonine-protein kinase PAK 2 Human genes 0.000 description 1
- 102100027940 Serine/threonine-protein kinase PAK 4 Human genes 0.000 description 1
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 description 1
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 1
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 description 1
- 102100032771 Serine/threonine-protein kinase SIK1 Human genes 0.000 description 1
- 102100034377 Serine/threonine-protein kinase SIK2 Human genes 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 1
- 102100038192 Serine/threonine-protein kinase TBK1 Human genes 0.000 description 1
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 1
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 description 1
- 102100039985 Serine/threonine-protein kinase ULK3 Human genes 0.000 description 1
- 102100028235 Serine/threonine-protein kinase VRK1 Human genes 0.000 description 1
- 102100028234 Serine/threonine-protein kinase VRK2 Human genes 0.000 description 1
- 102100029063 Serine/threonine-protein kinase WNK2 Human genes 0.000 description 1
- 102100038115 Serine/threonine-protein kinase WNK3 Human genes 0.000 description 1
- 102100036077 Serine/threonine-protein kinase pim-1 Human genes 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- 102100036119 Serine/threonine-protein kinase pim-3 Human genes 0.000 description 1
- 102100034136 Serine/threonine-protein kinase receptor R3 Human genes 0.000 description 1
- 102100032015 Serine/threonine-protein kinase tousled-like 1 Human genes 0.000 description 1
- 102100032014 Serine/threonine-protein kinase tousled-like 2 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229920001304 Solutol HS 15 Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102100033455 TGF-beta receptor type-2 Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 102100037671 TRAF2 and NCK-interacting protein kinase Human genes 0.000 description 1
- 102000027545 TRPM Human genes 0.000 description 1
- 108091008847 TRPM Proteins 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- 102100023277 Tau-tubulin kinase 1 Human genes 0.000 description 1
- 102100023276 Tau-tubulin kinase 2 Human genes 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 102100029355 Testis-specific serine/threonine-protein kinase 2 Human genes 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102100022651 Tyrosine-protein kinase ABL2 Human genes 0.000 description 1
- 102100026150 Tyrosine-protein kinase Fgr Human genes 0.000 description 1
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 description 1
- 102100023345 Tyrosine-protein kinase ITK/TSK Human genes 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 1
- 102100026857 Tyrosine-protein kinase Lyn Human genes 0.000 description 1
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 1
- 102100029654 Tyrosine-protein kinase Srms Human genes 0.000 description 1
- 102100039079 Tyrosine-protein kinase TXK Human genes 0.000 description 1
- 102100021788 Tyrosine-protein kinase Yes Human genes 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 1
- ZYVSOIYQKUDENJ-ASUJBHBQSA-N [(2R,3R,4R,6R)-6-[[(6S,7S)-6-[(2S,4R,5R,6R)-4-[(2R,4R,5R,6R)-4-[(2S,4S,5S,6S)-5-acetyloxy-4-hydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-7-[(3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-4,10-dihydroxy-3-methyl-5-oxo-7,8-dihydro-6H-anthracen-2-yl]oxy]-4-[(2R,4R,5R,6R)-4-hydroxy-5-methoxy-6-methyloxan-2-yl]oxy-2-methyloxan-3-yl] acetate Chemical class COC([C@@H]1Cc2cc3cc(O[C@@H]4C[C@@H](O[C@@H]5C[C@@H](O)[C@@H](OC)[C@@H](C)O5)[C@H](OC(C)=O)[C@@H](C)O4)c(C)c(O)c3c(O)c2C(=O)[C@H]1O[C@H]1C[C@@H](O[C@@H]2C[C@@H](O[C@H]3C[C@](C)(O)[C@@H](OC(C)=O)[C@H](C)O3)[C@H](O)[C@@H](C)O2)[C@H](O)[C@@H](C)O1)C(=O)[C@@H](O)[C@@H](C)O ZYVSOIYQKUDENJ-ASUJBHBQSA-N 0.000 description 1
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 1
- 229950008167 abamectin Drugs 0.000 description 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 description 1
- 229960004103 abiraterone acetate Drugs 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 108010052004 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
- 150000001278 adipic acid derivatives Chemical class 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229940045713 antineoplastic alkylating drug ethylene imines Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960003982 apatinib Drugs 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 125000004659 aryl alkyl thio group Chemical group 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 150000001509 aspartic acid derivatives Chemical class 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000011717 athymic nude mouse Methods 0.000 description 1
- AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
- 229960005207 auranofin Drugs 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 208000027625 autoimmune inner ear disease Diseases 0.000 description 1
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- SGZWYNUJLMTSMJ-UHFFFAOYSA-N benzyl n-phenylcarbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1=CC=CC=C1 SGZWYNUJLMTSMJ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- STSBIYSZXHSXHH-UHFFFAOYSA-N but-2-ynamide Chemical compound CC#CC(N)=O STSBIYSZXHSXHH-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 102100029402 cAMP-dependent protein kinase catalytic subunit PRKX Human genes 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- KVUAALJSMIVURS-ZEDZUCNESA-L calcium folinate Chemical compound [Ca+2].C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 KVUAALJSMIVURS-ZEDZUCNESA-L 0.000 description 1
- 235000008207 calcium folinate Nutrition 0.000 description 1
- 239000011687 calcium folinate Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical class CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 229960002688 choline salicylate Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 101150116749 chuk gene Proteins 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
- 229960003608 clomifene Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229960005061 crizotinib Drugs 0.000 description 1
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- MRKZAZMYXYSBDG-UHFFFAOYSA-N cyclopentyl propanoate Chemical compound CCC(=O)OC1CCCC1 MRKZAZMYXYSBDG-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 229960002272 degarelix Drugs 0.000 description 1
- MEUCPCLKGZSHTA-XYAYPHGZSA-N degarelix Chemical compound C([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CC=1C=CC(NC(=O)[C@H]2NC(=O)NC(=O)C2)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(NC(N)=O)C=C1 MEUCPCLKGZSHTA-XYAYPHGZSA-N 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960000605 dexrazoxane Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- ONIHPYYWNBVMID-UHFFFAOYSA-N diethyl benzene-1,4-dicarboxylate Chemical compound CCOC(=O)C1=CC=C(C(=O)OCC)C=C1 ONIHPYYWNBVMID-UHFFFAOYSA-N 0.000 description 1
- DENRZWYUOJLTMF-UHFFFAOYSA-N diethyl sulfate Chemical compound CCOS(=O)(=O)OCC DENRZWYUOJLTMF-UHFFFAOYSA-N 0.000 description 1
- 229940008406 diethyl sulfate Drugs 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- GAFRWLVTHPVQGK-UHFFFAOYSA-N dipentyl sulfate Chemical compound CCCCCOS(=O)(=O)OCCCCC GAFRWLVTHPVQGK-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940042317 doxorubicin liposome Drugs 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 238000013100 final test Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- 229960002258 fulvestrant Drugs 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 1
- 230000005251 gamma ray Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 229960003690 goserelin acetate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- HHXHVIJIIXKSOE-QILQGKCVSA-N histrelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 HHXHVIJIIXKSOE-QILQGKCVSA-N 0.000 description 1
- 229960003911 histrelin acetate Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 238000009474 hot melt extrusion Methods 0.000 description 1
- 102000046485 human PRMT2 Human genes 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002429 hydrazines Chemical class 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003521 interferon alfa-2a Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 229960005280 isotretinoin Drugs 0.000 description 1
- 229960002014 ixabepilone Drugs 0.000 description 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 150000002680 magnesium Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940072082 magnesium salicylate Drugs 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-UHFFFAOYSA-N n-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amin Chemical compound C1CCC(C(=O)NNC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)C(COC(C)(C)C)NC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 BLCLNMBMMGCOAS-UHFFFAOYSA-N 0.000 description 1
- WPEWQEMJFLWMLV-UHFFFAOYSA-N n-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide Chemical compound C=1C=CN=C(NCC=2C=CN=CC=2)C=1C(=O)NC(C=C1)=CC=C1C1(C#N)CCCC1 WPEWQEMJFLWMLV-UHFFFAOYSA-N 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960003940 naproxen sodium Drugs 0.000 description 1
- CDBRNDSHEYLDJV-FVGYRXGTSA-M naproxen sodium Chemical compound [Na+].C1=C([C@H](C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CDBRNDSHEYLDJV-FVGYRXGTSA-M 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007837 negative regulation of B cell activation Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 125000005188 oxoalkyl group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 238000010951 particle size reduction Methods 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- FHHJDRFHHWUPDG-UHFFFAOYSA-N peroxysulfuric acid Chemical compound OOS(O)(=O)=O FHHJDRFHHWUPDG-UHFFFAOYSA-N 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 108010056274 polo-like kinase 1 Proteins 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920001987 poloxamine Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- JDOZJEUDSLGTLU-VWUMJDOOSA-N prednisolone phosphate Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP(O)(O)=O)[C@@H]4[C@@H]3CCC2=C1 JDOZJEUDSLGTLU-VWUMJDOOSA-N 0.000 description 1
- 229960002943 prednisolone sodium phosphate Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 108010061269 protein kinase D Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000649 purine antagonist Substances 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 239000003790 pyrimidine antagonist Substances 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000013037 reversible inhibitor Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 102220197961 rs1057519784 Human genes 0.000 description 1
- 102220198074 rs1057519859 Human genes 0.000 description 1
- 102200152078 rs1057520045 Human genes 0.000 description 1
- 102200003101 rs113994087 Human genes 0.000 description 1
- 102200003102 rs863225281 Human genes 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229960000714 sipuleucel-t Drugs 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 1
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 150000003462 sulfoxides Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- FMLPQHJYUZTHQS-QMMMGPOBSA-N tert-butyl (3s)-3-methylpiperazine-1-carboxylate Chemical compound C[C@H]1CN(C(=O)OC(C)(C)C)CCN1 FMLPQHJYUZTHQS-QMMMGPOBSA-N 0.000 description 1
- DMBQNPSOTXYUBO-UHFFFAOYSA-N tert-butyl 1,2,3,4-tetrahydropyridine-6-carboxylate Chemical compound CC(C)(C)OC(=O)C1=CCCCN1 DMBQNPSOTXYUBO-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- NBRKLOOSMBRFMH-UHFFFAOYSA-N tert-butyl chloride Chemical class CC(C)(C)Cl NBRKLOOSMBRFMH-UHFFFAOYSA-N 0.000 description 1
- IEUIEMIRUXSXCL-UHFFFAOYSA-N tert-butyl n-(3-aminophenyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=CC=CC(N)=C1 IEUIEMIRUXSXCL-UHFFFAOYSA-N 0.000 description 1
- DGDARTXQYQWIDD-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1.CC(C)(C)OC(=O)N1CCCCC1 DGDARTXQYQWIDD-UHFFFAOYSA-N 0.000 description 1
- 108091008743 testicular receptors 4 Proteins 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 125000003441 thioacyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000005323 thioketone group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229960001196 thiotepa Drugs 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06K—GRAPHICAL DATA READING; PRESENTATION OF DATA; RECORD CARRIERS; HANDLING RECORD CARRIERS
- G06K19/00—Record carriers for use with machines and with at least a part designed to carry digital markings
- G06K19/06—Record carriers for use with machines and with at least a part designed to carry digital markings characterised by the kind of the digital marking, e.g. shape, nature, code
- G06K19/067—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components
- G06K19/07—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips
- G06K19/0723—Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards also with resonating or responding marks without active components with integrated circuit chips the record carrier comprising an arrangement for non-contact communication, e.g. wireless communication circuits on transponder cards, non-contact smart cards or RFIDs
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
- G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
- G06Q20/341—Active cards, i.e. cards including their own processing means, e.g. including an IC or chip
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q20/00—Payment architectures, schemes or protocols
- G06Q20/30—Payment architectures, schemes or protocols characterised by the use of specific devices or networks
- G06Q20/34—Payment architectures, schemes or protocols characterised by the use of specific devices or networks using cards, e.g. integrated circuit [IC] cards or magnetic cards
- G06Q20/349—Rechargeable cards
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Business, Economics & Management (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Microelectronics & Electronic Packaging (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Computer Networks & Wireless Communication (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Strategic Management (AREA)
- Accounting & Taxation (AREA)
- General Business, Economics & Management (AREA)
- Computer Hardware Design (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cash Registers Or Receiving Machines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
本公开包括式(I)的化合物,其中Q1、Q2、Q3、W、X、Y、Z1、m、n、弹头(warhead)、R1、R2、R3、R4和R5在本文中定义。还公开了用这些化合物治疗新生物性疾病、自身免疫性疾病和炎性病症的方法
Description
对相关申请的交叉引用
本申请根据35 U.S.C.119(e)要求于2018年2月19日提交的美国临时专利申请号62/631,945的申请目的权益,其全部内容通过引用并入本文。
发明背景
Bruton酪氨酸激酶(Btk)是Tec家族的非受体蛋白激酶,在大多数造血细胞如B细胞、肥大细胞和巨噬细胞中表达,但在T细胞、自然杀伤细胞和浆细胞中不表达[Smith,C.I.et a1.Journal of Immunology(1994),152(2),557-65]。Btk是BCR和FcR信号传导途径的关键部分,并且对Btk的靶向抑制是一种治疗许多不同人类疾病(如B细胞恶性肿瘤、自身免疫性疾病和炎性病症)的新方法[Uckun,Fatih M.et al,Anti-Cancer Agents inMedicinal Chemistry(2007),Shinohara et al,Cell 132(2008)pp794-806;Pan,Zhengying,Drug News&Perspectives(2008),21(7);7(6),624-632;Gilfillan et al,Immunological Reviews 288(2009)pp 149-169;Davis et a1,Nature,463(2010)pp 88-94]。
共价Bruton酪氨酸激酶(BTK)抑制剂(包括伊布替尼(ibrutinib)和acalabrutinib)已经改变了一些BTK依赖性B细胞恶性肿瘤的治疗方式,所述B细胞恶性肿瘤包括慢性淋巴细胞性白血病、Waldenstrom巨球蛋白血症、套细胞淋巴瘤和边缘区淋巴瘤。尽管伊布替尼在B细胞恶性肿瘤中具有令人印象深刻的临床反应,但仍出现原发性和继发性抗性病例,其中预后不良且治疗选择有限。对不可逆的BTK抑制剂(如伊布替尼)产生抗性的大多数CLL患者都发生BTK-C481S突变。据报道,80%的复发CLL的患者将具有C481S突变[Maddocks KJ,et a1..JAMA Onco1.2015;1:80-87]。俄亥俄州立大学的另一个研究小组在Journal of Clinical Oncology[Vol 35,第13号,2017,第1437页]上报道,在第四年,约有20%的使用伊布替尼的患者有临床进展。在这些复发的患者中,85%获得了C481S突变。此外,这些突变平均在复发前九个月内被检测到。
尽管BTK抑制剂如伊布替尼和ACP-196对本领域做出了重大贡献,但强烈需要在本领域继续寻找高效力且选择性的BTK甲制剂,所述BTK抑制剂不仅可以不可逆地抑制WTBTK,而且还可逆地抑制C481S突变体BTK。
发明概述
本发明涉及一类有力且选择性的Btk抑制剂,其合理地设计为不仅不可逆地抑制WT BTK,而且还可逆地抑制C481S突变体BTK。因此,本发明的化合物可以用于治疗对第一代BTK抑制剂如伊布替尼和ACP-196(Acalabrutinib)具有抗性/难治性的患者,特别是具有BTK C481S突变的患者。本发明的化合物可以用于治疗患有疾病如自身免疫性疾病或炎性病症的患者。
在一方面,本发明涉及式(I)的化合物或其N-氧化物,或所述式(I)的化合物或其N-氧化物的药学上可接受的盐、溶剂合物、多形体、互变异构体、立体异构体、同位素形式或前药:
其中
Q1是5-6元芳基或杂芳基;
Q2是5-7元杂环烷基或杂芳基;
Q3是5元杂芳基;
W、X、Y、Z1各自独立是C(Ra)或N;
R1和R5各自独立是H、D、烷基、螺烷基、烯基、炔基、环烷基、环烯基、杂环烷基、螺杂环烷基、杂环烯基、芳基、杂芳基、卤代、硝基、氧代、氰基、ORa、SRa、烷基-Ra、NH(CH2)pRa、C(O)Ra、S(O)Ra、SO2Ra、C(O)ORa、OC(O)Ra、NRbRc、C(O)N(Rb)Rc、N(Rb)C(O)Rc、-P(O)RbRc、-烷基-P(O)RbRc、-S(O)(=N(Rb))Rc、-N=S(O)RbRc、=NRb、SO2N(Rb)Rc或N(Rb)SO2Rc,其中所述环烷基、环烯基、杂环烷基、杂环烯基、芳基、杂芳基任选地用一个或多个Rd取代;
R2是H或烷基;
R3是H、卤代、烷基、卤代烷基或羟基烷基;
R4是H、卤代或低烷基;
R1基团的两个与其附接的原子一起可以任选地形成任选地用一个或多个Rd取代的环烷基或杂环烷基;
R5基团的两个与其附接的原子一起可以任选地形成任选地用一个或多个Rd取代的环烷基或杂环烷基;
Ra、Rb、Rc和Rd独立是H、D、烷基、螺烷基、烯基、炔基、卤代、氰基、胺、硝基、羟基、=O、-P(O)RbRc、-烷基-P(O)RbRc、-S(O)(=N(Rb))Rc、-N=S(O)RbRc、=NRb、C(O)NHOH、C(O)OH、C(O)NH2、烷氧基、烷氧基烷基、卤代烷基、羟基烷基、氨基烷基、烷基羰基、烷氧基羰基、烷基羰基氨基、烷基氨基、氧代、卤代-烷基氨基、环烷基、环烯基、杂环烷基、螺杂环烷基、杂环烯基、芳基或杂芳基,其中所述烷基、环烷基、环烯基、杂环烷基、杂环烯基、芳基、杂芳基任选地用一个或多个Re取代;
Re是H、D、烷基、螺烷基、烯基、炔基、卤代、氰基、胺、硝基、羟基、=O、C(O)NHOH、烷氧基、烷氧基烷基、卤代烷基、羟基烷基、氨基烷基、烷基羰基、烷氧基羰基、烷基羰基氨基、烷基氨基、氧代、卤代-烷基氨基、环烷基、环烯基、杂环烷基、螺杂环烷基、杂环烯基、芳基或杂芳基;
m、n、p和q各自独立是0、1、2、3或4;并且
弹头(warhead)是
在一个优选的实施方案中,化合物以式(II)表示:
其中
k是0、1或2;
s是0、1、2或3;并且
Q4是5-7元环烷基、环烯基、杂环烷基或杂环烯基;并且其余变量如式(I)所定义。
在一个更优选的实施方案中,化合物以式(III)表示:
其中
r是0、1、2或3;并且其余变量如式(I)或式(II)所定义。
在一个更优选的实施方案中,化合物以式(IV)表示:
其中
k是1或2;并且
r是1或2;并且其余变量如式(I)或式(II)所定义。
本发明的化合物可以含有一个或多个不对称碳原子。因此,化合物可以以非对映异构体、对映异构体或其混合物存在。每个不对称碳原子可以为R或S构型,并且这两种构型在本发明的范围内。
还考虑了此类化合物中的任一种的经修饰的化合物,包括与未修饰的化合物相比具有改善的(例如,增强的,更大的)药物溶解性、稳定性、生物利用度和/或治疗指数的修饰。示例性的修饰包括(但不限于)适用的前药衍生物和富含氘的化合物。
应当认识到,本发明的化合物可以以盐或溶剂合物的形式存在并以此形式任选施用。本发明涵盖上述化合物及其修饰中任一种的任何药学上可接受的盐和溶剂合物。
用于治疗新生物性疾病、自身免疫性疾病和炎性病症的药物组合物、其治疗用途和化合物在制备用于治疗疾病/病症的药物中的用途也在本发明的范围内,所述药物组合物含有上述一种或多种化合物、其修饰和/或盐。
本发明还涉及通过向有此需要的受试者施用有效量的上述一种或多种化合物、其修饰和/或盐和组合物治疗新生物性疾病的方法,特别是B细胞恶性肿瘤,包括但不限于B细胞淋巴瘤、淋巴瘤(包括霍奇金淋巴瘤和非霍奇金淋巴瘤)、毛细胞淋巴瘤、小淋巴细胞性淋巴瘤(SLL)、套细胞淋巴瘤(MCL)和弥漫性大B细胞淋巴瘤(DLBCL)、多发性骨髓瘤、慢性和急性骨髓性白血病以及慢性和急性淋巴细胞性白血病。
可以使用根据本发明的化合物和组合物影响的自身免疫性和/或炎性疾病包括但不限于:银屑病、变态反应、克罗恩氏病、肠易激综合征、干燥综合征(Sjogren’s disease)、组织移植物排斥和移植器官的超急性排斥、哮喘、系统性红斑狼疮(及相关的肾小球肾炎)、皮肌炎、多发性硬化、硬皮病、血管炎(ANCA相关和其他血管炎病)、自身免疫性溶血和血小板减少状态、肺出血肾炎综合征(Goodpasture′s syndrome)(及相关的肾小球肾炎和肺出血)、动脉粥样硬化、类风湿关节炎、慢性特发性血小板减少性紫癜(ITP)、艾迪生氏病(Addison′s disease)、帕金森氏病、阿尔茨海默氏病、糖尿病、败血性休克和重症肌无力。
在下面的描述中阐述了本发明的一个或多个实施方案的细节。通过说明书和权利要求书,本发明的其他特征、目的和优点将变得明显。应当理解,本文所述的本发明的所有实施方案/特征(化合物、药物组合物、制备/使用方法等),包括实施例和原始权利要求书中所述的任何特定特征可以彼此组合,除非不适用或明确排除。
发明详述
本文所述的示例性化合物包括但不限于以下:
N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
(E)-N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)-4-(二甲基氨基)丁-2-烯酰胺、
(R)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(3-(二甲基氨基)吡咯烷-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丙烯酰胺、
N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(2-(4-(4,4-二氟环己基)-2-甲基哌嗪-1-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-4-(2,6-二甲基四氢-2H-吡喃-4-基)-2-甲基哌嗪-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(甲基(氧杂环丁烷-3-基)氨基)哌啶-1-基)苯基)丙烯酰胺、
N-(2-((2′S)-4,4-二氟-2′-甲基-[1,4′-联哌啶]-1′-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(2-((2S)-4-(3,3-二氟吡咯烷-1-基)-2-甲基哌啶-1-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-4-(二甲基氨基)-2-甲基哌啶-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)一3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(1-(氧杂环丁烷-3-基)哌啶-4-基)苯基)丙烯酰胺、
N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(1-(氧杂环丁烷-3-基)哌啶-4-基)苯基)丙烯酰胺、
N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)丙烯酰胺、
N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-5-((4-甲基哌嗪-1-基)甲基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丁-2-炔酰胺、
N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丁-2-炔酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丁-2-炔酰胺、
N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丁-2-炔酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丁-2-炔酰胺、
(S)-N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丁-2-炔酰胺、
(Z)-2-氰基-N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)-4-甲基-4-(4-(氧杂环丁烷-3-基)哌嗪-1-基)戊-2-烯胺、
(Z)-2-氰基-N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)-4-甲基-4-(4-甲基哌嗪-1-基)戊-2-烯胺、
(Z)-2-氰基-N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)-4-甲基-4-(甲基(氧杂环丁烷-3-基)氨基)戊-2-烯胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-(4-甲基哌嗪-1-基)丙-2-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-吗啉代丙-2-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-(甲基(氧杂环丁烷-3-基)氨基)丙-2-基)苯基)丙烯酰胺、
N-(2-(2-(4,4-二氟哌啶-1-基)丙-2-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(2-(2-(3,3-二氟吡咯烷-1-基)丙-2-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-(4-(氧杂环丁烷-3-基)哌嗪-1-基)丙-2-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-1-吗啉代丙-2-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-1-(4-甲基哌嗪-1-基)丙-2-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(哌啶-3-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪e-1-羰基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(2-(4-(4,4-二氟环己基)-2-甲基哌嗪-1-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
N-(2-(4,4-二氟-[1,4′-联哌啶]-1′-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-氟-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-甲基-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)-3-(三氟甲基)苯基)丙烯酰胺、
(S)-N-(3-氰基-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-(异丙基磺酰基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)-3-((三氟甲基)磺酰基)苯基)丙烯酰胺、
N-(2-((2′S)-4,4-二氟-2′-甲基-[1,4′-联哌啶]-1′-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺。
本发明的化合物可以含有一个或多个不对称碳原子。因此,化合物可以以非对映异构体、对映异构体或其混合物存在。化合物的合成可以采用外消旋体、非对映异构体或对映异构体作为起始材料或中间体。非对映异构化合物可以通过层析或结晶法分离。类似地,对映体混合物可以使用相同的技术或本领域已知的其他技术分离。每个不对称碳原子可以为R或S构型,并且这两种构型在本发明的范围内。
也涵盖任何一种此类化合物的经修饰的化合物,包括与未修饰的化合物相比具有改善的(如,增强的、更大的)药学溶解度、稳定性、生物利用性和/或治疗指数的修饰。修饰的实例包括但不限于前药衍生物和氘富集的化合物。例如:
·前药衍生物:当对受试者施用时,前药将在体内转化为本发明的活性化合物[Nature Reviews of Drug Discovery,2008,Volume 7,p255]。注意到,在多个实例中,前药自身也落入根据本发明的化合物的范围范畴内。本发明的化合物的前药可通过标准有机反应制备,例如,通过与氨甲酰化剂(如,1,1酰氧烷基氯化碳(1,1-acyloxyalkylcarbonochloridate)、碳酸对硝基苯酯(para-nitrophenyl carbonate)等)或酰化剂反应制备。制备前药的方法及策略的其他实例记载于Bioorganic and MedicinalChemistry Letters,1994,Vo1.4,p.1985。
·氘富集的化合物:氘(D或2H)是氢的稳定的非放射性同位素,并且具有2.0144的原子量。氢天然作为同位素XH(氢或氕)、D(2H或氘)、及T(3H或氚)的混合物存在。氘的天然丰度是0.015%。本领域技术人员认识到在所有具有H原子的化合物中,H原子实际上以H和D的混合物表示,约0.015%是D。因此,具备已经富集至大于其天然丰度0.015%的氘含量的化合物应视为非天然的,因此相对于其非富集的对应体是新的。
应当认识到,本发明的化合物可以以盐及溶剂合物的形式存在并以此形式任选施用。例如,根据本领域中公知的过程,将本发明的化合物转化为衍生自多种有机酸和无机酸以及有机碱和无机碱的其药学上可接受的形式并以此形式使用该化合物,处于本发明的范围内。
当本发明的化合物拥有游离碱形式时,可通过使游离碱形式的化合物与药学上可接受的无机酸或有机酸反应而将该化合物制备为药学上可接受的酸加成盐,例如,氢卤酸盐,如盐酸盐、氢溴酸盐、氢碘酸盐;其他矿物酸,如硫酸盐、硝酸盐、磷酸盐等;以及烷基和单芳基磺酸盐如乙磺酸盐、甲苯磺酸盐和苯磺酸盐;以及其他有机酸及其相对应的盐,如醋酸盐、酒石酸盐、马来酸盐、琥珀酸盐、柠檬酸、苯甲酸盐、水杨酸盐和抗坏血酸盐。本发明的其他酸加成盐包括但不限于:己二酸盐、藻酸盐、精氨酸盐、天冬氨酸盐、硫酸氢盐、亚硫酸氢盐、溴化物、丁酸盐、樟脑酸盐、樟脑磺酸盐、辛酸盐、盐酸盐、氯苯甲酸盐、环戊基丙酸盐、双葡萄糖酸盐、磷酸二氢盐、二硝基苯甲酸盐、十二烷基硫酸盐、延胡索酸盐、半乳糖酸盐(来自粘酸)、半乳糖醛酸盐、葡庚糖酸盐、葡萄糖酸盐、谷氨酸盐、甘油磷酸盐、半琥珀酸盐、半硫酸盐、庚酸盐、己酸盐、马尿酸盐、2-羟基乙磺酸盐、碘化物、羟乙基磺酸盐、异丁酸盐、乳酸盐、乳糖醛酸盐、丙二酸盐、扁桃酸盐、偏磷酸盐、甲磺酸盐、甲基苯甲酸盐、磷酸一氢盐、2-萘磺酸盐、烟酸盐、草酸盐、油酸盐、双羟萘酸盐、果胶酸盐、过硫酸盐、苯乙酸盐、3-苯基丙酸盐、膦酸酯及邻苯二甲酸盐。应当理解,游离碱形式的物理性质,如在极性溶剂中的溶解度,典型地在某种程度上不同于其各自的盐形式,但用于本发明的目的时,该盐与其各自的游离碱形式等效。
当本发明的化合物拥有游离酸形式时,可通过使游离酸形式的化合物与药学上可接受的无机碱或有机碱反应而制备药学上可接受的碱加成盐。此类碱的实例是碱金属氢氧化物,包括氢氧化钾、氢氧化钠和氢氧化锂;碱土金属氢氧化物,如氢氧化钡和氢氧化钙;碱金属烷氧化物,如乙醇钾和丙醇钠;以及各种有机碱,如氢氧化铵、哌啶、二乙醇胺和N-甲基谷氨酰胺。还包括本发明的化合物的铝盐。本发明的其他碱加成盐包括但不限于:铜盐、铁盐、亚铁盐、锂盐、镁盐、锰盐、亚锰盐、钾盐、钠盐和锌盐。有机碱加成盐包括但不限于伯胺盐、仲胺盐、叔胺盐、包括天然存在的取代胺在内的取代胺的盐、环状胺的盐和碱性离子交换树脂的盐,如精氨酸、甜菜碱、咖啡因、氯普鲁卡因(chloroprocaine)、胆碱、N,N’-二苄基乙二胺(苄星青霉素(benzathine))、二环己基胺、二乙醇胺、2-二乙基氨基乙醇、2-二甲氨基乙醇、乙醇胺、乙二胺、N-乙基吗啉、N-乙基哌啶、还原葡糖胺(glucamine)、葡糖胺、组氨酸、海巴明青霉素(hydrabamine)、异丙胺、利多卡因(1idocaine)、赖氨酸、葡甲胺、N-甲基-D-葡糖胺、吗啉、哌嗪、哌啶、聚胺树脂、普鲁卡因(procaine)、嘌呤、可可碱、三乙醇胺、三乙胺、三甲胺、三丙胺和三(羟基甲基)甲胺(氨丁三醇)。应当理解,游离酸形式的物理性质,如在极性溶剂中的溶解度,典型地在某种程度上不同于其各自的盐形式,但用于本发明的目的时,该盐与其各自的游离酸形式等效。
在一方面,药学上可接受的盐是盐酸盐、氢溴酸盐、甲磺酸盐、甲苯磺酸盐、醋酸盐、延胡索酸盐、硫酸盐、硫酸氢盐、琥珀酸盐、柠檬酸盐、磷酸盐、马来酸盐、硝酸盐、酒石酸盐、苯甲酸盐、碳酸氢盐、碳酸盐、氢氧化钠盐、氢氧化钙盐、氢氧化钾盐、氨丁三醇盐、或其混合物。
本发明的包含含有叔氮的基团的化合物可使用例如下述试剂季胺化:(C1-4)烷基卤化物,如甲基、乙基、异丙基及叔丁基的氯化物、溴化物和碘化物;硫酸二(C1-4)烷基酯,如硫酸二甲酯、硫酸二乙酯和硫酸二戊酯;烷基卤化物,如癸基、十二烷基、月桂基、肉豆蔻基和硬脂基的氯化物、溴化物和碘化物;以及芳基(C1-4)烷基卤化物,如苄基氯和苯乙基溴。此类盐允许制备本发明的水溶性和油溶性化合物两者。
具有叔氮原子的抗癌剂的氨氧化物,亦称氨-N-氧化物和N-氧化物,已经作为前药被研发[Mol Cancer Therapy.2004Mar;3(3):233-44]。包含叔氮原子的本发明的化合物可通过试剂,例如过氧化氢(H2O2)、Caro酸或过酸如间氯过氧苯甲酸(mCPBA)氧化以形成氨氧化物。
本发明涵盖包含本发明的化合物和药物赋形剂,以及其他常规的无药学活性剂的药物组合物。一般用作载体或稀释剂的任何惰性赋形剂均可用于本发明的组合物中,如糖、多元醇、可溶性聚合物、盐和脂质。可采用的糖和多元醇包括但不限于,乳糖、蔗糖、甘露醇、及山梨醇。例示性的可采用的可溶性聚合物为聚氧乙烯、泊洛沙姆(poloxamer)、聚乙烯基吡咯烷酮、及葡聚醣。可用的盐包括但不限于氯化钠、氯化镁和氯化钙。可采用的脂质包括但不限于脂肪酸、甘油脂肪酸酯、糖脂质、及磷脂质。
此外,药物组合物可以进一步包含粘合剂(如,阿拉伯胶、玉米淀粉、明胶、卡波姆、乙基纤维素、瓜尔胶、羟丙基纤维素、羟丙基甲基纤维素、聚维酮)、崩解剂(如,玉米淀粉、马铃薯淀粉、藻酸、二氧化硅、交联羧甲基纤维素钠、交聚维酮、瓜尔胶、羧基乙酸淀粉钠、Primogel)、各种pH和离子强度的缓冲剂(如,tris-HCL、醋酸盐、磷酸盐)、用以防止吸收至表面的添加剂如白蛋白或明胶、洗涤剂(如,Tween 20、Tween 80、Pluronic F68、胆汁酸盐)、蛋白酶抑制剂、表面活性剂(如,月桂基硫酸钠)、渗透促进剂、增溶剂(如,甘油、聚乙烯甘油、环糊精)、助流剂(如,胶体二氧化硅)、抗氧化剂(如,抗坏血酸、偏亚硫酸氢钠、丁酸化羟基苯甲醚)、稳定剂(如,羟丙基纤维素、羟丙基甲基纤维素)、黏度增强剂(如,卡波姆、胶体二氧化硅、乙基纤维素、瓜尔胶)、甜味剂(如,蔗糖、阿斯巴甜、柠檬酸)、芳香剂(如,薄荷油、水杨酸甲酯、或橙味剂)、防腐剂(如,硫柳汞、苯甲醇、对羟基苯甲酸酯类)、润滑剂(如,硬脂酸、硬脂酸镁、聚乙二醇、月桂基硫酸钠)、流动助剂(如,胶体二氧化硅)、增塑剂(如,对苯二甲酸二乙酯、柠檬酸三乙酯)、乳化剂(如,卡波姆、羟丙基纤维素、月桂基硫酸钠、甲基纤维素、羟乙基纤维素、羧甲基纤维素钠)、聚合物涂层(如,泊洛沙姆或泊洛沙胺)、涂层及膜形成剂(如,乙基纤维素、丙烯酸酯、聚甲基丙烯酸酯)及/或佐剂。
在一个实施方案中,药物组合物制备为具有会保护该化合物不被从身体快速清除的载体,如控释配制剂,包括植入物和微胶囊化的递送系统。可使用生物可降解的、生物相容的聚合物,如乙烯-醋酸乙烯酯、聚酸酐、聚乙醇酸、胶原、聚原酸酯、及聚乳酸。制备此类配制剂的方法对于本领域技术人员是明显的。材料亦可从Alza Corporation和NovaPharmaceuticals,Inc商购。脂质体悬浮体(包括用针对病毒抗原的单克隆抗体靶向到感染细胞的脂质体)也可用作药学上可接受的载体。这些可根据本领域技术人员已知的方法制备,例如如US专利号4,522,811中描述。
另外,本发明涵盖包含任何固体或液体物理形式的本发明化合物的药物组合物。例如,化合物可以是晶体形式或无定形的形式,且具有任何粒径。该颗粒可以是微粒化的或者可以是成块的微粒、粉末、油、油状悬浮体或任何其他固体或液体物理形式。
当根据本发明的化合物展现不足够的溶解度时,可使用使化合物增溶的方法。此类方法是本领域技术人员已知的,且包括但不限于,pH调节和盐形成;使用共溶剂如乙醇、丙二醇、聚乙二醇(PEG)300、PEG 400、DMA(10-30%)、DMSO(10-20%)、NMP(10-20%);使用表面活性剂如聚山梨醇酯80、聚山梨醇酯20(1-10%)、cremophor EL、Cremophor RH40、Cremophor RH60(5-10%)、Pluronic F68/Poloxamer 188(20-50%)、Solutol HS15(20-50%)、维生素ETPGS、以及d-α-生育酚PEG 1000琥珀酸酯(20-50%);使用络合作用如HPβCD和SBEβCD(10-40%);以及使用先进的途径,如胶束、聚合物的加入、纳米颗粒悬浮体、以及脂质体形成。
极其多种施用方法可与本发明的化合物联用。本发明的化合物可口服、胃肠外、腹膜内、静脉内、动脉内、透皮、舌下、肌肉内、直肠、经口含、鼻内、脂质体、经由吸入、阴道、眼内、经由局部递送(例如,通过导管或支架)、皮下、脂肪内、关节内、或鞘内施用或组合施用。根据本发明的化合物亦可以缓释剂型施用或共施用。化合物可以是气体、液体、半液体或固体形式,以适用于待使用的施用途径的模式配制。对于口服施用,适当的固体口服配制剂包括片剂、胶囊剂、丸剂、颗粒剂、微丸剂、囊剂和泡腾剂、粉末剂等。适当的液体口服配制剂包括溶液、悬浮体、分散体、乳液、油等。对于胃肠外施用,典型使用冻干粉末的重建。
如本文中使用,“酰基”指以式-C(O)-R表示的含有羰基的取代基,其中,R是H、烷基、碳环、杂环、碳环取代的烷基或杂环取代的烷基,其中,该烷基、烷氧基、碳环和杂环如本文中定义。酰基包括烷酰基(如,乙酰基)、芳酰基(如,苯甲酰基)、及杂芳酰基。
“脂肪族”指以构造碳原子的直链或支链排列为特征的部分,且可以是饱和的,或是具有一个或多个双键或三键的部分不饱和的。
术语“烷基”指含有1至20个碳原子的直链或支链烃(如,C1-C10)。烷基的实例包括但不限于,甲基、亚甲基、乙基、亚乙基、正丙基、异丙基、正丁基、异丁基和叔丁基。优选地,烷基具有1至10个碳原子。更优选地,烷基具有1至4个碳原子。
术语“烯基”指含有2至20个碳原子(如,C2-C10)和一个或多个双键的直链或支链烃。烯基的实例包括但不限于乙烯基、丙烯基和烯丙基。优选地,烯基具有2至10个碳原子。更优选地,烯基具有2至4个碳原子。
术语“炔基”指含有2至20个碳原子(如,C2-C10)和一个或多个三键的直链或支链烃。炔基的实例包括但不限于乙炔基、1-丙炔基、1-丁炔基和2-丁炔基和1-甲基-2-丁炔基。优选地,炔基具有2至10个碳原子。更优选地,炔基具有2至4个碳原子。
术语“烷基氨基”指-N(R)-烷基,其中R可以是H、烷基、烯基、炔基、环烷基、环烯基、杂环烷基、杂环烯基、芳基、或杂芳基。
“烷氧基”指具有进一步烷基取代基的氧部分。
“烷氧基羰基”指附接至羰基的烷氧基。
“氧代烷基”指进一步经羰基取代的烷基。该羰基可以是醛、酮、酯、酰胺、酸或酰氯。
术语“环烷基”指具有3至30个碳原子(如,C3-C12,C3-C8,C3-C6)的饱和烃环系统。环烷基的实例包括但不限于,环丙基、环丁基、环戊基、环己基、环庚基、及环辛基。术语“环烯基”指具有3至30个碳原子(如,C3-C12)和一个或多个双键的非芳烃环系统。实例包括环戊烯基、环己烯基、及环庚烯基。
术语“杂环烷基”指非芳香族的5至8元的单环状、8至12元的双环状、或11至14元的三环状的环系统,该环系统具有一个或多个杂原子(如,O、N、S、P或Se)。杂环烷基的实例包括但不限于哌嗪基、吡咯烷基、二口恶烷基、吗啉基和四氢呋喃基。
术语“杂环烯基”指非芳香族的5至8元的单环状、8至12元的双环状、或11至14元的三环状的环系统,该环系统具有一个或多个杂原子(如,O、N、S、P或Se)和一个或多个双键。
术语“芳基”指6个碳原子的单环状、10个碳原子的双环状、14个碳原子的三环状的芳环系统。芳基的实例包括但不限于,苯基、萘基和蒽基。术语“杂芳基”指5至8元的单环状、8至12元的双环状、或11至14元的三环状的芳香族环系统,该环系统具有一个或多个杂原子(如,O、N、S、P、或Se)。杂芳基的实例包括吡啶基、呋喃基、咪唑基、苯并咪唑基、嘧啶基、噻吩基、喹啉基、吲哚基和噻唑基。
上文提及的烷基、烯基、炔基、环烷基、杂环烷基、环烯基、杂环烯基、烷基氨基、芳基和杂芳基包括取代部分和非取代部分两者。位于烷基氨基、环烷基、杂环烷基、环烯基、杂环烯基、芳基和杂芳基上的可能的取代基包括但不限于,C1-C10烷基、C2-C10烯基、C2-C10炔基、C3-C20环烷基、C3-C20环烯基、C1-C20杂环烷基、C1-C20杂环烯基、C1-C10烷氧基、芳基、芳氧基、杂芳基、杂芳氧基、氨基、C1-C10烷基氨基、芳基氨基、羟基、卤素、氧代(O=)、硫代(S=)、硫基、硅基、C1-C10烷硫基、芳硫基、C1-C10烷基磺酰基、芳基磺酰基、酰基氨基、氨基酰基、氨基硫代酰基、脒基、巯基、酰氨基、硫脲基、硫氰酸酯基、磺酰胺基、胍、脲基、氰基、硝基、酰基、硫代酰基、酰氧基、脲基、氨甲酰基、羧基和羧酸酯。另一方面,位于烷基、烯基或炔基上的可能的取代基包括除C1-C10烷基以外的上文提及的全部取代基。环烷基、环烯基、杂环烷基、杂环烯基、芳基和杂芳基也可彼此稠合。
“氨基”指进一步具有两个取代基的氮部分,其中,每个取代基具有与氮进行α键结的氢或碳原子。除非明确指出,否则本发明的含有氨基部分的化合物可包括其经保护的衍生物。用于氨基部分的适当的保护基包括乙酰基、叔丁氧羰基、苄氧羰基等。
“芳香族”指如下部分,其中构造原子构成不饱和的环系统,该环系统中所有原子均为sp2杂化,且π电子总数等于4n+2。芳香族环可以使得环原子仅为碳原子或可包括碳原子和非碳原子(见杂芳基)。
“氨甲酰基”指基团-OC(O)NRaRb,其中Ra和Rb各自独立为两个进一步的取代基,该取代基中,氢或碳原子位于氮的α位。注意,氨甲酰基部分可包括其经保护的衍生物。适用于氨甲酰基部分的保护基的实例包括乙酰基、叔丁氧羰基、苄氧羰基等。注意,未保护的衍生物和经保护的衍生物均落入本发明的范围内。
“羰基”指基团-C(O)-。注意,羰基可进一步经多种取代基取代以形成不同的羰基,包括酸、酰卤、酰胺、酯和酮。
“羧基”指基团-C(O)O-。注意,本发明的含有羧基部分的化合物可包括其经保护的衍生物,即,其中氧原子经保护基取代。适用于羧基部分的保护基包括苄基、叔丁基等。
“氰基”指基团-CN。
“甲酰基”指基团-CH=O。
“亚胺甲基”指基团-HC=NH。
“卤素”指氟、氯、溴或碘。
作为分离的基团或较大基团的一部分,“卤素取代的烷基”指经一个或多个“卤素”原子取代的“烷基”,此类术语如本申请中所定义。卤素取代的烷基包括卤代烷基、二卤代烷基、三卤代烷基、全卤代烷基等。
“羟基”指基团-OH。
“亚胺衍生物”指包含-C(=NR)-部分的衍生物,其中R包含位于该氮的α位的氢或碳原子。
“异构体”意为任何具有相同分子式,但其原子键结的特性或序列不同或其原子在空间中的排列不同的化合物。其原子在空间中的排列不同的异构体称为“立体异构体”。彼此不是镜像的立体异构体称为“非对映异构体”,而作为无法重叠的镜像的立体异构体称为“对映异构体”或有时“光学异构体”。键结有四个不同取代基的碳原子称为“手性中心”。具有一个手性中心的化合物具有两种相反手性的对映异构形式。两种对映异构形式的混合物称为“外消旋混合物”。
“硝基”指基团-NO2。
“经保护的衍生物”指化合物的衍生物,其中,反应性位点被保护基所阻断。经保护的衍生物可用于制备药物或其本身可能具有抑制剂活性。适用保护基的综合列表可见于T.W.Greene,Protecting Groups in Organic Synthesis,第3版,Wiley&Sons,1999。
术语“取代的”指原子或原子组已经作为附接至另一基团的取代基替换氢。对于芳基和杂芳基,术语“取代的”指其中此类取代被允许的任何水平的取代,即单取代、二取代、三取代、四取代或五取代。独立选择取代基,且该取代可位于任何化学上可及的位置处。术语“未取代的”指给定部分通过可用的价态可仅由氢取代基组成(未取代的)。
如果官能团描述为“任选取代”,则该官能团可以是(1)没有被取代或(2)经取代。如果官能团的碳描述为任选经一系列取代基中的一个或多个取代,则该碳上的一个或多个氢原子(只要存在,可为任何程度)可独立地及/或一起被替换为独立选定的任选的取代基。
“硫化物”意为-S-R,其中,R是H、烷基、碳环、杂环、碳环烷基或杂环烷基。具体的硫化物基团是巯基;烷基硫化物,例如,甲基硫化合物(-S-Me);芳基硫化合物,如苯基硫化合物;芳烷基硫化合物,如,苄基硫化合物。
“亚磺酰基”意为基团-S(O)-。注意,亚磺酰基可进一步经多种取代基取代以形成不同的亚磺酰基团,包括亚磺酸、亚磺酰胺、亚磺酸酯和亚砜。
“磺酰基”意为基团-S(O)(O)-。注意,磺酰基团可进一步经多种取代基取代以形成不同的磺酰基团,包括磺酸、磺酰胺、磺酸酯和砜。
“硫代羰基”意为基团-C(S)-。注意,硫代羰基可进一步经多种取代基取代以形成不同的硫代羰基,包括硫代酸、硫代酰胺、硫代酯、和硫代酮。
“动物”包括人、非人类哺乳动物(如,非人灵长动物、啮齿动物、小鼠、大鼠、仓鼠、狗、猫、兔、牛、马、绵羊、山羊、猪、鹿等)和非哺乳动物(如,鸟类等)。
如本文中使用的“生物利用度”是施用剂量的药物或药物组合物中,完整到达体循环的分数或百分比。通常,当静脉内施用药物时,其生物利用度是100%。但当经由其他途径(如,口服)施用药物时,其生物利用度下降(如,由于不完全吸收和首过代谢而造成生物利用度下降)。改善生物利用度的方法包括前药途径、盐合成、减小粒径、络合、改变物理形态、固体分散体、喷射干燥和热熔融挤出。
“疾病”具体包括动物或其部位的任何不健康状况,且包括可能由施加至该动物的医疗或兽药治疗造成或伴随医疗或兽药治疗的不健康状况,即,此类疗法的“副作用”。
“药学上可接受的”指可用于制备药物组合物的通常为安全、非毒性、且既不在生物学上也不在其他方面是不希望的,且包括可为兽医学用途以及人类医药用途所接受的。
“药学上可接受的盐”指本发明的化合物的如上文定义的药学上可接受的有机盐或无机盐,且该盐具备所希望的药理活性。此类盐包括与无机酸或有机酸形成的酸加成盐。药学上可接受的盐也包括碱加成盐,其可在存在能与无机碱或有机碱反应的酸性质子存在时形成。例示性的盐包括但不限于,硫酸盐、柠檬酸盐、醋酸盐、草酸盐、氯化物、溴化物、碘化物、硝酸盐、硫酸氢盐、磷酸盐、酸性磷酸盐、异烟酸盐、乳酸盐、水杨酸盐、酸性柠檬酸盐、酒石酸盐、油酸盐、单宁酸盐、泛酸盐、酒石酸氢盐、抗坏血酸盐、琥珀酸盐、马来酸盐、龙胆酸盐、延胡索酸盐、葡糖酸盐、葡萄糖醛酸盐、蔗糖盐、甲酸盐、苯甲酸盐、谷氨酸盐、甲磺酸盐“去铁胺(mesylate)”、乙磺酸盐、苯磺酸盐、对甲苯磺酸盐、双羟萘酸盐(即,1,1’-亚甲基-双(2-羟基-3-萘甲酸盐))、碱金属(如,钠和钾)盐、碱土金属(如,镁)盐和铵盐。药学上可接受的盐可牵涉纳入另一分子如醋酸根离子、琥珀酸根离子或其他抗衡离子。该抗衡离子可以是任何使母体化合物电荷稳定的有机部分或无机部分。此外,药学上可接受的盐在其结构中可具有超过一个的带电原子。对于多个带电原子作为药学上可接受的盐的一部分的例子,该盐可具有多个抗衡离子。因此,药学上可接受的盐可具有一个或多个带电原子及/或一个或多个抗衡离子。
“药学上可接受的载体”指与本发明的化合物混合以形成药物组合物的无毒溶剂、分散剂、赋形剂、佐剂或其他材料,即能够向患者施用的剂型。药学上可接受的载体的实例包括合适的聚乙二醇(例如PEG400)、表面活性剂(例如Cremophor)或环多糖(例如羟丙基-β-环糊精或磺丁基醚β-环糊精)、聚合物、脂质体、胶束、纳米球等。
如国际纯化学和应用化学联合会(The Intemational Union of Pure andApplied Chemistry)所界定,“药效团”是确保与特定生物学靶点的最优超分子相互作用并触发(或阻断)其生物学应答所必需的空间和电子特征的集合。例如,喜树碱(Camptothecin)是公知的药物拓扑替康(topotecan)和伊立替康(irinotecan)的药效团。氮芥是一系列广泛使用的氮芥药物如美法仑(Melphalan)、环磷酰胺(Cyclophosphamide)、苯达莫司汀(Bendamustine)等的药效团。
“前药”意为一种化合物,其在体内可代谢性地转化为根据本发明的活性药物。例如,包含羟基的抑制剂可以以酯的形式施用,该酯在体内可通过水解转化为羟基化合物。
“稳定性”通常指药物保留其特性而不丧失潜能的时间长度。有时这指货架期。影响药物稳定性的因素还特别包括药物的化学结构、配方中的杂质、pH、含水量、以及环境因素如温度、氧化、光和相对湿度。可通过提供适当的化学及/或晶体修饰(如,可改变水合作用动力学的表面修饰;可具有不同性质的不同晶体)、赋形剂(如,除该剂型中该活性物质外的任何物质)、封装条件、存储条件等来改善稳定性。
本文中描述的组合物的“治疗有效量”指以适用于任何医疗处置的合理的效益/风险比,对所治疗的受试者提供治疗效果的该组合物的量。该治疗效果可以是客观的(即,可通过一些测试或标志物测量)或主观的(即,受试者呈现效果的迹象或感觉)。上述组合物的有效量可以是从约0.1mg/kg至约500mg/kg的范围,优选从约0.2至约50mg/kg。有效剂量还将依据施用途径以及与其他药剂合用的可能性而改变。但应理解,本发明的组合物的每日总剂量将由主治医生在可靠医疗判断的范畴内决定。对于特定患者的具体治疗有效剂量水平将取决于多种因素,包括被治疗的病症和该病症的严重性;所采用的具体化合物的活性;所采用的具体组合物;患者的年龄、体重、一般健康情况、性别和饮食;施用时间、施用途径、以及所采用的具体化合物的排泄速率;治疗的持续时间;与所采用的具体化合物组合使用或同时使用的药物;以及医疗领域公知的类似因素。
如本文中所用,术语“治疗”指将化合物施用于具有新生物性或免疫病症、或具有其症状或素因的受试者,目的为治愈、痊愈、缓解、解除、改变、补救、减轻、改善或影响该病症、该病症的症状或该病症的素因。
术语“有效量”指在该受试者中赋予所希望的疗效所需的活性剂的量。如本领域技术人员所知,有效量可依据施用途径、赋形剂的使用、以及与其他试剂共用的可能性而改变。
“受试者”指人类和非人类动物。非人类动物的实例包括所有脊椎动物,如哺乳动物,如非人灵长动物(尤其是高级灵长动物)、狗、啮齿动物(如,小鼠或大鼠)、豚鼠、猫、和非哺乳动物如鸟类、两栖动物、爬行动物等。在优选的实施方案中,受试者是人类。另一具体实施例中,受试者是实验动物或适合作为疾病模型的动物。
“组合疗法”包括对受试者施用本发明的受试化合物以及与该化合物进一步组合的另一生物活性成分(例如但不限于,第二种且不同的抗新生物剂)和非药物疗法(例如但不限于手术或放射治疗)。例如,本发明的化合物可以与其他药学活性化合物或非药物疗法,优选能够增强本发明化合物的效果的化合物组合使用。本发明的化合物可与其他疗法同时施用(作为单一制剂或分离的制剂)或序贯施用。通常,组合疗法设想在单个治疗周期或单个疗程中施用两种或多种药物/治疗。
在一个实施方案中,本发明的化合物与一种或多种传统化学治疗剂组合施用。传统的化学治疗剂包括肿瘤学领域中的多种治疗方法。为了缩小肿瘤,破坏手术后剩余的剩余癌细胞,诱导缓解,维持缓解和/或减轻与癌症或其治疗有关的症状,在疾病的各个阶段施用这些药剂。此类药剂的实例包括但不限于烷基化试剂,例如氮芥(例如,苯达莫司汀,环磷酰胺,美法仑,氯丁酸苄酯,异环磷酰胺),亚硝基脲(例如卡莫司汀,洛莫司汀和链佐星),亚乙基亚胺(例如塞替派,六甲基黑色素),烷基磺酸盐(例如,白消安),肼和三嗪(例如,六甲蜜胺,丙卡巴肼,达卡巴嗪和替莫唑胺)和铂基试剂(例如,卡铂,顺铂和奥沙利铂);植物生物碱,例如鬼臼毒素(例如依托泊苷和替尼泊苷(Tenisopide)),紫杉烷类(例如紫杉醇和多西他赛),长春花生物碱(例如长春新碱,长春花碱和长春瑞滨);抗肿瘤抗生素,例如色霉素(例如放线菌素D和普卡霉素),蒽环类药物(例如多柔比星,柔红霉素,表柔比星,米托蒽醌和伊达比星),以及杂类抗生素例如丝裂霉素和博来霉素;抗代谢物,例如叶酸拮抗剂(例如甲氨蝶呤),嘧啶拮抗剂(例如5-氟尿嘧啶,氟尿苷(Foxuridine),阿糖胞苷,卡培他滨和吉西他滨),嘌呤拮抗剂(例如6-巯基嘌呤和6-硫代鸟嘌呤)和腺苷脱氨酶抑制剂(例如克拉屈滨,氟达拉滨,奈拉滨(Nelarabine)和喷司他丁);拓扑异构酶抑制剂,例如拓扑异构酶I抑制剂(托泊替康,伊立替康),拓扑异构酶II抑制剂(例如安吖啶,依托泊苷,磷酸依托泊苷,替尼泊苷),以及杂类抗新生物药物,例如核糖核苷酸还原酶抑制剂(羟基脲),肾上腺皮质类固醇抑制剂(米托坦)、抗微管剂(雌莫司汀)和类维生素A(贝沙罗汀,异维A酸,维甲酸(ATRA)。
在本发明的一方面,可以将化合物与一种或多种调节与多种疾病状态有关的蛋白激酶的靶向抗癌剂组合施用。此类激酶的实例可包括但不限于ABL1、ABL2/ARG、ACK1、AKT1、AKT2、AKT3、ALK、ALK1/ACVRL1、ALK2/ACVR1、ALK4/ACVR1B、ALK5/TGFBR1、ALK6/BMPR1 B、AMPK(A1/B1/G1)、AMPK(A1/B1/G2)、AMPK(A1/B1/G3)、AMPK(A1/B2/G1)、AMPK(A2/B1/G1)、AMPK(A2/B2/G1)、AMPK(A2/B2/G2)、ARAF、ARK5/NUAK1、ASK1/MAP3K5、ATM、Aurora A、AuroraB、Aurora C、AXL、BLK、BMPR2、BMX/ETK、BRAF、BRK、BRSK1、BRSK2、BTK、CAMK1a、CAMK1b、CAMKld、CAMK1g、CAMKIIa、CAMKIIb、CAMKIId、CAMKIIg、CAMK4、CAMKK1、CAMKK2、CDC7-DBF4、CDK1-细胞周期蛋白A、CDK1-细胞周期蛋白B、CDK1-细胞周期蛋白E、CDK2-细胞周期蛋白A、CDK2-细胞周期蛋白A1、CDK2-细胞周期蛋白E、CDK3-细胞周期蛋白E、CDK4-细胞周期蛋白D1、CDK4-细胞周期蛋白D3、CDK5-p25、CDK5-p35、CDK6-细胞周期蛋白D1、CDK6-细胞周期蛋白D3、CDK7-细胞周期蛋白H、CDK9-细胞周期蛋白K、CDK9-细胞周期蛋白T1、CHK1、CHK2、CK1al、CK1d、CKlepsilon、CK1g1、CK1g2、CK1g3、CK2a、CK2a2、c-KIT、CLK1、CLK2、CLK3、CLK4、c-MER、c-MET、COT1/MAP3K8、CSK、c-SRC、CTK/MATK、DAPK1、DAPK2、DCAMKL1、DCAMKL2、DDR1、DDR2、DLK/MAP3K12、DMPK、DMPK2/CDC42BPG、DNA-PK、DRAK1/STK17A、DYRK1/DYRK1A、DYRK1B、DYRK2、DYRK3、DYRK4、EEF2K、EGFR、EIF2AK1、EIF2AK2、EIF2AK3、EIF2AK4/GCN2、EPHA1、EPHA2、EPHA3、EPHA4、EPHA5、EPHA6、EPHA7、EPHA8、EPHB1、EPHB2、EPHB3、EPHB4、ERBB2/HER2、ERBB4/HER4、ERK1/MAPK3、ERK2/MAPK1、ERK5/MAPK7、FAK/PTK2、FER、FES/FPS、FGFR1、FGFR2、FGFR3、FGFR4、FGR、FIT1/VEGFR1、FIT3、FLT4/VEGFR3、FMS、FRK/PTK5、FYN、GCK/MAP4K2、GRK1、GRK2、GRK3、GRK4、GRK5、GRK6、GRK7、GSK3a、GSK3b、Haspin、HCK、HGK/MAP4K4、HIPK1、HIPK2、HIPK3、HIPK4、HPK1/MAP4K1、IGF1R、IKKa/CHUK、IKKb/IKBKB、IKKe/IKBKE、IR、IRAK1、IRAK4、IRR/INSRR、ITK、JAK1、JAK2、JAK3、JNK1、JNK2、JNK3、KDR/VEGFR2、KHS/MAP4K5、LATS1、LATS2、LCK、LCK2/ICK、LKB1、LIMK1、LOK/STK10、LRRK2、LYN、LYNB、MAPKAPK2、MAPKAPK3、MAPKAPK5/PRAK、MARK1、MARK2/PAR-1Ba、MARK3、MARK4、MEK1、MEK2、MEKK1、MEKK2、MEKK3、MELK、MINK/MINK1、MKK4、MKK6、MLCK/MYLK、MLCK2/MYLK2、MLK1/MAP3K9、MLK2/MAP3K10、MLK3/MAP3K11、MNK1、MNK2、MRCKa/、CDC42BPA、MRCKb/、CDC42BPB、MSK1/RPS6KA5、MSK2/RPS6KA4、MSSK1/STK23、MST1/STK4、MST2/STK3、MST3/STK24、MST4、mTOR/FRAP1、MUSK、MYLK3、MYO3b、NEK1、NEK2、NEK3、NEK4、NEK6、NEK7、NEK9、NEK11、NIK/MAP3K14、NLK、OSR1/OXSR1、P38a/MAPK14、P38b/MAPK11、P38d/MAPK13、P38g/MAPK12、P70S6K/KPS6KB1、p70S6Kb/、RPS6KB2、PAK1、PAK2、PAK3、PAK4、PAK5、PAK6、PASK、PBK/TOPK、PDGFRa、PDGFRb、PDK1/PDPK1、PDK1/PDHK1、PDK2/PDHK2、PDK3/PDHK3、PDK4/PDHK4、PHKg1、PHKg2、PI3Ka、(p110a/p85a)、PI3Kb、(p110b/p85a)、PI3Kd、(p110d/p85a)、PI3Kg(p120g)、PIM1、PIM2、PIM3、PKA、PKAcb、PKAcg、PKCa、PKXb1、PKCb2、PKCd、PKCepsilon、PKCeta、PKCg、PKCiota、PKCmu/PRKD1、PKCnu/PRKD3、PKCtheta、PKCzeta、PKD2/PRKD2、PKG1a、PKG1b、PKG2/PRKG2、PKN1/PRK1、PKN2/PRK2、PKN3/PRK3、PLK1、PLK2、PLK3、PLK4/SAK、PRKX、PYK2、RAF1、RET、RIPK2、RKPK3、RIPK5、ROCK1、ROCK2、RON/MST1R、ROS/ROS1、RSK1、RSK2、RSK3、RSK4、SGK1、SGK2、SGK3/SGKL、SIK1、SIK2、SLK/STK2、SNARK/NUAK2、SRMS、SSTK/TSSK6、STK16、STK22D/TSSK1、STK25/YSK1、STK32b/YANK2、STK32c/YANK3、STK33、STK38/NDR1、STK38L/NDR2、STK39/STLK3、SRPK1、SRPK2、SYK、TAK1、TAOK1、TAOK2/TAO1、TAOK3/JIK、TBK1、TEC、TESK1、TGFBR2、TIE2/TEK、TLK1、TLK2、TNIK、TNK1、TRKA、TRKB、TRKC、TRPM7/CHAK1、TSSK2、TSSK3/STK22C、TTBK1、TTBK2、TTK、TXK、TYK1/LTK、TYK2、TYRO3/SKY、ULK1、ULK2、ULK3、VRK1、VRK2、WEE1、WNK1、WNK2、WNK3、YES/YES1、ZAK/MLTK、ZAP70、ZIPK/DAPK3、KINASE、MUTANTS、ABL1(E255K)、ABL1(F317I)、ABL1(G250E)、ABL1(H396P)、ABL1(M351T)、ABL1(Q252H)、ABL1(T315I)、ABL1(Y253F)、ALK(C1156Y)、ALK(L1196M)、ALK(F1174L)、ALK(R1275Q)、BRAF(V599E)、BTK(E41K)、CHK2(I157T)、c-Kit(A829P)、c-KIT(D816H)、c-KIT(D816V)、c-Kit(D820E)、c-Kit(N822K)、C-Kit(T670I)、c-Kit(V559D)、c-Kit(V559D/V654A)、c-Kit(V559D/T670I)、C-Kit(V560G)、c-KIT(V654A)、C-MET(D1228H)、C-MET(D1228N)、C-MET(F1200I)、c-MET(M1250T)、C-MET(Y1230A)、C-MET(Y1230C)、C-MET(Y1230D)、C-MET(Y1230H)、c-Src(T341M)、EGFR(G719C)、EGFR(G719s)、EGFR(L858R)、EGFR(L861Q)、EGFR(T790M)、EGFR、(L858R,T790M)、EGFR(d746-750/T790M)、EGFR(d746-750)、EGFR(d747-749/A750P)、EGFR(d747-752/P753S)、EGFR(d752-759)、FGFR1(V561M)、FGFR2(N549H)、FGFR3(G697C)、FGFR3(K650E)、FGFR3(K650M)、FGFR4(N535K)、FGFR4(V550E)、FGFR4(V550L)、FLT3(D835Y)、FLT3(ITD)、JAK2(V617F)、LRRK2(G2019S)、LRRK2(I2020T)、LRRK2(R1441C)、p38a(T106M)、PDGFRa(D842V)、PDGFRa(T674I)、PDCFRa(V561D)、RET(E762Q)、RET(G691S)、RET(M918T)、RET(R749T)、RET(R813Q)、RET(V804L)、RET(V804M)、RET(Y791F)、TIF2(R849W)、TIF2(Y897S)和TIF2(Y1108F)。
在本发明的另一方面,本发明化合物可以与一种或多种调节非激酶生物学靶标,途径或过程的靶向抗癌剂联合给药。此类靶途径或过程包括但不限于热激蛋白(例如HSP90),聚ADP(二磷酸腺苷)-核糖聚合酶(PARP),缺氧诱导因子(HIF),蛋白酶体,Wnt/Hedgehog/Notch信号传导蛋白,TNF-α,基质金属蛋白酶,法呢基转移酶,凋亡途径(例如Bcl-xL,Bcl-2,Bcl-w),组蛋白脱乙酰基酶(HDAC),组蛋白乙酰基转移酶(HAT)和甲基转移酶(例如组蛋白赖氨酸甲基转移酶,组蛋白精氨酸甲基转移酶,DNA甲基转移酶等)。
在本发明的另一方面,将本发明的化合物与一种或多种其他抗癌剂组合施用,所述其他抗癌剂包括但不限于基因疗法,RNAi癌症疗法,化学保护剂(例如,氨磺汀(amfostine),美司钠,右雷佐生),药物-抗体缀合物(例如brentuximab vedotin,ibritumomab tioxetan),癌症免疫疗法(例如白介素-2),癌症疫苗(例如sipuleucel-T)或单克隆抗体(例如贝伐单抗(Bevacizumab),阿仑珠单抗(Alemtuzumab),利妥昔单抗,曲妥珠单抗等)。
在本发明的另一方面,主题化合物与放射疗法或手术组合施用。放射通常在内部(在癌症部位附近植入放射性物质)或从使用光子(X射线或γ射线)或粒子放射的机器外部传递。在组合疗法进一步包括放射治疗的情况下,可以在任何合适的时间进行放射治疗,只要获得了由治疗剂和放射治疗的组合的共同作用产生的有益效果即可。例如,在适当的情况下,当从治疗剂的施用暂时去除放射治疗时,可能直到几天甚至几周,仍可获得有益效果。
在某些实施方案中,本发明的化合物与放射疗法,手术或抗癌剂中的一种或多种组合施用,所述放射治疗剂,手术或抗癌剂包括但不限于DNA破坏剂,抗代谢物,拓扑异构酶抑制剂,抗微管剂,激酶抑制剂,表观遗传剂,HSP90抑制剂,PARP抑制剂、BCL-2抑制剂、药物-抗体缀合物和靶向VEGF,HER2,EGFR,CD50,CD20,CD30,CD33等的抗体。
在某些实施方案中,本发明的化合物与下列一种或多种组合施用:阿巴瑞克、醋酸阿比特龙、阿地白介素、阿仑珠单抗、六甲蜜胺、阿那曲唑、天冬酰胺酶、苯达莫司汀、贝伐单抗、贝沙罗汀、比卡鲁胺、博来霉素、硼替佐比(bortezombi)、brentuximab vedotin、白消安、卡培他滨、卡铂、卡莫司汀、西妥昔单抗、苯丁酸氮芥、顺铂、克拉屈滨、氯法拉滨、氯米芬、克唑替尼、环磷酰胺、达沙替尼、柔红霉素脂质体、地西他滨、地加瑞克(degarelix)、地尼白介素2(denileukin diftitox)、地尼白介素2、地诺单抗(denosumab)、多西他赛、多柔比星、多柔比星脂质体、表柔比星、甲磺酸艾日布林(eribulin mesylate)、厄洛替尼、雌莫司汀、磷酸依托泊苷、依维莫司、依西美坦、氟达拉滨、氟尿嘧啶、福莫司汀、氟维司群、吉非替尼、吉西他滨、gemtuzumab ozogamicin、醋酸戈舍瑞林、醋酸组氨瑞林、羟基脲、ibritumomab tiuxetan、伊达比星、异环磷酰胺、甲磺酸伊马替尼、干扰素alfa 2a、ipilimumab、ixabepilone、二苯磺酸拉帕替尼(1apatinib ditosylate)、来那度胺、来曲唑、亚叶酸钙、乙酸亮丙瑞林、左旋咪唑、洛莫司汀、氮芥、美法仑、甲氨蝶呤、丝裂霉素C、米托蒽醌、奈拉滨(nelarabine)、尼洛替尼(nilotinib)、奥沙利铂、紫杉醇、紫杉醇蛋白结合颗粒、帕米膦酸(pamidronate)、帕尼单抗(Panitumumab)、培门冬酶、PEG干扰素alfa-2b、培美曲塞二钠、喷司他丁、雷洛昔芬、利妥昔单抗、索拉非尼、链佐星、马来酸舒尼替尼、他莫昔芬、西罗莫司(temsirolimus)、替尼泊苷、沙利度胺、托瑞米芬、托西莫单抗、曲妥珠单抗、维甲酸、乌拉莫司汀、凡德他尼(Vandetanib)、威罗菲尼(vemurafenib)、长春瑞滨、唑来磷酸、放射疗法或手术。
在某些实施方案中,本发明的化合物与一种或多种抗炎剂组合施用。抗炎剂包括但不限于NSAID、非特异性和COX-2特异性环氧化酶抑制剂、金化合物、皮质类固醇、甲氨蝶呤、肿瘤坏死因子受体(TNF)受体拮抗剂、免疫抑制剂和甲氨蝶呤。NSAID的实例包括但不限于布洛芬(ibuprofen)、氟比洛芬(flurbiprofen)、萘普生(naproxen)和萘普生钠、双氯芬酸(diclofenac)、双氯芬酸钠和米索前列醇(misoprosto1)的组合、舒林酸(sulindac)、奥沙普秦(oxaprozin)、二氟尼柳(diflunisal)、吡罗昔康(piroxicam)、吲哚美辛(indomethacin)、依托度酸(etodolac)、非诺洛芬钙(fenoprofen calcium)、酮洛芬(ketoprofen)、萘丁美酮钠(sodium nabumetone)、柳氮磺吡啶(sulfasalazine)、托美丁钠(tolmetin sodium)和羟氯喹。NSAID的实例还包括COX-2特异性抑制剂,如塞来昔布(celecoxib)、伐地昔布(valdecoxib)、鲁米昔布(1umiracoxib)和/或依托昔布(etoricoxib)。
在一些实施方案中,抗炎剂是水杨酸盐(酯)。水杨酸盐(酯)包括但不限于乙酰水杨酸或阿司匹林、水杨酸钠和胆碱和水杨酸镁。抗炎剂也可以是皮质类固醇。例如,皮质类固醇可以是可的松、地塞米松、甲基泼尼松龙、泼尼松龙、磷酸泼尼松龙钠或泼尼松。
在另外的实施方案中,抗炎剂是金化合物,如硫代苹果酸金钠或金诺芬(auranofin)。
本发明还包括其中抗炎剂是代谢抑制剂,如二氢叶酸还原酶抑制剂,如甲氨蝶呤,或二氢乳清酸脱氢酶抑制剂,如来氟米特(leflunomide)。
本发明的其他实施方案涉及下述组合,其中至少一种抗炎化合物是抗C5单克隆抗体(如依库珠单抗(eculizumab)或培克珠单抗(pexelizumab))、TNF拮抗剂如恩那西普(entanercept)或英利昔单抗(infliximab),其是抗TNF alpha单克隆抗体。
在某些实施方案中,本发明的化合物与一种或多种免疫抑制剂组合施用。
在一些实施方案中,免疫抑制剂是糖皮质激素、甲氨蝶呤、环磷酰胺、硫唑嘌呤(azathioprine)、巯基嘌呤、来氟米特、环孢菌素、他克莫司(tacrolimus)和霉酚酸酯、放线菌素D、蒽环类、丝裂霉素C、博来霉素、光神霉素(mithramycin)或芬戈莫德(fingolimod)。
本发明进一步提供了用于预防或治疗新生物性疾病、自身免疫性疾病或炎性病症的方法。在一个实施方案中,本发明涉及在需要治疗的受试者中治疗新生物性疾病、自身免疫性疾病或炎性病症的方法,该方法包括对所述受试者施用治疗有效量的本发明化合物。在一个实施方案中,本发明进一步提供了本发明的化合物在制备用于中止或减少新生物性疾病、自身免疫性疾病或炎性病症的药物中的用途。
在一个实施方案中,新生物性疾病是B细胞恶性肿瘤,其包括但不限于B细胞淋巴瘤、淋巴瘤(包括霍奇金淋巴瘤和非霍奇金淋巴瘤)、毛细胞淋巴瘤、小淋巴细胞性淋巴瘤(SLL)、套细胞淋巴瘤(MCL)和弥漫性大B细胞淋巴瘤(DLBCL)、多发性骨髓瘤、慢性和急性骨髓性白血病以及慢性和急性淋巴细胞性白血病。
可以使用根据本发明的化合物和组合物影响的自身免疫性和或炎性疾病包括但不限于变态反应、阿尔茨海默氏病、急性播散性脑脊髓炎、艾迪生(Addison)氏病、强直性脊柱炎、抗磷脂抗体综合征、哮喘、动脉粥样硬化、自身免疫性溶血性贫血、自身免疫性溶血和血小板减少状态、自身免疫性肝炎、自身免疫性内耳疾病、大疱性类天疱疮、乳糜泻、chagas病、慢性阻塞性肺疾病、慢性特发性血小板减少性紫癜(ITP)、churg-strauss综合征、克罗恩氏病、皮肌炎、1型糖尿病、子宫内膜异位症、肺出血肾炎综合征(Goodpasture’ssyndrome)(及相关的肾小球肾炎和肺出血)、格雷夫斯病(graves’disease)、格-巴二氏综合征(guillain-barré syndrome)、桥本病、化脓性汗腺炎、特发性血小板减少性紫癜、间质性膀胱炎、肠易激综合征、红斑狼疮、硬斑病、多发性硬化、重症肌无力、发作性睡病、神经性肌强直、帕金森氏病、寻常型天疱疮、恶性贫血、多肌炎、原发性胆汁性肝硬化、银屑病、银屑病关节炎、类风湿性关节炎、精神分裂症、败血性休克、硬皮病、干燥综合征、系统性红斑狼疮(及相关肾小球肾炎)、颞动脉炎、移植器官的器官移植物排斥和超急性排斥、血管炎(与ANCA相关的血管炎病(vasculitides)和其他血管炎病)、白癜风和韦格纳肉芽肿病。
应理解,本发明并不限于本文中显示和描述的具体实施方案,可做出多种改变和修饰而不悖离由权利要求书所界定的本发明的精神和范畴。
根据本发明的化合物可根据多种反应方案合成。必要的起始材料可通过标准有机化学过程获得。联系下述代表性的合成方案和实施例,可更好地理解本发明的化合物和过程,这些方案和实施例仅用作例示而非限制本发明的范围。对于所公开的实施方案的各种改变和修饰对于该领域技术人员是显而易见的,且可做出改变和修饰,包括但不限于与化学结构、取代基、衍生物、及/或本发明的方法相关的改变和修饰,而不悖离本发明的精神和所附权利要求书的范围。
在方案A中,反应物5可以通过3,5-二溴-1-甲基吡嗪-2(1H)-酮与适当的苯胺反应来制备。反应物5中的硝基可以是其他基团,如经保护的胺基或-NHC(O)-弹头。
典型的起始材料(CAS 1346674-23-4)可商购。但是,至该中间体的报道的途径(例如在WO 2013067274中)需要至少7个合成步骤。合成不仅很长,而且还包括几种有毒或有害并具有环境责任的试剂和溶剂。我们在本文方案1中描述了一种关注于可持续化学使用的新的、更有效且更具成本效益的途径(三个合成步骤):
在方案1中,起始材料3-甲基环戊-2-烯-1-酮通过标准有机反应以高收率转化为3,3-二甲基环戊烷-1-酮,其可以进一步转化为中间体3。最后,中间体3可以与哌嗪-2-酮反应以产生CAS 1346674-23-4的靶分子。
中间体可以通过与方案1类似的方法,通过使用不同的起始材料和试剂来制备。
中间体可以通过与方案1类似的方法,通过使用不同的起始材料和试剂,或通过标准有机反应来制备。
中间体可以通过与方案1类似的方法,通过使用不同的起始材料和试剂,或通过标准有机反应来制备。/>
方案A中描述了合成其中R3为-CH2OH的式(IV)化合物的典型方法。一般方案A中的R1、R4、X、弹头和m与上述概述部分中描述的那些相同。
在方案A中,合适的起始材料1可以与2反应形成中间体3,该中间体3可以通过标准有机反应以高产率转化为4。同时,中间体5可以通过使可商购的3,5-二溴-1-甲基吡嗪-2(1H)-酮(CAS 87486-34-8)与适当的4-取代的3-硝基苯胺反应而获得。然后,4与5的偶联反应将生成硝基中间体6,可以将其还原为胺中间体7。最后,可以将7还原为醇中间体8,该中间体可以使适当的丙烯酰氯反应生成式(IV)。
式(III)化合物可以通过与方案A类似的方法,通过使用不同的起始材料和试剂来制备。
式(II)化合物可以通过与方案A类似的方法,通过使用不同的起始材料和试剂来制备。
式(I)化合物可以通过与方案A类似的方法,通过使用不同的起始材料和试剂来制备。
联系下述实施例,可更好地理解本发明的化合物和过程,所述实施例意图仅用作例示而非限制本发明的范围。对于所公开的实施方案的各种改变和修饰对于本领域技术人员是显而易见的,且可做出改变和修饰,包括但不限于与化学结构、取代基、衍生物、及/或本发明的方法相关的改变和修饰,而不悖离本发明的精神和所附权利要求书的范围。
若呈现NMR数据,则1H谱在XL400(400MHz)上获得并且以来自Me4Si的ppm低磁场报告,在括号中指示质子数、多重态和以赫兹计的偶联常数。若呈现HPLC数据,则使用Agilent1100系统进行分析。若呈现LC/MS数据,则使用Applied Biosystems API-100质谱仪和Shimadzu SCL-10A LC柱进行分析。
实施例1:制备7,7-二甲基-3,4,7,8-四氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-1(6H)-酮。
将CuI(47.6g,249.93mmol,1.20当量)在乙醚(500mL)中的溶液放入用氮气惰性气氛吹扫并维持的1000-mL的圆底烧瓶中。在0℃下向溶液中加入MeLi(286mL/2M,2.20当量),并将混合物在相同温度下搅拌2小时。在相同温度下向溶液中加入3-甲基环戊-2-烯-1-酮(20g,208.06mmol,1.00当量)。将所得溶液在0℃的水/冰浴中搅拌2小时。然后,当TLC显示SM消失(PE∶EA=1∶1)时,通过添加500mL的NH4Cl(aq.)淬灭反应。所得溶液用3×200ml的乙醚萃取,合并有机层,用无水硫酸钠干燥,并在真空下浓缩。得到21g(90%)的3,3-二甲基环戊-1-酮,为无色油。
将N,N-二甲基甲酰胺(41.6g,569.16mmol,3.00当量)在二氯甲烷(200mL)中的溶液放入用氮气惰性气氛吹扫并维持的500mL的圆底烧瓶中。在0℃下向溶液中加入POCl3(57.3g,373.70mmol,2.00当量),然后将反应混合物在室温下搅拌1.5小时。在相同温度下向溶液中加入3,3-二甲基环戊-1-酮(21.0g,187.22mmol,1.00当量)。将所得溶液在油浴中于55℃搅拌过夜。然后当TLC显示反应已完成(PE∶EA=1∶1)时,通过添加200mL水性NaAcO淬灭反应。所得溶液用3×200二氯甲烷萃取,合并有机层,用无水硫酸钠干燥,并在真空下浓缩。得到30g(粗品)的2-氯-4,4-二甲基环戊-1-烯-1-甲醛(carbaldehyde)为棕色油。
将哌嗪-2-酮(18.7g,186.78mmol,1.00当量)和DIEA(24.2g,187.25mmol,1.00当量)在NMP(45mL)中的溶液放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。然后在100℃下向溶液中滴加2-氯-4,4-二甲基环戊-1-烯-1-甲醛(29.7g,187.23mmol,1.00当量)。将所得溶液在油浴中于100℃搅拌30分钟。然后,当TLC显示反应已完成(EA)时,通过添加200mL水淬灭反应。通过过滤收集固体。得到20g(52%)4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为灰白色固体。LC-MS:(ES,m/z):205[M+H]+。1H-NMR:(300MHz,d6-DMSO,ppm):δ7.38(s,1H)、6.36(s,1H)、3.92(t,J=5.9Hz,2H)、3.45(m,2H)、2.50(s,2H)、2.38(s,2H)、1.19(s,6H)。
实施例2:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丙烯酰胺
将4-氟-3-硝基苯胺(100g,0.64mol)和N-甲基哌嗪(256g,2.56mol)的混合物溶解在乙醇中。将混合物保持回流24h,然后允许混合物冷却至室温,将反应真空浓缩并过滤,得到作为红色固体的4-(4-甲基哌嗪-1-基)-3-硝基苯胺(131g,86%)1H-NMR(300MHZ,CDCl3)7.11(d,1H)、7.02(d,1H)、6.807-6.845(m,1H)、3.76(s,2H)、2.98(m,4H)、2.557(m,4H)、2.35(s,3H)。
4-(4-甲基哌嗪-1-基)-3-硝基苯胺(14.53g,0.0615mol)、3,5-二溴-1-甲基吡嗪-2(1H)-酮(16.5g,0.0615mol)、碳酸铯(40.1g,0.123mol)、DMF(14ml)和1,4-二恶烷(200ml)的混合物在鼓泡氮气通入所得悬浮液30分钟后,加入Xantphons(3.5g,0.00615mol)和三(二苄叉基丙酮)二钯(tris(dibenzylideneacetone)dipalladium)(0)(6.3g,0.00615mol)。然后将反应混合物在100℃加热2h,此后,将混合物冷却至室温,并用90∶10的二氯甲烷/甲醇(500ml)和水(300m1)稀释,分离各层,用90∶10的二氯甲烷/甲醇(500ml)萃取水层,合并的有机层用卤水洗涤并用硫酸钠干燥。通过过滤除去干燥剂,将滤液减压浓缩,并将得到的残余物通过快速柱色谱法(90∶10二氯甲烷/甲醇)纯化,得到D(12g,46%)1H-NMR(300MHZ,CDCl3)、8.31(d,2H)、7.85(m,1H)、7.23(d,1H)、6.82(s,1H)、3.55(s,3H)、3.08(m,4H)、2.59(m,4H)、2.38(s,3H)。
可商购的起始材料4-氯-2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)烟醛(CAS#1434050-55-1,1.5g,4.37mmol,1.0当量)、Pin2B2(2.8g,11mmol,2.5当量)、Pd(dppf)Cl2(356mg,0.44mmol,0.1当量)和KOAc(1.3g,13moml,3.0当量)在1,4-二恶烷(150mL)中的混合物在N2气氛下回流4h。将混合物冷却至室温并过滤。浓缩滤液,得到(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲酰吡啶-4-基)硼酸(3.0g)为棕色油,其无需进一步纯化即可用于下一步。ESI-MS(M+H)+:354.2。
(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲酰吡啶-4-基)硼酸(来自上一步的粗品,4.37mmol,1.0当量)、5-溴-1-甲基-3-((4-(4-甲基哌嗪-1-基)-3-硝基苯基)氨基)吡嗪-2(1H)-酮(实施例1,900mg,2.2mmol,0.5eq)、Pd(dppf)Cl2(360mg,0.44mmol,0.1当量)和K2CO3(1.5g,13moml,3.0当量)在二恶烷(50mL)和H2O(5mL)中的混合物在90℃和N2气氛下搅拌4小时。将混合物冷却至室温并浓缩,并将残余物通过硅胶上的柱色谱法纯化(DCM∶MeOH=30∶1),得到2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-4-(4-甲基-6-((4-(4-甲基哌嗪-1-基)-3-硝基苯基)氨基)-5-氧代-4,5-二氢吡嗪-2-基)烟醛为棕色固体(600mg,两步Y:40%)。ESI-MS(M+H)+:652.1。
2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-4-(4-甲基-6-((4-(4-甲基哌嗪-1-基)-3-硝基苯基)氨基)-5-氧代-4,5-二氢吡嗪-2-基)烟醛(600mg,0.92mmol,1.0当量)(600mg,0.92mmol,1.0当量)和Pd/C(120mg,20%wt)在MeOH(20mL)中的混合物在1个H2压力的气氛下于室温氢化16小时。通过硅藻土(Celite)垫滤出催化剂,并将滤液浓缩,得到4-(6-((3-氨基-4-(4-甲基哌嗪-1-基)苯基)氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)烟醛为棕色固体(600mg)。ESI-MS(M+H)+:622.1。
向4-(6-((3-氨基-4-(4-甲基哌嗪-1-基)苯基)氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)烟醛(来自前一步骤的粗品,0.92mmol,1.0当量)在MeOH(10mL)中的溶液在0℃下添加NaBH4(70mg,1.8mmol,2.0当量)在MeOH(10mL)中的溶液。将溶液在室温搅拌16小时。浓缩,残余物通过Pre-HPLC纯化(A:H2O,0.05%NH3.H2O,B:MeCN)以得到2-(4-(6-((3-氨基-4-(4-甲基哌嗪-1-基)苯基)氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-(羟基甲基)吡啶-2-基)-7,7-二甲基-3,4,7,8-四氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-1(6H)-酮作为褐色固体(150mg,两步Y:56%)。ESI-MS(M+H)+:624.1。
向2-(4-(6-((3-氨基-4-(4-甲基哌嗪-1-基)苯基)氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-(羟基甲基)吡啶-2-基)-7,7-二甲基-3,4,7,8-四氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-1(6H)-酮(150mg,0.24mmol,1.0当量)、丙烯酸(26mg,0.36mmol,1.5当量)和HATU(123mg,0.36mmol,1.5当量)在DMF(5mL)中的混合物添加TEA(73mg,0.72mmol,3.0当量)。将混合物在室温搅拌4小时。反应混合物通过Pre-HPLC纯化(A:H2O,0.05%NH3.H2O;B:MeCN)以得到N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-基)苯基)丙烯酰胺作为棕色固体(38mg,Y:23%)。ESI-MS(M+H)+:678.1.1H NMR(400MHz,DMSO-d6)δ:9.24(s,1H)、9.06(s,1H)、8.88(s,1H)、8.46(d,J=5.2Hz,1H)、7.88(d,J=4.8Hz,1H)、7.75(s,1H)、7.63(dd,J=2.0Hz,4.4Hz,1H)、7.12(d,J=8.4Hz,1H)、6.66-6.56(m,1H)、6.57(s,1H)、6.33-6.28(m,1H)、5.79-5.76(m,1H)、5.04(br s,1H)、4.60-4.46(m,2H)、4.26-4.18(m,3H)、3.86-3.83(m,1H)、3.55(s,3H)、2.79-2.75(m,4H)、2.67-2.57(m,6H)、2.43(s,2H)、2.24(s,3H)、1.22(s,6H)。
实施例3:制备(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺
将4-氟-3-硝基苯胺(50g,320.28mmol,1.00当量)、CH3CN(500mL)、NMM(64.7g,639.64mmol,2.00当量)、Cbz-Cl(87.4g,512.34mmol,1.60当量)放入用氮气惰性气氛吹扫并维持的1000-mL的圆底烧瓶中。将所得溶液在室温搅拌过夜。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到45g(48%)的N-(4-氟-3-硝基苯基)氨基甲酸苄酯为黄色固体。LC-MS:(ES,m/z):[M+H]+=291,1H-NMR:(300MHz,CDCl3,ppm):δ8.15(m,1H)、7.65(m,1H)、7.42-7.32(m,5H)、7.22(m,1H)、6.80(s,2H)、5.22(s,2H)。
将DMSO(100mL)中的N-(4-氟-3-硝基苯基)氨基甲酸苄酯(10g,34.45mmol,1.00当量)的溶液、(3S)-3-甲基哌嗪-1-羧酸叔丁酯(7.58g,37.85mmol)、DIEA(6.67g,51.61mmol,1.50当量)放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在油浴中于110℃搅拌过夜。用水稀释所得溶液。所得溶液用乙酸乙酯萃取,合并有机层,并在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到10g(62%)的(3S)-4-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-3-甲基哌嗪-1-羧酸叔丁酯为棕色油。LC-MS:(ES,m/z):[M+H]+=471.1H-NMR:(300MHz,CDCl3,ppm):δ7.86(s,1H)、7.60(m,1H)、7.44-7.31(m,7H)、5.21(s,2H)、3.90(t,J=11.4Hz,2H)、3.21-3.02(m,3H)、2.79-2.72(m,2H)、1.49(s,9H)、0.80(d,J=6.3Hz,3H)。
将(3S)-4-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-3-甲基哌嗪-1-羧酸叔丁酯(12.5g,26.57mmol,1.00当量)在二恶烷(100mL)中的溶液、氯化氢二恶烷(25mL)放入氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。得到12.5g(粗品)的N-[4-[(2S)-2-甲基哌嗪-1-基]-3-硝基苯基]氨基甲酸苄酯为棕色油。LC-MS:(ES,m/z):371[M+H]+。
将乙醇(100ml)中的N-[4-[(2S)-2-甲基哌嗪-1-基]-3-硝基苯基]氨基甲酸苄酯溶液、氧杂环丁烷-3-酮(oxetan-3-one)(2.2g,30.53mmol,1.20当量)、NaBH3CN(1.67g,26.58mmol,1.00当量)放入氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌2h。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1:1)的硅胶柱上。得到5g(35%)的N-[4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]-3-硝基苯基]氨基甲酸苄酯为棕色油。LC-MS:(ES,m/z):427[M+H]+1H-NMR(300MHz,CD3OD,ppm):δ7.86(s,1H)、7.60(m,1H)、7.48-7.31(m,6H)、5.21(s,2H)、4.75-4.55(m,5H)、3.55(m,1H)、3.26-3.10(m,2H)、2.97-2.72(m,3H)、2.30-2.11(m,3H),1.80(t,J=4.7Hz,1H)、1.49(s,9H)、0.80(d,J=6.3Hz,3H)。
将乙醇(50ml)中的N-[4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]-3-硝基苯基]氨基甲酸苄酯(5.0g,11.72mmol,1.00当量)的溶液、AcOH(7.0g,116.57mmol,10.00当量)放入用氮气惰性气氛吹扫并维持的100-mL圆底烧瓶中。随后加入粉尘Zn(4.6g,6.00当量)。将所得溶液在室温搅拌1h。滤出固体。将所得混合物在真空下浓缩,并施加在硅胶柱上。得到1.0g(22%)的N-[3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸苄酯为棕色油。LC-MS:(ES,m/z):397[M+H]+.1H-NMR(300MHz,CD3OD,ppm):δ7.46-7.31(m,5H)、7.02(m,2H)、6.75(d,J=8.4,1H)、5.20(s,2H)、4.85-4.64(m,4H)、3.67-3.55(m,3H),3.17(m,1H)、2.92-2.78(m,4H)、2.25(m,1H)、1.95(m,1H)、0.80(d,J=6.0Hz,3H)。
将N-[3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸苄酯在四氢呋喃(10mL)中的溶液、NMM(510mg,5.04mmol,2.00当量)、(Boc)2O(820mg,3.76mmol,1.50当量)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到0.9g(72%)N-(3-[[(terr-butoxy)羰基]氨基]-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)氨基甲酸苄酯为棕色油。LC-MS:(ES,m/z):497[M+H]+。
将N-(3-[[(叔丁氧基)羰基]氨基]-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)氨基甲酸苄酯在甲醇(10mL)的溶液、钯碳(0.1g,0.10当量)放入用H2惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在室温搅拌1h。滤出固体。将得到的混合物在真空下浓缩。得到0.6g(91%)的N-[5-氨基-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸叔丁酯为棕色油。LC-MS:(ES,m/z):363[M+H]+1H-NMR-PH-:(300MHz,CD3OD,ppm):δ7.46-7.31(m,5H)、7.02(m,2H)、6.75(d,J=8.4,1H)、4.78-4.64(m,4H)、3.60(m,1H)、3.10-2.70(m,5H)、2.22(m,1H)、1.95(m,1H)、0.77(d,J=6.0Hz,3H)。
将N-[5-氨基-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸叔丁酯在IPA(10mL)中的溶液、3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(980mg,3.66mmol,1.00当量)、DIEA(640mg,4.95mmol,1.50当量)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在油浴中于80℃搅拌过夜。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到1.2g(66%)的N1[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸叔丁酯为棕色油。LC-MS:(ES,m/z):551[M+H]+ 1H-NMR:(300MHz,CDCl3,ppm):δ8.31(s,1H)、8.20(s,1H)、7.99(s,1H)、7.20(d,J=8.7,1H)、6.95(d,J=8.7,1H)、6.75(s,1H)、4.78-4.64(m,5H)、3.60(m,1H)、3.20-2.72(m,7H)、2.22(m,1H)、1.95(m,1H)、0.79(d,J=6.0Hz,3H)。
将N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基甲酸叔丁酯(600mg,1.09mmol,1.00当量)在二氯甲烷中(6ml)的溶液、三氟乙酸(1.2mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在室温搅拌1h。将得到的混合物在真空下浓缩。得到500mg(粗品)的3-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为棕色油。LC-MS:(ES,m/z):451[M+H]+。
将3-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(500mg,1.11mmol,1.00当量)在二恶烷(15mL)/H2O(1mL)的溶液、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-[(恶烷2-基氧基)甲基]吡啶-4-基)硼酸(431mg,0.98mmol,1.10当量)、Pd(dppf)Cl2(50mg,0.07mmol,0.10当量)、碳酸钾(307mg,2.22mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液在油浴中于100℃搅拌1小时。将得到的混合物在真空下浓缩,用H2O稀释并用EA萃取。得到500mg(59%)10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(粗品)为棕色油。LC-MS:(ES,m/z):764[M+H]+。
将10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(500mg,0.65mmol,1.00当量)在二氯甲烷(5mL)中的溶液、三氟乙酸(1mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在油浴中于40℃搅拌15分钟。将得到的混合物在真空下浓缩。粗产物通过Prep-HPLC纯化。得到80mg(18%)的10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS:(ES,m/z):680[M+H]+。
将10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(80mg,0.12mmol,1.00当量)在CH3CN(1mL)中的溶液、丙-2-烯酸(10mg,0.14mmol,1.20当量)、HATU(49.2mg,0.13mmol,1.10当量)、NMM(17.7mg,0.17mmol,1.50当量)放入用氮气惰性气氛吹扫并维持的25-mL的圆底烧瓶中。将所得溶液在室温搅拌1h。粗产物通过Prep-HPLC纯化。得到27mg(31%)的N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)丙-2-烯酰胺为灰白色固体。LC-MS:(ES,m/z):734[M+H]+.1H-NMR:(300MHz,d6-DMSO,ppm):δ9.25(s,1H)、9.19(s,1H)、9.11(s,1H)、8.49(d,J5.1Hz,1H)、7.95(d,J=5.1Hz,1H)、7.77(s,1H)、7.60(d,J=8.7,1H)、7.25(d,J=8.7,1H)、6.63-6.57(m,2H)、6.30(m,1H)、5.80(d,J=3.9Hz,1H)、5.02(m,1H)、4.65-4.41(m,6H)、4.35-4.15(m,3H)、3.85(m,1H)、3.60-3.43(m,4H)、3.10(m,1H)、2.85-2.54(m,6H)、2.45(m,2H)、2.22(m,1H)、1.95(t,J=6.6Hz,1H)、1.25(s,6H)、0.76(d,J=6.0Hz,3H)。
实施例4:制备(S)N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺
将4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(3.0g,14.69mmol,1.00当量)在二恶烷(30mL)中的溶液、2,6-二溴苯甲醛(4.65g,17.62mmol,1.20当量)、Cs2CO3(9.6g,29.46mmol,2.00当量)、Pd2(dba)3(300mg,0.33mmol,0.10当量)、Xantphos(300mg,0.52mmol,0.10当量)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在油浴中于100℃搅拌1小时。将反应混合物冷却至RT。滤出固体。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1:1)的硅胶柱上。得到4.0g(70%)的2-溴-6-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]苯甲醛为灰白色固体。(ES,m/z):387[M+H]+.1H-NMR:(300MHz,CD3OD,ppm):δ10.36(s,1H)、7.43(d,J=7.8Hz,1H),7.25(m,2H)、6.60(s,1H)、3.99(t,J=6.0Hz,2H)、3.63(t,J=6.0Hz,3H)、2.55(s,2H)、2.45(s,2H)、1.24(s,6H)。
将2-溴-6-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]苯甲醛(1.0g,2.58mmol,1.00当量)在二恶烷(10mL)中的溶液、Pin2B2(1.64g,2.50当量)、Pd(dppf)Cl2(100mg,0.14mmol,0.10当量)、KOAc(760mg,7.74mmol,3.00当量)放入用氮气惰性气氛吹扫并维持的50-mL的圆底烧瓶中。将所得溶液在油浴中于100℃搅拌30分钟。将反应混合物冷却至RT。滤出固体。将得到的混合物在真空下浓缩。得到400mg(44%)的(3-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-2-甲酰苯基)硼酸为棕色固体。LC-MS:(ES,m/z):353[M+H]+。
将(3-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-2-甲酰苯基)硼酸(346mg,0.98mmol,1.00当量)、3-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(441mg,0.98mmol,1.00当量)在二恶烷(10mL)/H2O(1mL)中的溶液、Pd(dppf)Cl2(30mg,0.04mmol,0.10当量)、碳酸钾(271mg,1.96mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的50-mL的圆底烧瓶中。将所得溶液在油浴中于100℃搅拌1小时。滤出固体。将得到的混合物在真空下浓缩。得到500mg(75%)的2-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-6-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]苯甲醛为棕色油。LC-MS:(ES,m/z):677[M+H]+。
将2-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-6-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]苯甲醛(500mg,0.74mmol,1.00当量)在乙醇(10mL)中的溶液、NaBH4(16.8mg,0.44mmol,0.60当量)放入用氮气惰性气氛吹扫并维持的25-mL的圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。粗产物通过Prep-HPLC纯化。得到240mg(48%)的10-[3-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-2-(羟基甲基)苯基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为浅棕色固体。LC-MS:(ES,m/z):679[M+H]+。
将10-[3-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-2-(羟基甲基)苯基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(240mg,0.35mmol,1.00当量)在CH3CN(10mL)中的溶液、丙-2-烯酸(30.5mg,0.42mmol,1.20当量)、HATU(147.7mg,0.39mmol,1.10当量)、NMM(71.4mg,0.71mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的10-mL的圆底烧瓶中。将所得溶液在室温搅拌1h。粗产物通过制备型HPLC纯化。得到60mg(23%)的N-(5-[[6-(3-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)丙-2-烯酰胺为灰白色固体。LC-MS:(ES,m/z):733[M+H]+.1H-NMR:(300MHz,d6-DMSO,ppm):δ9.17(m,2H)、8.91(s,1H)、7.82-7.63(m,2H)、7.49-7.42(m,2H)、7.40-7.23(m,2H)、6.67-6.49(m,2H)、6.25(m,1H)、5.80(d,J=10.5Hz,1H)、4.81(m,1H)、4.62-4.40(m,6H)、4.25-4.02(m,3H)、3.93(m,1H)、3.60-3.40(m,4H)、3.10(m,1H)、2.80-2.60(m,4H)、2.55(s,2H)、2.45(s,2H)、2.22(m,1H)、1.95(t,J=6.8Hz,1H)、1.22(s,6H)、0.73(d,J=6.0Hz,3H)。
实施例5:制备N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺
将N-(3-氨基苯基)氨基甲酸叔丁酯(5g,24.01mmol,1.00当量)、3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(5.8g,21.65mmol,1.50当量)、DIEA(4.9g,37.98mmol,2.00当量)、异丙醇(50mL)放入250-mL圆底烧瓶中。将所得溶液在80℃下搅拌过夜。将得到的混合物在真空下浓缩。粗产物通过快速PE∶EA=100/20在30分钟内增加至PE∶EA=100/50纯化。得到7.4g(78%)的N-[3-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]苯基]氨基甲酸叔丁酯为浅黄色固体。LC-MS:(ES,m/z):[M+H]+=395.1H-NMR-:(300MHz,CDCl3,ppm):δ9.32(s,1H)、9.28(s,1H),7.91(s,1H)、7.52(d,J=5.4Hz,1H)、7.16-7.09(m,2H)、3.45(s,3H)、1.47(s,9H)。
将N-[3-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]苯基]氨基甲酸叔丁酯(400mg,0.51mmol,1.00当量)、氯化氢/二恶烷(10mL)。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。得到300mg(90%)的3-[(3-氨基苯基)氨基]-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为黄色固体。LC-MS:(ES,m/z):[M+H]+=295。
将3-[(3-氨基苯基)氨基]-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(200mg,0.68mmol,1.00当量)、(2-4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^2,6]十二-2(6),7-二烯-10-基-3-[(恶烷-2-基氧基)甲基]吡啶-4-基)硼酸(298mg,0.68mmol,1.00当量)、Pd(dppf)Cl2(58mg,0.07mmol,0.10当量)、碳酸钾(281mg,2.04mmol,3.00当量)、二恶烷(12mL)、水(2mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在100℃下搅拌30分钟。冷却后,将所得混合物在真空下浓缩。将所得溶液用甲醇稀释。粗产物通过快速MeCN:H2O=25/75在13分钟内增加至MeCN:H2O=50/50纯化。得到280mg(68%)的10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS(ES,m/z):[M+H]+=610。
将10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(230mg,0.38mmol,1.00当量)、三氟乙酸(1mL)、二氯甲烷(20mL)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。所得溶液用乙酸乙酯稀释。用碳酸氢钠饱和溶液将溶液的pH值调节至8。滤出固体。将得到的混合物在真空下浓缩。得到150mg(76%)的10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为无色油。LC-MS--714-4:(ES,m/z):[M+H]+=526。
将10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(150mg,0.28mmol,1.00当量)、丙-2-烯酸(20.1mg,0.28mmol,1.00当量)、NMM(58mg,0.38mmol,2.00当量)、HATU(141mg,0.25mmol,1.30当量)、MeCN(5mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。粗产物通过Prep-HPLC纯化。得到32.4mg(18%)的N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]苯基)丙-2-烯酰胺为灰白色固体。LC-MS:(ES,m/z):[M+H]+=580。1H-NMR:(300MHz,CDCl3,ppm):δ9.99(s,1H)、9.24(s,1H)、8.47(m,2H)、7.84-7.73(m,2H)、7.60(d,J=7.5Hz,1H)、7.30-7.20(m,2H)、6.58(s,1H)、6.55-6.25(m,2H)、5.76(d,J=9.9Hz,1H)、4.97(m,1H)、4.64-4.45(m,2H)、4.33-4.15(m,3H)、3.88(m,1H)、3.57(s,3H)、2.59(d,J=5.1Hz,2H)、2.42(d,J=5.1Hz,2H)、1.22(s,6H)。
实施例7:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(1-(氧杂环丁烷-3-基)哌啶-4-基)苯基)丙烯酰胺
将4-溴-3-硝基苯胺(5g,23.04mmol,1.00当量)、4-(四甲基-1,3,2-二氧杂硼杂环戊-2-基)-1,2,3,6-四氢吡啶-1-羧酸叔丁酯(14g,45.28mmol,2.00当量)、Pd(dppf)Cl2(2g,2.33mmol,0.10当量)、碳酸钾(19g,137.47mmol,6.00当量)、二恶烷(80mL)、水(20mL)放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在90℃C搅拌过夜。滤出固体。将得到的混合物在真空下浓缩。粗产物通过快速PE∶EA=50/50在30分钟内增加至PE∶EA=20/80纯化。得到5.7g(77%)的4-(4-氨基-2-硝基苯基)-1,2,3,6-四氢吡啶-1-羧酸叔丁酯为浅黄色油。LC-MS--1:(ES,m/z):[M+H]+=320。1H-NMR-PH--1:(300MHz,d6-DMSO,ppm):δ7.05(m,2H)、6.80(d,J=8.1Hz,1H),5.74(s,2H)、5.49(s,1H)、3.88(m,2H)、3.46(t,J=10.8Hz,2H)、2.17(s,2H)。
将4-(4-氨基-2-硝基苯基)-1,2,3,6-四氢吡啶-1-羧酸叔丁酯(7g,21.92mmol,1.00当量)、水(10mL)、碳酸钠(4.6g,43.40mmol,2.00当量)、二氯甲烷(50mL)放入250-mL圆底烧瓶中。将所得溶液在0℃搅拌30分钟。随后在在0℃滴加Cbz-Cl(4.5g,26.47mmol,1.20当量)并搅拌5分钟。将所得溶液在室温搅拌过夜。所得混合物用2x100mL的卤水洗涤。将得到的混合物在真空下浓缩。得到7g(70%)的4-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-1,2,3,6-四氢吡啶-1-羧酸叔丁酯为黄色油。LC-MS--2:(ES,m/z):[M+H]+=454。1H-NMR-PH--2:(300MHz,d6-DMSO,ppm):δ10.27(s,1H)、8.13(s,1H)、7.68(d,J=8.4Hz,1H)、7.46-7.32(m,7H),5.62(s,1H)、5.19(s,2H)、3.92(m,2H)、3.53(t,J=10.8Hz,2H)、2.24(s,2H)。
将4-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-1,2,3,6-四氢吡啶-1-羧酸叔丁酯(5g,11.03mmol,1.00当量)、氯化氢/二恶烷(40mL)放入250-mL圆底烧瓶中.将所得溶液在室温搅拌1.5小时。得到的混合物在真空下浓缩。得到4.5g(粗品)的N-[3-硝基-4-(1,2,3,6-四氢吡啶-4-基)苯基]氨基甲酸苄酯为浅黄色固体。LC-MS--3:(ES,m/z):[M+H]+=354。
将N-[3-硝基-4-(1,2,3,6-四氢吡啶-4-基)苯基]氨基甲酸苄酯(4.5g,25.47mmol,1.00当量)、氧杂环丁烷-3-酮(1.35g,37.47mmol,1.50当量)、NaCNBH3(1.6g,50.79mmol,2.00当量)、甲醇(30mL)放入250-mL圆底烧瓶中.将所得溶液在50℃搅拌4h。用乙酸乙酯萃取所得溶液,并合并有机层。所得混合物用2x100mL氯化钠洗涤。将固体在烘箱中减压干燥并在真空下浓缩。得到3.6g(61%)的N-[3-硝基-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基]氨基甲酸苄酯为白色固体。LC-MS--4:(ES,m/z):[M+H]+=410。1H-NMR-PH--4:(300MHz,d6-DMSO,ppm):δ10.27(s,1H)、8.09(s,1H)、7.67(d,J=8.4Hz,1H)、7.46-7.32(m,6H),5.59(s,1H)、5.19(s,2H)、4.56(t,J=9Hz,2H)、4.49(t,J=9Hz,2H)、3.60(m,1H)、2.92(s,2H)、2.48(m,2H)、2.26(s,2H)。
将N-[3-硝基-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基]氨基甲酸苄酯(3.6g,8.79mmol,1.00当量)、乙酸(5.25g,87.42mmol,10.00当量)、乙醇(25mL)、锌(2.8g,42.81mmol,5.00当量)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。滤出固体。将得到的混合物在真空下浓缩。所得溶液用乙酸乙酯稀释。用碳酸钠(1mol/L)将pH调节至8。所得混合物用2x200mL H2O洗涤。将混合物经无水硫酸钠干燥,并在真空下浓缩。粗产物通过快速PE:EA=100/30在45分钟内增加至PE:EA=100/50纯化。得到2.5g(75%)的N-[3-氨基-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基]氨基甲酸苄酯为黄色油。LC-MS--5:(ES,m/z):[M+H]+=380。1H-NMR-PH--5:(300MHz,d6-DMSO,ppm):δ9.61(s,1H)、7.52-7.28(m,5H)、6.87(s,1H)、6.77(d,J=7.8Hz,1H)、6.61(d,J=8.1Hz,1H)、5.60(s,1H)、5.13(s,2H)、4.74(s,2H)、4.57(t,J=9Hz,2H)、4.50(t,J=9Hz,2H)、3.52(m,1H)、2.92(s,2H)、2.48(m,2H)、2.28(s,2H)。
将N-[3-氨基-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基]氨基甲酸苄酯(2.5g,13.18mmol,1.00当量)、TEA(2g,39.53mmol,3.00当量)、二碳酸二叔丁酯(1.75g,16.04mmol,1.30当量)、四氢呋喃(30mL)放入250-mL圆底烧瓶中。将所得溶液在65℃搅拌过夜。将得到的混合物在真空下浓缩。粗产物通过快速PE:EA=100/30在25分钟内增加至PE:EA=100/50纯化。得到2g(63%)的N-(3-[[(叔丁氧基)羰基]氨基]-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基)氨基甲酸苄酯为黄色油。LC-MS--6:(ES,m/z):[M+H]+=480。1H-NMR-PH--6:(300MHz,d6-DMSO,ppm):δ9.74(s,1H)、8.20(s,1H)、7.47-7.28(m,6H)、7.24(d,J=8.1Hz,1H)、7.05(d,J=8.4Hz,1H)、5.75(s,1H)、5.14(s,2H)、4.57(s,2H)、4.57(t,J=9Hz,2H)、4.50(t,J=9Hz,2H)、3.54(m,1H)、2.92(s,2H)、2.48(m,2H)、2.28(s,2H)、1.22(s,9H)。
将N-(3-[[(叔丁氧基)羰基]氨基]-4-[1-(氧杂环丁烷-3-基)-1,2,3,6-四氢吡啶-4-基]苯基)氨基甲酸苄酯(1.4g,2.92mmol,1.00当量)、钯碳(140mg,0.10当量)、乙酸乙酯(40mL)放入用H2惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。滤出固体。将得到的混合物在真空下浓缩。得到610mg(60%)的N-[5-氨基-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基甲酸叔丁酯为浅黄色固体。LC-MS--7:(ES,m/z):[M+H]+=348。1H-NMR-PH--7:(300MHz,d6-DMSO,PPm):δ8.26(s,1H)、6.90(d,J=7.8Hz,1H)、6.40(m,2H)、4.87(s,2H)、4.54(t,J=7.2Hz,2H)、4.46(t,J=7.2Hz,2H)、3.37(m,1H)、2.78(d,J=10.8Hz,2H)、2.60(m,1H)、1.80-1.45(m,6H)、1.21(s,9H)。
将N-[5-氨基-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基甲酸叔丁酯(600mg,2.30mmol,1.00当量)、3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(550mg,2.74mmol,1.20当量)、DIEA(435mg,4.50mmol,2.50当量)、异丙醇(25mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在80℃搅拌过夜。将得到的混合物在真空下浓缩。粗产物通过快速PE:EA=100/85纯化。得到600mg(65%)的N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基甲酸叔丁酯为浅黄色固体。LC-MS--8:(ES,m/z):[M+H]+=534。1H-NMR-PH--8:(300MHz,d6-DMSO,ppm):δ9.40(s,1H)、8.57(s,1H)、7.79(s,1H)、7.72(d,J=8.4Hz,1H)、7.32(s,1H)、7.23(d,J=8.4Hz,1H)、4.54(t,J=6.3Hz,2H)、4.46(t,J=6.3Hz,2H)、3.45-3.37(m,5H)、2.83-2.70(m,3H)、1.83-1.52(m,6H)、1.38(s,9H)。
将N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基甲酸叔丁酯(600mg,1.12mmol,1.00当量)、三氟乙酸(2mL)、二氯甲烷(20mL)放入250-mL圆底烧瓶中。将所得溶液在室温搅拌3h。将得到的混合物在真空下浓缩。将所得溶液用甲醇稀释,并用碳酸钾将pH调节至8。滤出固体。将得到的混合物在真空下浓缩。得到410mg(84%)的3-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为浅黄色固体。LC-MS--9:(ES,m/z):[M+H]+=434。
将3-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(300mg,0.7mmol,1.00当量)、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十-二-2(6),7-二烯-10-基]-3-[(恶烷-2-基氧基)甲基]吡啶-4-基)硼酸(350mg,0.8mmol,1.10当量)、Pd(dppf)Cl2(60mg,0.03mmol,0.10当量)、K2CO3(286mg,2.03mmol,3.00当量)、二恶烷(20mL)、水(2mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在100℃搅拌30分钟。将得到的混合物在真空下浓缩。将所得溶液用甲醇稀释。粗产物通过快速MeCN:H2O=20/80在12分钟内增加至MeCN:H2O=55/45纯化。得到210mg(81%)的10-[4-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为浅黄色固体。LC-MS--10:(ES,m/z):[M+H]+=749。
将10-[4-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(210mg,0.28mmol,1.00当量)、二氯甲烷(10mL)、三氟乙酸(1mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌1h。将得到的混合物在真空下浓缩,并用碳酸氢钠溶液将pH调节至8。所得混合物用EA萃取并用卤水洗涤。将混合物经无水硫酸钠干燥,并在真空下浓缩。得到135mg(72%)的10-[4-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为浅黄色固体。LC-MS--11:(ES,m/z):[M+H]+=665。1H-NMR-PH--11:(300MHz,CDCl3,ppm):δ8.55(d,J=5.1Hz,1H)、8.20(s,1H)、8.00(s,1H)、7.76(d,J=5.1Hz,1H)、7.29(s,1H)、7.23(d,J=5.7Hz,1H)、7.23(d,J=5.4Hz,1H)、6.85(s,1H)、5.02(m,1H)、4.82-4.37(m,7H)、4.20(m,2H)、3.92(m,1H)、3.70-3.50(m,5H)、2.98(m,2H)、2.62-2.47(m,5H)、2.07-1.82(m,6H)、1.73-1.45(m,5H)、1.28(s,6H)。
将10-[4-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(135mg,0.23mmol,1.00当量)、丙-2-烯酸(17mg,0.23mmol,1.00当量)、HATU(94mg,0.25mmol,1.10当量)、NMM(54mg,0.53mmol,2.50当量)、MeCN(5mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。粗产物通过Prep-HPLC纯化。得到15.2mg(11%)的N-(5-[[6-(2-[4,4-甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基)丙-2-烯酰胺为白色固体。LC-MS--0:(ES,m/z):[M+H]+=719。1H-NMR-PH--0:(300MHz,CDCl3,ppm):δ9.54(s,1H)、9.32(s,1H)、8.45(d,J=4.8Hz,1H)、8.32(m,1H)、7.79-7.70(m,3H)、7.25(d,J=8.7Hz,1H)、6.61-6.44(m,2H)、6.27(m,1H)、5.75(d,J=10.8Hz,1H)、5.01(m,1H)、4.67-4.42(m,6H)、4.35-4.15(m,3H)、3.87(m,1H)、3.57(s,3H)、3.40(m,1H)、2.85-2.57(m,5H)、2.45(m,2H)、1.84-1.55(m,6H)、1.23(s,6H)。
实施例8:制备N-(5-((6-(3-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(1-(氧杂环丁烷-3-基)哌啶-4-基)苯基)丙烯酰胺
将3-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(300mg,0.69mmol,1.00当量)、(3-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-2-formyl苯基)硼酸(260mg,0.74mmol,1.10当量)、Pd(dppf)Cl2(35mg,0.05mmol,0.10当量)、碳酸钾(286mg,2.07mmol,3.00当量)、二恶烷(15mL)、水(2mL)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液搅拌40分钟在100℃2h。将得到的混合物在真空下浓缩。将得到的溶液用甲醇萃取,并合并有机层。粗产物通过快速MeCN∶H2O=30/70在12分钟内增加到MeCN∶H2O=65/35纯化。得到268mg(59%)的2-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-6-[4,4-甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]苯甲醛为浅黄色固体。LC-MS--1:(ES,m/z):662[M+H]+。
将2-[6-(3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-6-4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^2,6]十二-2(6),7-二烯-10-基苯甲醛(240mg,0.36mmol,1.00当量)、NaBH4(7mg,0.18mmol,0.50当量)、乙醇(8mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将所得溶液浓缩并用甲醇稀释。用碳酸钾将pH调节至8。滤出固体,并在真空下浓缩滤液。得到132mg(55%)的10-[3-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-2-(羟基甲基)苯基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为浅黄色油。LC-MS--2:(ES,m/z):664[M+H]+1H-NMR-PH--2:(300MHz,d6-DMSO,ppm):δ8.71(s,1H)、7.53-7.25(m,5H)、7.04(d,J=8.4Hz,1H)、6.90(d,J=8.4Hz,1H)、6.53(s,1H)、4.81(m,3H)、4.62-4.40(m,6H)、4.25-4.02(m,3H)、3.93(m,1H)、3.55(s,1H)、3.35(m,1H),2.80(m,2H)、2.55(s,2H)、2.45(s,2H)、1.95-1.4(m,7H)、1.22(s,6H)。
将10-[3-[6-([3-氨基-4-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-2-(羟基甲基)苯基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(100mg,0.15mmol,1.00当量)、丙-2-烯酸(12mg,0.17mmol,1.10当量)、HATU(68mg,0.18mmol,1.20当量)、NMM(30mg,0.30mmol,2.00当量)、MeCN(4mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。粗产物通过Prep-HPLC纯化。得到20.5mg(20%)的N-(5-[[6-(3-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.v^[2,6]]十二-2(6),7-二烯-10-基]-2-(羟基甲基)苯基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[1-(氧杂环丁烷-3-基)哌啶-4-基]苯基)丙-2-烯酰胺为白色固体。LC-MS--0:(ES,m/z):718[M+H]+1H-NMR-PH--0:(300MHz,CDCl3,ppm):δ8.28(s,1H)、7.95(s,1H)、7.70-7.20(m,7H)、6.80(s,1H)、6.45-6.25(m,2H)、5.73(s,1H)、4.70(m,4H)、4.62-4.37(m,3H)、4.25-4.10(m,3H)、3.95(m,1H)、3.65(s,3H)、3.55(m,1H)、2.90(m,2H)、2.70-2.45(m,6H)、2.04-1.80(m,5H)、1.26(s,6H)。
实施例9:制备N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-5-(4-甲基哌嗪-1-基)苯基)丙烯酰胺
将1-溴-3,5-二硝基苯(5.5g,22.27mmol,1.00当量)在二恶烷(50mL)中的溶液、1-甲基哌嗪(2.64g,26.36mmol,1.20当量)、Cs2CO3(14.5g,44.50mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。随后添加Pd2(dba)3(550mg,0.60mmol,0.10当量)、BINAP(770mg,1.24mmol,0.15当量)。将所得溶液在油浴中于100℃搅拌过夜。将反应混合物冷却至25℃。滤出固体。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/己烷(1∶1)的硅胶柱上。得到4.0g(67%)的1-(3,5-di硝基苯基)-4-甲基哌嗪为黄色固体。LC-MS-1:(ES,m/z):267[M+H]+。
将1-(3,5-二基苯基)-4-甲基哌嗪(1.3g,4.88mmol,1.00当量)在甲醇(10mL)中的溶液、钯碳(0.1g,0.10当量)放入用H2惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液在室温搅拌2h。滤出固体。将得到的混合物在真空下浓缩。得到1.0g(99%)的5-(4-甲基哌嗪-1-基)苯-1,3-二胺为棕色油。LC-MS-2:(ES,m/z):207[M+H]+。1H-NMR-PH-1:(300MHz,d6-DMSO,ppm):δ5.44(s,2H)、5.38(s,1H)、4.49(s,4H)、2.95(t,J=6.5Hz,4H)、2.38(t,J=6.5Hz,4H)、2.19(s,3H)。
将3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(1.0g,3.73mmol,1.00当量)在IPA(10mL)中的溶液、5-(4-甲基哌嗪-1-基)苯-1,3-二胺(1.0g,4.85mmol,1.00当量)、DIEA(530mg,4.10mmol,1.10当量)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在油浴中于40℃搅拌1h。将反应混合物冷却至25℃。通过过滤收集固体。得到0.5g(34%)的3-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为棕色固体。LC-MS-3:(ES,m/z):392[M+H]+。
将3-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-5-溴-1-甲基-1,2-二-氢吡嗪-2-酮(300mg,0.76mmol,1.00当量)在二恶烷(10mL)/H2O(1mL)中的溶液、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-[(恶烷-2-基氧基)甲基]吡啶-4-基)硼酸(300mg,0.68mmol,1.00当量)、碳酸钾(240mg,1.74mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。随后添加Pd(dppf)Cl2(30mg,0.04mmol,0.10当量)。将所得溶液在油浴中与100℃搅拌1h。将得到的混合物在真空下浓缩。将残余物施加到具有CH3CN∶H2O(1∶1)的柱上。得到190mg(35%)的10-[4-(6-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS-4:(ES,m/z):708[M+H]+。
将10-[4-(6-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(190mg,0.27mmol,1.00当量)在二氯甲烷(5mL)中的溶液、三氟乙酸(1mL)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液在油浴中于40℃搅拌20分钟。将得到的混合物在真空下浓缩。得到190mg(粗品)的10-[4-(6-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色油。LC-MS-5:(ES,m/z):624[M+H]+。
将丙-2-烯酸(21mg,0.29mmol,1.10当量)、HATU(122.5mg,0.32mmol,1.20当量)、NMM(54mg,0.53mmol,2.00当量)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得混合物搅拌10分钟。向混合物中添加10-[4-(6-[[3-氨基-5-(4-甲基哌嗪-1-基)苯基]氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基)-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(190mg,0.30mmol,1.00当量)。将所得溶液在室温搅拌1h。粗产物通过快速Prep-HPLC纯化。得到23mg(11%)的N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-5-(4-甲基哌嗪-1-基)苯基)丙-2-烯酰胺为浅棕色固体。LC-MS-0:(ES,m/z):678[M+H]+。1H-NMR-PH-1:(300MHz,d6-DMSO,ppm):δ9.88(s,1H)、9.02(s,1H)、8.49(d,J=5.1Hz,1H)、7.80-7.74(m,3H)、7.50(s,1H)、6.97(s,1H)、6.57(s,1H)、6.52-6.25(m,2H)、5.75(d,J=9.6H,1H)、5.02(m,1H)、4.67-4.49(m,2H)、4.32-4.15(m,3H)、3.90(m,1H)、3.55(s,3H)、3.13(m,4H)、2.60(m,2H)、2.45(m,6H)、2.25(s,3H)、1.23(s,3H)。
实施例10:制备N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-5-((4-甲基哌嗪-1-基)甲基)苯基)丙烯酰胺
合成1-[(3,5-二基苯基)甲基]-4-甲基哌嗪:将1-(氯甲基)-3,5-二基苯(3g,13.85mmol,1.00当量)、1-甲基哌嗪(1.38g,13.78mmol,1.00当量)、碳酸钾(4.8g,34.73mmol,2.50当量)、四氢呋喃(30mL)放入250-mL圆底烧瓶中。将所得溶液在70℃搅拌过夜。将反应混合物冷却至室温。滤出固体。将滤液在真空下浓缩。粗产物通过从乙醚中重结晶来纯化。得到3g(77%)的1-[(3,5-二基苯基)甲基]-4-甲基哌嗪为黄色固体。LC-MS--718-1:(ES,m/z):281[M+H]+1H-NMR-PH--718-1:(300MHz,d6-DMSO,ppm):δ8.73(s,1H)、8.56(s,2H)、3.74(s,2H)、2.44(br s,4H),2.34(br s,4H)、2.16(s,3H)。
合成5-[(4-甲基哌嗪-1-基)甲基]苯-1,3-二胺:将1-[(3,5-二基苯基)甲基]-4-甲基哌嗪(2.0g,7.14mmol,1.00当量)、钯碳(0.2g,0.10当量)、甲醇(40mL)放入用H2惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌3h。滤出固体。将滤液在真空下浓缩。得到1.1g(70%)的5-[(4-甲基哌嗪-1-基)甲基]苯-1,3-二胺为无色油。LC-MS--718-2:(ES,m/z):221[M+H]+。1H-NMR-PH--718-2:(300MHz,d6-DMSO,ppm):δ5.76(s,2H),5.70(s,1H)、4.61(s,4H),3.12(s,2H)、2.30(br s,8H)、2.15(s,3H)。
合成3-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮:将3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(1.0g,1.00当量)、5-[(4-甲基哌嗪-1-基)甲基]苯-1,3-二胺(0.7g,1.00当量)、DIEA(1.0g,7.74mmol,2.50当量)、异丙醇(15mL)放入50-mL圆底烧瓶中。将所得溶液在80℃搅拌过夜。将反应混合物冷却至室温。将得到的混合物在真空下浓缩。粗产物通过Prep-HPLC纯化。得到153mg(14%)的3-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为浅黄色固体。LC-MS--718-3:(ES,m/z):407[M+H]+。1H-NMR-PH--718-3:(300MHz,d6-DMSO,ppm):δ8.92(s,1H),7.28(s,1H)、6.95-6.93(m,2H)、6.28(s,1H),5.01(s,2H)、3.44(s,3H)、3.27(s,2H)、2.39-2.36(m,8H)、2.15(s,3H)。
合成10-[4-[6-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将3-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(100mg,0.25mmol,1.00当量)、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-[(恶烷-2-基氧基)甲基]吡啶-4-基)硼酸(120mg,0.27mmol,1.10当量)、Pd(dppf)Cl2(20mg,0.03mmol,0.10当量)、碳酸钾(68mg,0.49mmol,2.00当量)、二恶烷(10mL)、水(1mL)放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。将所得溶液在80℃搅拌30分钟。将反应混合物冷却至室温。滤出固体。将滤液在真空下浓缩。粗产物通过Prep-HPLC纯化。得到30mg(17%)的10-[4-[6-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS--718-4:(ES,m/z):722[M+H]+。
合成10-[4-[6-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将二氯甲烷(2mL)、三氟乙酸(0.2mL)、10-4-[6-(3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^2,6]十二-2(6),7-二烯-9-酮(30mg,0.03mmol,1.00当量)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。得到20mg(74%)的10-[4-[6-([3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基]氨基)-4-甲基-5-氧代-4,5-氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为黄色油。LC-MS--718-5:(ES,m/z):638[M+H]+。
合成N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-5-[(4-甲基哌嗪-1一基)甲基]苯基)丙-2-烯酰胺:将丙-2-烯酸(20mg,0.28mmol,1.00当量)、10-4-[6-(3-氨基-5-[(4-甲基哌嗪-1-基)甲基]苯基氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^2,6]十二-2(6),7-二烯-9-酮(2.7mg,1.20当量)、HATU(14mg,1.20当量)、NMM(8mg,2.50当量)、MeCN(2mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。粗产物通过Prep-HPLC纯化。得到5mg(3%)的N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-5-[(4-甲基哌嗪-1-基)甲基]苯基)丙-2-烯酰胺为棕色固体。LC-MS--718-0:(ES,m/z):692[M+H]+。1H-NMR-PH--718-0:(300MHz,d6-DMSO,ppm):δ8.56-8.52(m,2H)、8.33(s,1H)、7.83-7.78(m,3H)、7.30(s,2H)、6.82(s,1H)、6.44(d,J=15.3Hz,1H)、6.30(dd,J=17.1,9.9Hz,1H)、5.74(dd,J=9.9,1.5Hz,1H)、4.84-4.79(m,1H)、4.54-4.50(m,2H)、4.16-4.12(m,2H)、3.93-3.90(m,1H)、3.65(s,3H)、3.49(s,2H)、2.56-2.51(m,13H)、2.32(s,3H)、1.27(s,6H)。
实施例11:制备(S)N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺
合成2,4-二溴-3-甲基吡啶:将(i-Pr)2NH(3.19g,1.50当量)在四氢呋喃(50mL)中的溶液放入用氮气惰性气氛吹扫并维持的250-mL三颈圆底烧瓶中。随后在-30℃添加n-C4H9Li(10ml,1.5当量)并将混合物在相同温度下搅拌30分钟。随后在-70℃添加2,4-二溴吡啶(5g,21.11mmol,1.00当量)并将混合物在相同温度下搅拌30分钟。在-70℃向上述溶液中加入碘甲烷(4.5g,1.50当量)。将所得溶液在-70℃搅拌30分钟。然后通过加入100mL水性NH4Cl淬灭反应。将所得溶液用3x50mL的乙酸乙酯萃取,并将有机层合并,并用Na2SO4干燥。滤出固体。将滤液在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到3.0g(57%)的2,4-二溴-3-甲基吡啶为白色固体。LC-MS--727-1:(ES,m/z):252[M+H]+ 1H-NMR-PH--727-1:(300MHz,CDCl3,ppm):δ7.99(d,J=5.1Hz,1H)、7.45(d,J=5.1Hz,1H)、2.58(s,3H)。
合成10-(4-溴-3-甲基吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(1.0g,4.90mmol,1.00当量)在二恶烷(10mL)中的溶液放入用氮气惰性气氛吹扫并维持的50-mL圆底烧瓶中。然后将2,4-二溴-3-甲基吡啶(1.59g,6.34mmol,1.30当量)、Pd2(dba)3(100mg,0.11mmol,0.10当量)、Xantphos(100mg,0.17mmol,0.10当量)、Cs2CO3(3.19g,9.79mmol,2.00当量、)添加到混合物。将所得溶液在油浴中于100℃搅拌1.5小时。将反应混合物冷却至室温。滤出固体。将滤液在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(1∶1)的硅胶柱上。得到1.0g(55%)的10-(4-溴-3-甲基吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS--727-2(ES,m/z):374[M+H]+。1H-NMR-PH--727-1:(300MHz,CDCl3,ppm):δ8.10(d,J=5.4Hz,1H)、7.41(d,J=5.1Hz,1H)、6.79(s,1H)、4.44-4.41(m,1H)、4.15-4.09(m,2H)、3.90-3.86(m,1H)、2.54(s,2H)、2.49(s,2H)、2.34(s,3H)、1.25(s,6H)。
合成(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)硼酸:将10-(4-溴-3-甲基吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(500mg,1.34mmol,1.00当量)在二恶烷(5mL)中的溶液放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中,然后向溶液中添加Pin2B2(850mg,2.50当量)、KOAc(400mg,4.08mmol,3.00当量)、Pd(dppf)Cl2(50mg,0.07mmol,0.10当量)。将所得溶液在油浴中于100℃搅拌1h。将反应混合物冷却至室温。滤出固体。将滤液在真空下浓缩。用CH3CN:H2O(1∶1)通过快速Prep-HPLC纯化残余物。得到150mg(33%)的(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)硼酸为棕色固体。LC-MS--727-3:(ES,m/z):340[M+H]+。
合成10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-甲基吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)硼酸(120mg,0.35mmol,1.00当量)在二恶烷(1mL)中的溶液放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中,然后向溶液中添加3-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(100mg,0.22mmol,1.10当量)、Pd(dppf)Cl2(10mg,0.01mmol,1.00当量)、碳酸钾(73mg,0.53mmol,2.00当量)。将所得溶液在油浴中于100℃搅拌1h。将反应混合物冷却至室温。将得到的混合物在真空下浓缩。通过快速Prep-HPLC纯化残余物。得到120mg(51%)的10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-甲基吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为棕色固体。LC-MS--727-4:(ES,m/z):664[M+H]+。
合成N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)丙-2-烯酰胺:将10-[4-[6-([3-氨基-4-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基]氨基)-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-甲基吡啶-2-基]-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(200mg,0.30mmol,1.00当量)在CH3CN(1mL)中的溶液放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中,然后向溶液中添加丙-2-烯酸(21.7mg,0.30mmol,1.00当量)、HATU(115mg,0.30mmol,1.00当量)、NMM(61mg,0.60mmol,2.00当量)。将所得溶液在室温搅拌4h。将得到的混合物在真空下浓缩。粗产物通过快速Prep-HPLC纯化。得到21.1mg(10%)的N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]-2-[(2S)-2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基]苯基)丙-2-烯酰胺为浅黄色固体。LC-MS--727-0:(ES,m/z):718[M+H]+。1H-NMR-PH--727-1:(300MHz,d6-DMSO3,ppm):δ8.88(d,J=5.7Hz,1H)、8.32(d,J=5.7Hz,1H)、7.67-7.59(m,2H)、7.33-7.27(m,2H)、6.64-6.55(m,2H)、6.24(d,J=16.5Hz,1H)、5.76(d,J=11.4Hz,1H)、4.72-4.65(m,4H)、4.19-4.09(m,4H)、3.90-3.83(m,2H)、3.54(s,3H)、3.30-3.12(m,3H)、3.00-2.83(m,3H)、2.51(s,2H)、2.40(s,2H)、2.26(s,3H)、1.18(s,6H)、0.74-0.71(m,3H)。
实施例12:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-吗啉代哌啶-1-基)苯基)丙烯酰胺
合成2-甲基-4-(吗啉-4-基)哌啶-1-羧酸叔丁酯:将2-甲基-4-氧代哌啶-1-羧酸叔丁酯(18g,84.40mmol,1.00当量)、吗啉(8g,91.83mmol,1.10当量)、NaCNBH3(10g,2.00当量)、乙醇(200mL)放入500-mL圆底烧瓶中。将所得溶液在50℃搅拌过夜。将得到的混合物在真空下浓缩。粗产物通过快速Prep-HPLC纯化。得到9.4g(39%)的2-甲基-4-(吗啉-4-基)哌啶-1-羧酸叔丁酯为无色油。LC-MS--729-1:(ES,m/z):285[M+H]+。1H-NMR-PH--729-1:(300MHz,CDCl3,ppm):δ4.01-3.94(m,1H)、3.75-3.72(m,4H)、3.17-3.07(m,1H)、2.56-2.51(m,4H)、2.42-2.37(m,1H)、1.89-1.83(m,2H)、1.68-1.53(m,3H)、1.48(s,9H)、1.27(d,J=6.3Hz,3H)。
合成4-(2-甲基哌啶-4-基)吗啉:将2-甲基-4-(吗啉-4-基)哌啶-1-羧酸叔丁酯(5g,17.58mmol,1.00当量)、氯化氢/二恶烷(50mL)放入250-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。将所得混合物用MeCN稀释,并用碳酸钾碱化。将混合物过滤并将滤液浓缩。得到3g(93%)的4-(2-甲基哌啶-4-基)吗啉为白色固体。LC-MS--729-2:(ES,m/z):185[M+H]+。
合成N-[4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]-3-硝基苯基]氨基甲酸苄酯,将4-(2-甲基哌啶-4-基)吗啉(3g,16.28mmol,1.00当量)、N-(4-氟-3-硝基苯基)氨基甲酸苄酯(5.6g,19.29mmol,1.20当量)、碳酸钾(6.75g,48.91mmol,3.00当量)、MeCN(60mL)放入250-mL圆底烧瓶中。将所得溶液在90℃搅拌过夜。通过过滤收集固体。将得到的混合物在真空下浓缩,并施加到具有乙酸乙酯/石油醚(75∶25)的硅胶柱上。粗产物通过快速Prep-HPLC纯化,其中MeCN∶0.1%TFA/H2O=20/80在12分钟内增加到MeCN∶0.1%TFA/H2O=45/55。得到1.5g(21%)的N-[4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]-3-硝基苯基]氨基甲酸苄酯为黄色固体。LC-MS--729-3:(ES,m/z):455[M+H]+。1H-NMR-PH--729-3:(300MHz,d6-DMSO,ppm):δ10.21(s,1H)、9.90(br s,1H)、7.87(s,1H)、7.64-7.52(m,2H)、7.50-7.30(m,5H)、5.18(s,2H)、4.10-3.96(m,2H)、3.80-3.60(m,2H)、3.55-3.30(m,3H)、3.20-2.97(m,4H)、2.69(t,J=11.1Hz,1H)、2.25-2.10(m,2H)、1.75-1.55(m,1H)、1.40-1.30(m,1H)、0.74(d,J=6.0Hz,3H)。
合成N-[3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸苄酯:将N-[4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]-3-硝基苯基]氨基甲酸苄酯(1.2g,2.64mmol,1.00当量)、Zn(1.0g,15.38mmol,6.00当量)、NH4Cl(1.7g,31.78mmol,12.00当量)、MeOH(15mL)放入100-mL圆底烧瓶中。将所得溶液在室温搅拌1h。通过过滤收集固体。将滤液在真空下浓缩。将残余物施加到具有二氯甲烷/甲醇(15∶1)的硅胶柱上。得到0.84g(75%)的N-[3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸苄酯为棕色固体。LC-MS--729-4:(ES,m/z):425[M+H]+。
合成N-(3-[[(叔丁氧基)羰基]氨基]-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基)氨基甲酸苄酯:将N-[3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸苄酯(0.5g,3.53mmol,1.00当量)、Boc2O(0.38g,5.28mmol,1.50当量)、DIEA(0.38g,8.84mmol,2.50当量)、四氢呋喃(15mL)放入250-mL圆底烧瓶中。将所得溶液在75℃搅拌过夜。将反应混合物冷却至室温。将得到的混合物在真空下浓缩。将残余物施加到具有乙酸乙酯/石油醚(75∶25)的硅胶柱上。得到0.5g(80%)的N-(3-[[(叔丁氧基)羰基]氨基]-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基)氨基甲酸苄酯为浅黄色固体。LC-MS--729-5:(ES,m/z):252[M+H]+。1H-NMR-PH--729-5:(300MHz,d6-DMSO,ppm):δ9.69(s,1H)、8.19(s,1H)、8.05(s,1H)、7.46-7.30(m,5H)、7.18-7.15(m,1H)、7.10-7.06(m,1H)、5.14(s,2H)、3.59(br s,4H)、2.90-2.47(m,4H)、2.42-2.25(m,2H)、2.0-1.82(m,2H)、1.72-1.60(m,1H)、1.50-1.32(m,12H)、0.71(d,J=6.0Hz,3H)。
合成N-[5-氨基-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯:将N-(3-[[(叔丁氧基)羰基]氨基]-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基)氨基甲酸苄酯(500mg,1.52mmol,1.00当量)、钯碳(50mg)、甲醇(30mL)放入用H2惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在25℃搅拌3h。将混合物在真空下浓缩。得到381mg(粗品)的N-[5-氨基-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯为无色油。LC-MS--729-6:(ES,m/z):391[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯:将N-[5-氨基-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯(300mg,1.54mmol,1当量)、3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(250mg,1.87mmol,1.21当量)、DIEA(250mg,3.87mmol,2.52当量)、i-PrOH(10mL)放入100-mL圆底烧瓶中。将所得溶液在80℃搅拌过夜。将反应混合物冷却至室温。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯的硅胶柱上。得到265mg(59.73%)的N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯为黄色固体。LC-MS--729-7:(ES,m/z):577[M+H]+。1H-NMR-PH--729-7:(300MHz,d6-DMSO,ppm):δ9.38(s,1H)、8.41(s,1H)、8.04(s,1H)、7.59-7.55(m,1H)、7.32(s,1H)、7.23(d,J=0.9Hz,1H)、3.65-3.55(m,4H)、3.44(s,3H)、2.92-2.52(m,4H)、2.42-2.28(m,2H)、2.00-1.82(m,2H)、1.50-1.30(m,13H)、0.73-0.69(m,3H)。
合成3-([3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮:将N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基甲酸叔丁酯(200mg,0.31mmol,1当量)、HCl/二恶烷(5mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌4小时。将得到的混合物浓缩。得到160mg(96.45%)的3-([3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为浅黄色固体。LC-MS--729-8:(ES,m/z):477[M+H]+。
合成10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将3-([3-氨基-4-[2-甲基-4-(吗啉-4-基)哌啶-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮(160mg,0.34mmol,1当量)、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-[(恶烷-2-基氧基)甲基]吡啶-4-基)硼酸(147mg,0.33mmol,1.00当量)、Pd(dppf)Cl2(30mg,0.03mmol,0.10当量)、K2CO3(116mg,0.84mmol,2.50当量)、二恶烷(5mL,无限mmol,无限当量)、H2O(0.5mL)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中。将所得溶液在90℃搅拌40分钟。将反应混合物冷却至室温。将得到的混合物浓缩。并通过快速Prep-HPLC纯化。得到210mg(79.12%)的10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为固体。LC-MS--729-9:(ES,m/z):792[M+H]+。
合成10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮:将10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-[(恶烷-2-基氧基)甲基]吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(200mg,0.38mmol,1.00当量)、三氟乙酸(1mL)、二氯甲烷(20mL)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物在真空下浓缩。将所得溶液用乙酸乙酯稀释,并用碳酸氢钠水溶液碱化。滤出固体,并将滤液在真空下浓缩。得到130mg(76%)的10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮为无色油。LC-MS--729-10:(ES,m/z):708[M+H]+。
合成N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]苯基)丙-2-烯酰胺:将10-(4-[6-[(3-氨基苯基)氨基]-4-甲基-5-氧代-4,5-二氢吡嗪-2-基]-3-(羟基甲基)吡啶-2-基)-4,4-二甲基-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-9-酮(100mg,0.19mmol,1.00当量)、丙-2-烯酸(13.7mg,0.19mmol,1.00当量)、NMM(38.5mg,0.38mmol,2.00当量)、HATU(94mg,0.25mmol,1.30当量)、MeCN(5mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。粗产物通过Prep-HPLC纯化。得到19.7mg(18%)的N-(3-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基]氨基]苯基)丙-2-烯酰胺为灰白色固体。LC-MS--729-0:(ES,m/z):762[M+H]+。1H-NMR-PH--729-0:(300MHz,DMSO,ppm):δ9.23(s,2H)、9.14(s,1H)、8.49(d,J=5.1Hz,1H)、7.96-7.95(m,1H)、7.77(s,1H)、7.61(d,J=8.1Hz,1H)、7.23(d,J=8.7Hz,1H)、6.68-6.62(m,1H)、6.57(s,1H)、6.30(d,J=17.1Hz,1H)、5.80(d,J=11.7Hz,1H)、5.03-5.00(m,1H)、4.65-4.40(m,2H)、4.32-4.16(m,4H)、3.85-3.83(m,1H)、3.68-3.55(m,7H)、3.01-2.72(m,2H)、2.71-2.52(m,4H)、2.48-2.25(m,4H)、1.98-1.78(m,2H)、1.72-1.52(m,1H)、1.46-1.30(m,1H)、1.23(s,6H)、0.76(d,J=5.7Hz,3H)。
实施例13:制备(R)N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(3-(二甲基氨基)吡咯烷-1-基)苯基)丙烯酰胺
合成N-[4-[(3R)-3-(二甲基氨基)吡咯烷-1-基]-3-硝基苯基]氨基甲酸苄酯为黄色固体:将(3R)-N,N-二甲基吡咯烷-3-胺二盐酸盐(5g,26.72mmol,1当量)、N-(4-氟-3-硝基苯基)氨基甲酸苄酯(9.3g,32.07mmol,1.20当量)、TEA(10.8g,106.89mmol,4.00当量)、DMF(80mL)放入250-mL圆底烧瓶中。将所得溶液在100℃搅拌过夜。将反应混合物冷却至室温。然后通过加入200mL的水淬灭反应。将所得溶液用2x200ml的乙酸乙酯萃取。有机混合物用2x200ml卤水洗涤。有机相用无水硫酸钠干燥。滤出固体。将滤液在真空下浓缩。粗产物通过从MeCN中重结晶来纯化。得到5.2g(50.62%)的N-[4-[(3R)-3-(二甲基氨基)吡咯烷-1-基]-3-硝基苯基]氨基甲酸苄酯为黄色固体。LC-MS--729-C-1:(ES,m/z):385[M+H]+。1H-NMR-PH--729-C-1:(300MHz,d6-DMSO,ppm):δ9.78(s,1H)、7.96(s,1H)、7.52-7.37(m,6H)、7.06(d,J=9.3Hz,1H)、5.15(s,2H)、3.30-3.27(m,1H)、3.13-3.01(m,3H)、2.71-2.68(m,1H)、2.17(s,6H)、1.83-1.71(m,1H)。
合成N-[3-氨基-4-[3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸苄酯:将N-[4-[3-(二甲基氨基)吡咯烷-1-基]-3-硝基苯基]氨基甲酸苄酯(5g,13.01mmol,1当量)、锌(5.1g,78.04mmol,6.00当量)、NH4Cl(8.3g,156.07mmol,12.00当量)、MeOH(100mL)放入250-mL圆底烧瓶中。将所得溶液在室温搅拌1小时。将得到的混合物浓缩。得到3.9g(84.60%)的N-[3-氨基-4-[3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸苄酯为灰色固体。LC-MS--729-C-2:(ES,m/z):365[M+H]+。
合成N-(3-[[(叔丁氧基)羰基]氨基]-4-[3-(二甲基氨基)吡咯烷-1-基]苯基)氨基甲酸苄酯:将N-[3-氨基-4-[3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸苄酯(3g,16.93mmol,1当量)、二碳酸二叔丁酯(2.2mg,20mmol)、DIEA(2.73g,40mmol)、THF(50mL)放入250-mL圆底烧瓶中。将所得溶液在75℃搅拌过夜。将反应混合物冷却至室温。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(50∶50)的硅胶柱上。得到2.6g(68%)的N-(3-[[(叔丁氧基)羰基]氨基]-4-[3-(二甲基氨基)吡咯烷-1-基]苯基)氨基甲酸苄酯为黄色固体。LC-MS--729-C-3:(ES,m/z):465[M+H]+。1H-NMR-PH--729-C-3:(300MHz,DMSO,ppm):δ9.51(s,1H)、8.06(s,1H)、7.54(s,1H)、7.41-7.33(m,5H)、7.14-7.11(m,1H)、6.89(d,J=9.0Hz,1H)、5.13(s,2H)、3.21-3.12(m,1H)、3.09-2.99(m,3H)、2.79-2.69(m,1H)、2.17(s,6H)、2.09-2.00(m,1H),1.78-1.65(m,1H),1.44(s,9H)。
合成N-[5-氨基-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯:将N-(3-[[(叔丁氧基)羰基]氨基]-4-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基)氨基甲酸苄酯(2g,0.44mmol,1当量)、Pd/C(200mg)、MeOH(50mL)放入用H2惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌2小时。滤出固体。将滤液在真空下浓缩。将得到的混合物浓缩。得到1.15g的N-[5-氨基-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯为棕色油。LC-MS--729-C-4:(ES,m/z):321[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯:将N-[5-氨基-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯(1g,1当量)、3,5-二溴-1-甲基-1,2-二氢吡嗪-2-酮(1g,1.20当量)、DIEA(1g,2.49当量)、i-PrOH(10mL)放入250-mL圆底烧瓶中。将所得溶液在80℃搅拌过夜.将反应混合物冷却至室温。将得到的混合物浓缩。将残余物施加到具有EA/PE(50∶50)的硅胶柱上。得到1g(60.62%)的N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯为黄色固体。LC-MS--729-C-5:(ES,m/z):507[M+H]+。
合成3-([3-氨基-4-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮:将N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基甲酸叔丁酯(1g,0.39mmol,1当量)、HCl/二恶烷(10mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物浓缩。得到750mg(93.43%)的3-([3-氨基-4-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二氢吡嗪-2-酮为浅黄色固体。LC-MS--729-C-6:(ES,m/z):407[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[3-(二甲基氨基)吡咯烷-1-基]苯基]丙-2-烯酰胺:将3-([3-氨基-4-[3-(二甲基氨基)吡咯烷-1-基]苯基]氨基)-5-溴-1-甲基-1,2-二二氢吡嗪-2-酮(600mg,1.96mmol,1当量)、丙-2-烯酸(127.2mg,2.36mmol,1.2当量)、HATU(672mg,2.36mmol,1.2当量)、NMM(596mg,7.86mmol,4.0当量)、MeCN(15mL)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物浓缩。粗产物通过Prep-HPLC纯化。得到307mg(45.25%)的N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[3-(二甲基氨基)吡咯烷-1-基]苯基]丙-2-烯酰胺为浅黄色固体。LC-MS--729-C-1:(ES,m/z):461[M+H]+。
合成N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(3-(二甲基氨基)吡咯烷-1-基)苯基)丙烯酰胺:将N-[5-[(6-溴-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基]-2-[(3S)-3-(二甲基氨基)吡咯烷-1-基]苯基]丙-2-烯酰胺(50mg,0.11mmol,1当量)、(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-(羟基甲基)吡啶-4-基)硼酸(50.0mg,0.14mmol,1.3当量)、Pd(dppf)Cl2(9.3mg,0.01mmol,0.1当量)、K2CO3(37.4mg,0.27mmol,2.5当量)、二恶烷(5mL)、H2O(0.5mL)放入用氮气惰性气氛吹扫并维持的25-mL圆底烧瓶中.将所得溶液在90℃搅拌1小时。将反应混合物冷却至室温。滤出固体。浓缩滤液。粗产物通过Prep-HPLC纯化。得到14mg(18.67%)的N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(3-(二甲基氨基)吡咯烷-1-基)苯基)丙烯酰胺为白色固体。LC-MS--729-C-0:(ES,m/z):692[M+H]+。1H-NMR-PH--729-C-0:(300MHz,DMSO,ppm):δ9.38(d,J=5.1Hz,1H)、9.17(s,1H)、8.44(d,J=5.1Hz,1H)、8.34-8.32(m,1H)、7.76-7.63(m,3H)、6.86(d,J=8.7Hz,1H)、6.62-6.48(m,2H)、6.27(d,J=16.2Hz,1H)、5.73(d,J=11.4Hz,1H)、5.05-4.95(m,1H)、4.70-4.38(m,2H)、4.29-4.20(m,3H)、3.89-3.84(m,1H)、3.55(s,3H)、3.14-3.07(m,3H)、2.74-2.49(m,6H)、2.15(s,6H)、2.05(m,1H)、1.75-1.69(m,1H)、1.23(s,6H)。
实施例14:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-氢吡嗪-2-基)氨基)-2-(哌啶-3-基)苯基)丙烯酰胺
合成3-(4-氨基-2-硝基苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯:将3-(4,4,5,5-四甲基-1,3,2--二氧杂硼杂环戊-2-基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯(8.55g,27.647mmol,1.20当量)、4-溴-3-硝基苯胺(5.00g,23.039mmol,1.00当量)、Pd(dppf)Cl2CH2Cl2(1.88g,2.304mmol,0.10当量)、K2CO3(6.37g,46.091mmol,2.00当量)、二恶烷(80.00mL)、H2O(20.00mL)放入用氮气惰性气氛吹扫并维持的500-mL圆底烧瓶中。将所得溶液在100℃搅拌2小时。滤出固体。浓缩合并的有机层。将残余物施加到具有乙酸乙酯/石油醚(60:40)的硅胶柱上。得到7g(95.14%)的3-(4-氨基-2-硝基苯基)-5,6-二氢-2H-吡啶e-1-羧酸叔丁酯为白色固体。LC-MS--751-1:(ES,m/z):320[M+H]+。
合成3-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-5,6-二氢-2H-吡啶e-1-羧酸叔丁酯:将3-(4-氨基-2-硝基苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯(7.00g,21.919mmol,1.00当量)、Na2CO3(4.65g,43.838mmol,2.00当量)、DCM(50.00mL)放入250-mL三颈圆底烧瓶中。随后在0℃搅拌下添加H2O(10.00mL)。在0℃下向其中加入氯甲酸苄酯(4.49g,26.303mmol,1.20当量)。将所得溶液在室温搅拌过夜。然后通过添加水将反应淬灭。混合物经无水硫酸钠干燥并浓缩。得到9g的3-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-5,6-二氢-2H-吡啶e-1-羧酸叔丁酯为浅黄色油。LC-MS--751-2:(ES,m/z):454[M+H]+。
合成3-(2-氨基-4-[[(苄氧基)羰基]氨基]苯基)-5,6-二氢-2H-吡啶e-1-羧酸叔丁酯:将3-(4-[[(苄氧基)羰基]氨基]-2-硝基苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯(5.00g,11.025mmol,1.00当量)、Fe(3.08g,55.127mmol,5.00当量)、CH3COOH(20.00mL)、H2O(2.00mL)放入100-mL圆底烧瓶中。将所得溶液在60℃搅拌1小时。将得到的混合物浓缩。将所得溶液用乙酸乙酯萃取。用NaHCO3将溶液的pH值调节至7。所得混合物用卤水洗涤。混合物经无水硫酸钠干燥并浓缩。将残余物施加到具有乙酸乙酯/石油醚(60:40)的硅胶柱上。得到4g(85.66%)的3-(2-氨基-4-[[(苄氧基)羰基]氨基]苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯为黄色固体。LC-MS--751-3:(ES,m/z):424[M+H]+。1HNMR--751-3:(300MHz,DMSO-d6,ppm):δ9.49(s,1H)、7.49-7.32(m,5H)、6.88(d,J=2.0Hz,1H)、6.76(d,J=8.2Hz,1H)、6.61(dd,J=8.2,2.1Hz,1H)、5.78-5.70(s,1H)、5.13(s,2H)、4.84(s,2H)、3.89(d,J=2.7Hz,2H)、3.48(t,J=5.6Hz,2H)、2.25-2.13(s,2H)、1.42(s,9H)。
合成3-(4-[[(苄氧基)羰基]氨基]-2-[(叔丁氧基羰基)氨基]苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯:将3-(2-氨基-4-[[(苄氧基)羰基]氨基]苯基)-5,6-二氢-2H-吡啶-1-羧酸叔丁酯(4.00g,9.445mmol,1.00当量)、二碳酸二叔丁酯(4.12g,18.890mmol,2.00当量)、K2CO3(2.61g,18.885mmol,2.00当量)、二恶烷(80.00mL)、H2O(40.00mL)放入250-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。然后通过添加水将反应淬灭。所得溶液用乙酸乙酯萃取。所得混合物用卤水洗涤。混合物经无水硫酸钠干燥并浓缩。将残余物施加到具有乙酸乙酯/石油醚(40∶60)的硅胶柱上。得到5g(101.10%)的3-(4-[[(苄氧基)羰基]氨基]-2-[(叔丁氧基羰基)氨基]苯基)-5,6-二氢-2H-吡啶e-1-羧酸叔丁酯为白色固体。LC-MS--751-4:(ES,m/z):524[M+H]+。1H NMR--751-4:(300MHz,DMSO-d6,ppm):δ9.79(s,1H)、8.31(s,1H)、7.51(d,J=2.1Hz,1H)、7.50-7.31(m,5H)、7.25(dd,J=8.4,2.2Hz,1H)、7.07(d,J=8.4Hz,1H)、5.69(s,1H)、5.16(s,2H)、3.97(s,2H)、3.45(t,J=5.7Hz,2H)、2.18(s,2H)、1.42(s,18H)。
合成3-[4-氨基-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯:将3-(4-[[(苄氧基)羰基]氨基]-2-[(叔丁氧基羰基)氨基]苯基)-5,6-二氢-2H-吡啶-羧酸叔丁酯(5.00g,9.549mmol,1.00当量)、Pd/C(500.00mg)、MeOH(100mL)、EA(50.00mL)放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。通过过滤收集固体。浓缩合并的有机层。得到3.4g(90.95%)的3-[4-氨基-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯为无色油。LC-MS--751-5:(ES,m/z):392[M+H]+。
合成3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯:将3-[4-氨基-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯(3.40g,8.684mmol,1.00当量)、3,5-二溴-1-甲基吡嗪-2-酮(2.56g,9.553mmol,1.1当量)、i-PrOH(50.00mL)、DIEA(2.24g,17.369mmol,2.0当量)放入250-mL圆底烧瓶中。将所得溶液在90℃搅拌过夜。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(40∶60)的硅胶柱上。得到4g(79.62%)的3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯为浅黄色固体。
LC-MS--751-6:(ES,m/z):578[M+H]+。
合成3-[[3-氨基-4-(哌啶-3-基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮:将3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[(叔丁氧基羰基)氨基]苯基]哌啶-1-羧酸叔丁酯(4.00g)放入250-mL圆底烧瓶中。向上述添加HCl(g)/MeOH(80.00mL)。将所得溶液在室温搅拌2小时。将得到的混合物浓缩。得到2.9g的3-[[3-氨基-4-(哌啶-3-基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮为白色固体。LC-MS--751-7:(ES,m/z):378[M+H]+。
合成3-[2-氨基-4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]苯基]哌啶-1-羧酸叔丁酯:将3-[[3-氨基-4-(哌啶-3-基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮(2.90g,7.666mmol,1.00当量)、Boc2O(1.84g,8.431mmol,1.10当量)、TEA(1.55g,15.333mmol,2.00当量)、DCM(50ml)放入250-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。将得到的混合物浓缩。粗产物通过从乙醚中重结晶来纯化。得到2.5g(68.17%)的3-[2-氨基-4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]苯基]哌啶-1-羧酸叔丁酯为白色固体。LC-MS--751-8:(ES,m/z):478[M+H]+。1HNMR--751-8:(300MHz,DMSO-d6,ppm):δ8.99(s,1H)、7.27(s,1H)、7.11-7.01(m,2H)、6.92(d,J=9.0Hz,1H)、4.90(s,2H)、3.98(s,2H)、3.43(s,3H)、2.84-2.54(m,3H)、1.90-1.82(m,1H)、1.73-1.64(m,1H)、1.60-1.46(m,2H)、1.42(s,9H)。
合成3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(丙-2-烯酰胺基)苯基]哌啶-1-羧酸叔丁酯:将3-[2-氨基-4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]苯基]哌啶-1-羧酸叔丁酯(500.00mg,1.045mmol,1.00当量)、丙烯酰氯(141.90mg,1.568mmol,1.5当量)、NMM(211.43mg,2.090mmol,2.00当量)、DCM(10mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌2小时。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(70:30)的硅胶柱上。得到300mg(53.91%)的3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(丙-2-烯酰胺基)苯基]哌啶-1-羧酸叔丁酯为黄色固体。LC-MS--751-9:(ES,m/z):532[M+H]+。1HNMR--751-9:(300MHz,DMSO-d6,ppm):δ9.67(s,1H)、9.47(s,1H)、7.86-7.75(m,2H)、7.36-7.25(m,2H)、6.58-6.43(m,1H)、6.24(dd,J=17.0,2.1Hz,1H)、5.75(d,J=7.6Hz,1H)、4.10-3.81(m,2H)、3.44(s,3H)、2.83-2.62(m,3H)、1.87-1.76(m,1H)、1.70(d,J=13.4Hz,1H)、1.65-1.50(m,1H)、1.37(s,9H)。
合成3-(4-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-(丙-2-烯酰胺基)苯基)哌啶-1-羧酸叔丁酯:将3-[4-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(丙-2-烯酰胺基)苯基]哌啶-1-羧酸叔丁酯(300.00mg,0.563mmol,1.00当量)、2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基硼酸(248.46mg,0.732mmol,1.30当量)、Pd(dppf)Cl2 CH2Cl2(46.01mg,0.056mmol,0.10当量)、K2CO3(155.51mg,1.127mmol,2.00当量)、DME(10.00mL)、H2O(2.00mL)放入用氮气惰性气氛维持的40-mL微波管中。将所得溶液在90℃搅拌1小时。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(40∶60)的硅胶柱上。得到240mg(57.03%)的3-(4-[[6-(2-[4,4--二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-(丙-2-烯酰胺基)苯基)哌啶-1-羧酸叔丁酯为黄色固体。LC-MS--751-10:(ES,m/z):747[M+H]+。
合成N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-(哌啶-3--基)苯基)丙-2-烯酰胺-:将3-(4-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基.3-氧代吡嗪-2-基]氨基]-2-(丙-2-烯酰胺基)苯基)哌啶-1-羧酸叔丁酯(150.00mg,0.201mmol,1.00当量)、DCM(8.00mL)、TFA(1.5.mL)放入25-mL圆底烧瓶中。将所得溶液在室温搅拌2.5小时。将得到的混合物浓缩。然后通过添加NaHCO3淬灭反应。经所得溶液用二氯甲烷萃取。所得混合物用卤水洗涤。混合物经无水硫酸钠干燥并浓缩。粗产物通过Prep-HPLC纯化。得到80mg(61.59%)的N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-(哌啶-3-基)苯基)丙-2-烯酰胺为白色固体。LC-MS--751-0:(ES,m/z):647[M+H]+。1H NMR--751-0:(300MHz,DMSO-d6,ppm):δ9.61(s,1H)、9.29(s,1H)、8.32(d,J=5.0Hz,1H)、8.16(d,J=7.2Hz,1H)、7.77(d,J=8.5Hz,1H)、7.49(d,J=4.8Hz,1H)、7.43(s,1H)、7.21(d,J=8.6Hz,1H)、6.60-6.47(m,2H)、6.23(d,J=16.6Hz,1H)、5.70(d,J=10.2Hz,1H)、4.30-4.11(m,3H)、3.84(d,J=12.5Hz,1H)、3.57(s,3H)、2.99-2.73(m,3H)、2.58(d,J=5.5Hz,2H)、2.43(s,3H)、2.29(s,3H)、1.83-1.69(m,1H)、1.69-1.58(m,1H)、1.58-1.37(m,2H)、1.23(s,7H)。
实施例15:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-甲基哌嗪-1-羰基)苯基)丙烯酰胺
合成2-氨基-4-硝基苯甲酸甲酯。将2-氨基-4-硝基苯甲酸(2.00g)、SOCl2(4.00mL)、MeOH(20.00mL)放入100-mL圆底烧瓶中。将所得溶液在55℃搅拌3小时。将反应混合物冷却。粗产物通过从乙醚中重结晶来纯化。通过过滤收集固体。得到1g的2-氨基-4-硝基苯甲酸甲酯为黄色固体。LC-MS--752-1:(ES,m/z):197[M+H]+。1H NMR--752-1:(300MHz,CDCl3,ppm):δ8.02(d,J=8.8Hz,1H)、7.53(d,J=2.2Hz,1H)、7.42(dd,J=8.8,2.2Hz,1H)、6.05(brs,2H)、3.94(s,3H)。
合成2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸甲酯:将2-氨基-4-硝基苯甲酸甲酯(1.00g,5.098mmol,1.00当量)、Boc2O(3.34g,15.293mmol,3.00当量)、TEA(1.03g,10.196mmol,2.00当量)、DMAP(0.06g,0.510mmol,0.10当量)、THF(20.00mL)放入100-mL圆底烧瓶中。将所得溶液在室温搅拌4小时。然后通过添加水将反应淬灭。将所得溶液用乙酸乙酯萃取,用无水硫酸钠干燥并浓缩。得到1.8g(89.08%)的2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸甲酯为黄色固体。LC-MS--752-2:(ES,m/z):397[M+H]+。1HNMR--752-2:(300MHz,CDCl3,ppm):δ8.26(dd,J=8.6,2.2Hz,1H)、8.17(d,J=8.6Hz,1H)、8.10(d,J=2.2Hz,1H)、3.94(s,3H)、1.42(s,18H)。
合成2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸:将2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸甲酯(1.80g,1当量)、LiOH(300.00mg)、H2O(4.00mL)、THF(20.00mL)放入100-mL圆底烧瓶中。将所得溶液在室温搅拌过夜。然后通过添加1N盐酸水溶液到反应溶液中将反应淬灭,并用乙酸乙酯萃取。有机层经无水Na2SO4干燥,浓缩。得到1g(57.59%)的2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸为黄色固体。
LC-MS--752-3:(ES,m/z):383[M+H]+。
合成N-(叔丁氧基羰基)-N-[2-(4-甲基哌嗪-1-羰基)-5-硝基苯基]氨基甲酸叔丁酯-:将2-[双(叔丁氧基羰基)氨基]-4-硝基苯甲酸(1.00g,2.615mmol,1.00当量)、哌嗪、1-甲基-(0.31g,3.138mmol,1.20当量)、HATU(1.49g,3.923mmol,1.50当量)、NMM(0.53g,5.231mmol,2.00当量)、DCM(15.00mL)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌4小时。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(100∶1)的硅胶柱上。得到500mg(41.16%)的N-(叔丁氧基羰基)-N-[2-(4-甲基哌嗪-1-羰基)-5-硝基苯基]氨基甲酸叔丁酯为浅黄色固体。LC-MS--752-4:(ES,m/z):465[M+H]+。
合成N-[5-氨基-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯:将N-(叔丁氧基羰基)-N-[2-(4-甲基哌嗪-1-羰基)-5-硝基苯基]氨基甲酸叔丁酯(500.00mg)、MeOH(20.00ml)、Pd/C(500.00mg)放入用H2惰性气氛吹扫并维持的100-mL圆底烧瓶中。将所得溶液在室温搅拌6小时。通过过滤收集固体。浓缩合并的有机层。得到400mg的N-[5-氨基-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯为无色油。LC-MS--752-5:(ES,m/z):435[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯:将N-[5-氨基-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯(400.00mg,0.921mmol,1.00当量)、3,5-二溴-1-甲基吡嗪-2-酮(369.92mg,1.381mmol,1.5当量)、Pd2(dba)3(168.59mg,0.184mmol,0.2当量)、XantPhos(213.05mg,0.368mmol,0.4当量)、Cs2CO3(599.85mg,1.841mmol,2.0当量)、甲苯(25.00mL)放入用氮气惰性气氛吹扫并维持的250-mL圆底烧瓶中。将所得溶液在100℃搅拌4小时。将得到的混合物浓缩。将残余物施加到具有乙酸乙酯/石油醚(70:30)的硅胶柱上。得到200mg(34.96%)的N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯为浅黄色固体。LC-MS--752-6:(ES,m/z):621[M+H]+。
合成3-[[3-氨基-4-(4-甲基哌嗪-1-羰基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮:将N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]-N-(叔丁氧基羰基)氨基甲酸叔丁酯(200.00mg)、在1,4-二恶烷(10.00mL)中的HCl(气体)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌2小时。将得到的混合物浓缩。得到120mg的3-[[3-氨基-4-(4-甲基哌嗪-1-羰基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮为白色固体。LC-MS--752-7:(ES,m/z):421[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]丙-2-烯酰胺:将3-[[3-氨基-4-(4-甲基哌嗪-1-羰基)苯基]氨基]-5-溴-1-甲基吡嗪-2-酮(120.00mg,0.285mmol,1.00当量)、丙烯酰氯(28.36mg,0.313mmol,1.10当量)、NMM(57.62mg,0.570mmol,2.00当量)、DCM(10.00mL)放入50-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物浓缩。粗产物通过快速Prep-HPLC 0.1%NH3.H2O:MeCN=30%在9分钟内增加至0.1%NH3.H2O:MeCN=58%来纯化。得到80mg(59.09%)的N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]丙-2-烯酰胺为白色固体。LC-MS--752-8:(ES,m/z):475[M+H]+。
合成-752-0:将N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-(4-甲基哌嗪-1-羰基)苯基]丙-2-烯酰胺(80.00mg,0.168mmol,1.00当量)、2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基硼酸(73.00mg,0.219mmol,1.30当量)、Pd(dppf)Cl2 CH2Cl2(13.74mg,0.017mmol,0.10当量)、K2CO3(46.52mg,0.337mmol,2.00当量)、DME(8.00mL)、H2O(2.00mL)放入用氮气惰性气氛吹扫并维持的8-mL小瓶中。将所得溶液在90℃搅拌1小时。粗产物通过Prep-HPLC纯化。得到20mg(17.23%)的N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-(4-甲基哌嗪-1-羰基)苯基)丙-2-烯酰胺为白色固体。LC-MS--752-0:(ES,m/z):690[M+H]+。1HNMR--752-0:(300MHz,DMSO-d6,ppm):δ9.76(s,1H)、9.52(s,1H)、8.48(s,1H)、8.34(d,J=5.0Hz,1H)、7.81(dd,J=8.8,1.8Hz,1H)、7.58-7.47(m,2H)、7.20(d,J=8.5Hz,1H)、6.59-6.44(m,2H)、6.24(dd,J=17.1,1.8Hz,1H)、5.74(dd,J=12.2,2.4Hz,1H)、4.29-4.10(m,3H)、3.86(d,J=11.9Hz,1H)、3.59(s,3H)、2.68-2.54(m,2H)、2.43(s,2H)、2.29(s,7H)、2.16(s,3H)、1.23(s,6H)。
实施例16:制备N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-1-吗啉代丙-2-基)苯基)丙烯酰胺
合成5-溴-1-甲基-3-([4-[2-甲基-1-(吗啉-4-基)丙-2-基]-3-硝基苯基]氨基)吡嗪-2-酮:将4-[2-甲基-1-(吗啉-4-基)丙-2-基]-3-硝基苯胺(400.00mg,1.432mmol,1.00当量)、3,5-二溴-1-甲基吡嗪-2-酮(498.72mg,1.862mmol,1.30当量)、Pd2(dba)3(131.13mg,0.143mmol,0.10当量)、XantPhos(165.71mg,0.286mmol,0.20当量)、Cs2CO3(933.11mg,2.864mmol,2.00当量)、二恶烷(20.00mL)放入用氮气惰性气氛吹扫并维持的100-mL圆底烧瓶中。将所得溶液在100℃搅拌4小时。通过过滤收集固体。浓缩合并的有机层。粗产物通过从MeCN中重结晶来纯化。得到350mg(52.41%)的5-溴-1-甲基-3-([4-[2-甲基-1-(吗啉-4-基)丙-2-基]-3-硝基苯基]氨基)吡嗪-2-酮为棕色固体。LC-MS--753-1:(ES,m/z):466[M+H]+。1H NMR--753-1:(300MHz,DMSO-d6,ppm):δ9.90(s,1H)、8.19(d,J=2.4Hz,1H)、8.08(dd,J=8.9,2.5Hz,1H)、7.62(d,J=9.0Hz,1H)、7.43(s,1H)、3.53-3.39(m,7H)、2.53-2.47(m,2H)、2.23(t,J=4.6Hz,4H)、1.29(s,6H)。
合成3-([3-氨基-4-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]氨基)-5-溴-1-甲基吡嗪-2-酮:将5-溴-1-甲基-3-([4-[2-甲基-1-(吗啉-4-基)丙-2-基]-3-硝基苯基]氨基)吡嗪-2-酮(350.00mg,0.751mmol,1.00当量)、CH3COOH(1352.13mg,22.516mmol,30.00当量)、Zn(736.37mg,11.258mmol,15.00当量)、EtOH(30.00mL)放入100-mL圆底烧瓶中。将所得溶液在室温搅拌2小时。通过过滤收集固体。浓缩合并的有机层。将所得溶液用乙酸乙酯萃取。将所得混合物用卤水洗涤。混合物经无水硫酸钠干燥并浓缩。得到300mg(91.60%)的3-([3-氨基-4-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]氨基)-5-溴-1-甲基吡嗪-2-酮为棕色油。LC-MS--753-2:(ES,m/z):436[M+H]+。
合成N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]丙-2-烯酰胺:将3-([3-氨基-4-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]氨基)-5-溴-1-甲基吡嗪-2-酮(300.00mg,0.688mmol,1.00当量)、丙烯酰氯(74.67mg,0.825mmol,1.20当量)、NMM(139.08mg,1.375mmol,2.00当量)、DCM(10.00mL)放入100-mL圆底烧瓶中。将所得溶液在室温搅拌30分钟。将得到的混合物浓缩。粗产物通过快速Prep-HPLC 0.1%NH4HCO3:MeCN=30%在9分钟内增加至0.1%NH4HCO3:MeCN=70%来纯化。得到260mg(77.11%)的N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]丙-2-烯酰胺为白色固体。LC-MS--753-3:(ES,m/z):490[M+H]+。1H NMR--753-3:(300MHz,DMSO-d6,ppm):δ10.75(s,1H)、9.40(s,1H)、7.95(s,1H)、7.77(d,J=8.5Hz,1H)、7.39-7.25(m,2H)、6.61-6.44(m,1H)、6.27(dd,J=16.9,2.1Hz,1H)、5.81(d,J=11.0Hz,1H)、3.54(s,4H)、3.44(s,3H)、2.36(s,4H)、1.35(s,6H)。
合成N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基)丙-2-烯酰胺:将N-[5-[(6-溴-4-甲基-3-氧代吡嗪-2-基)氨基]-2-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基]丙-2-烯酰胺(200.00mg,0.408mmol,1.00当量)、2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基硼酸(193.67mg,0.571mmol,1.40当量)、Pd(dppf)Cl2 CH2Cl2(33.30mg,0.041mmol,0.10当量)、K2CO3(112.73mg,0.816mmol,2.00当量)、DME(10.00mL)、H2O(2.00mL)放入用氮气惰性气氛维持的40-mL微波管中。将所得溶液在95℃搅拌2小时。粗产物通过Prep-HPLC纯化。得到150mg(52.18%)的N-(5-[[6-(2-[4,4-二甲基-9-氧代-1,10-二氮杂三环[6.4.0.0^[2,6]]十二-2(6),7-二烯-10-基]-3-甲基吡啶-4-基)-4-甲基-3-氧代吡嗪-2-基]氨基]-2-[2-甲基-1-(吗啉-4-基)丙-2-基]苯基)丙-2-烯酰胺为浅棕色固体。LC-MS--753-0:(ES,m/z):705[M+H]+。1H NMR--753-0:(300MHz,DMSO-d6,ppm):δ10.78(s,1H)、9.26(s,1H)、8.38-8.29(m,2H)、7.69(d,J=8.6Hz,1H)、7.54(d,J=5.2Hz,1H)、7.43(s,1H)、7.28(d,J=8.8Hz,1H)、6.58-6.45(m,2H)、6.27(d,J=16.8Hz,1H)、5.76(d,J=10.2Hz,1H)、4.31-4.10(m,3H)、3.84(d,J=12.4Hz,1H)、3.57(s,3H)、3.57-3.47(m,4H)、2.58(d,J=5.8Hz,2H)、2.43(s,2H)、2.34(d,J=4.7Hz,4H)、2.29(s,3H)、1.34(d,J=4.2Hz,6H)、1.23(s,6H)。
实施例A:以下化合物是通过与通用方案和以上实施例中公开的方法基本相同、相似或类似的方法制备的。
/>
生物实施例1:结合常数(Ka)测定
通过KINOMEscanTM测定法测定化合物的Kd,该测定法是业内最全面的用于针对大量人类激酶筛选化合物的高通量系统。KINOMEscanTM测定法是基于竞争结合测定法,该测定法定量测量化合物与固定化的,活性位点定向的配体竞争的能力。通过组合三个组分进行测定法:加DNA标签的激酶;固定化配体;和测试化合物。经由DNA标签的定量PCR测量测试化合物与固定化的配体竞争的能力。在衍生自BL21菌株的大肠杆菌宿主中制备了加激酶标签的T7噬菌体菌株。使大肠杆菌生长至对数期并用T7噬菌体感染,并在32℃摇动温育直至裂解。将裂解物离心并过滤以除去细胞碎片。其余的激酶在HEK-293细胞中产生,随后用DNA加标签以进行qPCR检测。在室温下,用生物素化的小分子配体处理链霉抗生物素蛋白包被的磁珠30分钟,以生成用于激酶测定法的亲和树脂。用过量的生物素封闭配体珠,并用封闭缓冲液(SeaBlock(Pierce),1%BSA,0.05%Tween 20、1mM DTT)洗涤,以去除未结合的配体并减少非特异性结合。通过在1x结合缓冲液(20%SeaBlock,0.17xPBS,0.05%Tween 20、6mMDTT)中组合激酶、有配体的亲和珠和测试化合物来组装结合反应。所有反应均在聚苯乙烯96孔板中以0.135ml的最终体积进行。将测定板在室温下摇动温育1小时,并用洗涤缓冲液(1x PBS,0.05%Tween 20)洗涤亲和珠。然后将珠重悬于洗脱缓冲液(1x PBS,0.05%Tween20、0.5μM非生物素化的亲和配体)中,并在室温下摇动温育30分钟。通过qPCR测量洗脱液中的激酶浓度。在以100x最终测试浓度在100%DMSO中制备每种测试化合物的11点3倍系列稀释液,然后在测定法中稀释至1x(最终DMSO浓度=1%)。使用化合物最高浓度=30,000nM测定大多数Kd。如果测定的初始Kd<0.5nM(测试的最低浓度),则以从较低的最高浓度开始的系列稀释液重复进行测量。Kd值报告为40,000nM,表明Kd被确定为>30,000nM。结合常数(Kd)是使用Hill方程通过标准剂量反应曲线计算的:反应=背景+(信号-背景)/[1+(Kd Hi1l斜率/剂量Hill斜率)]。Hill斜率设置为-1。使用非线性最小平方拟合(1east square fit)和Levenberg-Marquardt算法拟合曲线。用一定范围剂量的测试化合物进行的此类测定法允许确定近似的Kd值的测定。尽管本发明化合物的Kd随预期的结构变化而变化,但是这些试剂通常表现出的活性在Kd=0.1-1000nM的范围内。
生物学实施例2:体外透析测定法(不可逆测定法)
在存在0.1nM酶和40mM ATP的情况下测定测试化合物的IC50。将0.003mM化合物(39xIC50@40mM ATP)与2nM BTK在不含ATP的测定缓冲液中预温育2小时。将化合物-酶复合物针对补充有40mM ATP的相同缓冲液进行透析24小时。累积透析因子>160,000x。透析后,在存在40mM ATP和1mM底物肽的情况下测量BTK活性,并与未透析样品中的BTK活性进行比较。测定缓冲液:100mM HEPES,pH7.5;0.1%BSA,0.01%Triton-X 100;5mM MgCl2;1mMDTT。在这项研究中,伊布替尼(FDA批准的不可逆BTK抑制剂)用作阳性对照,而Saurosporine(可逆BTK抑制剂)用作阴性对照。下表显示了24小时透析后的回收。
在该测定法中,可逆的BTK抑制剂GDC-0853用作参考化合物。在WO 2013067274中公开的GDC-0853是一种口服生物可利用的、选择性的和可逆的Bruton酪氨酸激酶(BTK)抑制剂,其IC50范围为2-9nM,用于嗜碱性粒细胞活化、B细胞受体活化和全血裂解物中的组成型p-BTK活性。1,2在大鼠中,治疗超过7天导致胰腺中毒,但即使剂量更高,它也不会在小鼠或狗中发生。含有GDC-0853的配制剂在I期临床试验中具有良好的耐受性,并且处于类风湿关节炎、红斑狼疮和其他自身免疫性疾病的另外的临床试验中。
WT BTK透析测定法的数据清楚地表明,伊布替尼、实施例2、实施例3、实施例11、实施例12是WT BTK的不可逆抑制剂,而GDC-0853是可逆WT BTK抑制剂。
透析24小时后回收 | 结论(WT BTK) | |
伊布替尼 | ~1% | 不可逆/共价抑制 |
实施例2 | ~1% | 不可逆/共价抑制 |
实施例3 | ~1% | 不可逆/共价抑制 |
实施例11 | ~1% | 不可逆/共价抑制 |
实施例12 | ~1% | 不可逆/共价抑制 |
GDC-0853 | ~100% | 可逆 |
对于C481S BTK酶,伊布替尼和我们的化合物(如实施例2)与C481S BTK可逆结合,因为半胱氨酸残基不再可用于共价结合。
生物实施例3:针对WT和C481S BTK的生化酶促测定法(IC50)
基于卡尺(Caliper)的激酶测定法(Caliper LifeSciences,Hopkinton,MA)用于测量本公开化合物的对WT和C481S Btk激酶活性的抑制。伊布替尼和ACP=196用作对照化合物。将测试化合物的系列稀释液与人重组WT BTK或C481S Btk(0.5nM)、ATP(16μM)和磷酸受体肽底物FAM-GEEPLYWSFPAKKK-NH2(1μM)在室温下温育3小时。然后用EDTA,终浓度20mM终止反应,并在Caliper Desktop Profiler(Caliper LabChip 3000)上定量磷酸化的反应产物。计算每种化合物稀释液的抑制百分比,并计算产生50%抑制的浓度。
下表显示了WT BTK、C481S BTK的IC 50,以及对于伊布替尼、ACP-196、本公开的某些化合物,C481S与WT BTK的IC 50比率。如预期的那样,伊布替尼和ACP-196两者都大大丧失了与C481S BTK酶的结合亲和力:伊布替尼在C481S BTK中比WT BTK弱X990倍,而ACP-196在C481S BTK中比WT BTK弱X483倍。相反,发明人出乎意料地发现,与WT BTK相比,我们的化合物仍有力地抑制C481S BTK。实施例2在C481S BTK测定法中比伊布替尼更有力X64,且比ACT-196更有力X477。这些数据表明我们的化合物(如实施例2)通过与常规共价BTK抑制剂(如伊布替尼和ACP-196)不同的机制可逆地与BTK结合,因此对于那些由于C481结合位点的突变而对伊布替尼和ACP-196具有抗性的患者可能是重要的选项。
生物实施例4:基于钙通量荧光的测定法
根据制造商的说明,在FlexStation II384荧光测量成像读板器(MolecularDevices)中进行基于钙通量荧光的测定法。简而言之,洗涤在补充有10%FBS(Invitrogen)的RPM1培养基中活跃生长的Ramos细胞(ATCC),并以每100μl每孔约5x105个细胞重新分配于96孔板中的低血清培养基中。将要测定的化合物溶于DMSO中,然后在低血清培养基中稀释至范围为0至10μM的终浓度(以0.3的稀释系数)。然后将稀释的化合物添加到每个孔中(最终DMSO浓度为0.01%),并在5%CO2培养箱中于37度温育1小时。之后,将100μl的钙敏感染料(来自Calcium 3测定试剂盒,Molecular Devices)添加到每个孔中,并再温育1小时。用山羊抗人IgM抗体(80ug/ml;Jackson ImmunoResearch)刺激经化合物处理的细胞,并使用λEx=485nm和λEm=538nm在FlexStation II384中读取200秒。使用内置的SoftMax程序(Molecular devices)记录并分析相对荧光单位(RFU)和IC50。
生物学实施例5:抑制B细胞活化-Ramos细胞中的B细胞FLIPR测定法
通过确定测试化合物对经抗IgM刺激的B细胞应答的作用,证明了本发明化合物对B细胞活化的抑制。B细胞FLIPR测定法是基于细胞的功能性方法,其确定抗IgM抗体刺激引起的细胞内钙增加的潜在抑制剂的作用。在生长培养基中培养Ramos细胞(人伯基特氏淋巴瘤细胞系,ATCC-No.CRL-1596)(如下所述)。测定前一天,将Ramos细胞重悬于新鲜的生长培养基(与上述相同)中,并在组织培养瓶中设置为0.5x106/mL的浓度。在测定的当天,在组织培养瓶中补充有1μM FLUO-3AM(TefLabs Cat-No.0116,在无水DMSO和10%丙酮酸中制备)的生长培养基中对细胞计数并设置为1x106/mL的浓度,并且在37℃(5%CO2)下温育1小时。为了去除细胞外染料,通过离心(5分钟,1000rpm)收集细胞,以1x106个细胞/mL重悬于FLIPR缓冲液(如下所述)中,然后以每孔1x105个细胞分配到96孔聚D-赖氨酸包被的黑色/透明板(BD Cat-No.356692)中。以范围为100μM至0.03μM的各种浓度(7个浓度,详情如下)加入测试化合物,并允许其与细胞在室温下温育30分钟。通过添加10μg/mL抗IgM(SouthernBiotech,Cat-No.2020-01)刺激Ramos细胞Ca2+信号传导,并在FLIPR(Molecular Devices,使用带有480nM激发的氩激光的CCD摄像机捕获96孔板的影像)上进行测量。
·生长培养基:RPMI 1640培养基,其具有L-谷氨酰胺(Invitrogen,Cat-No.61870-010)、10%胎牛血清(FBS,Summit Biotechnology Cat-No.FP-100-05);1mM丙酮酸钠(Invitrogen Cat.No.11360-070)。
·FLIPR缓冲液:HBSS(Invitrogen,Cat-No.141175-079)、2mM CaCl2(Sigma Cat-No.C-4901)、HEPES(Invitrogen,Cat-No.15630-080)、2.5mM丙磺舒(Probenecid)(Sigma,Cat-No.P-8761)、0.1%BSA(Sigma,Cat-No.A-7906)、llmM葡萄糖(Sigma,Cat-No.G-7528);
·测定法和分析:使用最大-最小统计量报告了细胞内钙的增加(使用MolecularDevices FLIPR对照和统计量导出软件从添加刺激性抗体引起的峰中减去静息基线)。使用非线性曲线拟合确定IC50(GraphPad Prism)。
生物学实施例6:体外抗增殖测定法
通过PerkinElmerATPliteTM发光测定系统测定细胞抗增殖。简而言之,将各种测试癌细胞系以每孔约1x104个细胞的密度在Costar 96孔板中分配,并在补充有5%FBS的培养基中与不同浓度的化合物温育约72小时。然后通过加入5mL的底物缓冲液来重建1个冻干的底物溶液小瓶,并轻轻搅拌直至溶液均匀。将约50μL的哺乳动物细胞裂解液添加到微孔板每孔100μL的细胞悬液中,并将该板在定轨摇床中以约700rpm摇动约5分钟。该规程用于裂解细胞并稳定化ATP。接下来,将50μL底物溶液添加到孔中,并将微孔板在定轨摇床中以约700rpm摇动5分钟。最后,通过PerkinElmer微孔板闪烁计数器测量发光。用一定剂量范围的测试化合物进行的此类测定允许测定本发明化合物的细胞抗增殖IC50。
生物学实施例7:体内异种移植物研究
通常,在6-8周龄时从供应商处获得无胸腺裸鼠(CD-1nu/nu)或SCID小鼠,并使其适应至少7天的时段。然后将癌细胞植入裸鼠中。根据具体的肿瘤类型,通常在植入后约两周就可检测到肿瘤。当肿瘤大小达到约100-200mm3时,将具有可察觉的肿瘤大小和形状的动物随机分为各8只小鼠的组,包括1个媒介物对照组和治疗组。剂量根据每次研究的目的和长度(通常进行约3-4周)而不同。每周通常测量三次肿瘤大小和体重。除了确定肿瘤大小变化之外,最后一次肿瘤测量还用于生成肿瘤大小变化率(T/C值),由美国国家癌症研究所(National Cancer Institute)开发的用于异种移植肿瘤评估的标准度量。在大多数情况下,使用以下公式计算%T/C值:%T/C=100×ΔT/ΔC,若ΔT>0的话。然而,当发生肿瘤消退(ΔT<0)时,使用以下公式:%T/T0=100×ΔT/T0。<42%的值被认为是显著的。
生物学实施例8:小鼠胶原诱导的关节炎(mCIA)
在第0天,用完全弗氏佐剂(CFA)中的II型胶原(i.d.)乳剂在尾巴的根部或背部的几个部位对小鼠进行注射。胶原免疫后,动物将在21至35天左右发展关节炎。在第21天,通过在不完全弗氏佐剂(IFA;i.d.)中系统施用胶原来同步(加强)关节炎的发作。第20天后每天对动物检查作为加强的信号的任何轻度关节炎发作(1或2的得分;参见下面的得分说明)。加强后,对小鼠进行评分,并且对于规定的时间(通常2-3周)和给药频率每日(QD)或每日两次(BID),给药候选治疗剂。使用评分系统对爪和肢关节发展的炎症进行定量,该评分系统涉及按照下述标准评估4个爪:
评分:
1=爪或一趾肿胀和/或发红。
2=两个或更多个关节肿胀。
3=爪的严重肿胀,超过两个关节受累。
4=整个爪和趾的严重关节炎。
在第0天进行评估,以进行基线测量,并在第一个体征或每周肿胀多达3次时再次开始评估,直到实验结束。通过将各个爪的四个得分相加,得出每只动物的最高得分16,获得每只小鼠的关节炎指数。
生物学实施例9:大鼠胶原诱发的关节炎(rCIA)
在第0天,用不完全弗氏佐剂(IFA)中的牛II型胶原的乳剂在背部的几个部位对大鼠进行皮内(i.d.)注射。在第7天左右在尾巴的根部或背部的交替部位给予胶原乳剂的加强注射(i.d.)。一般在初次注射胶原后12-14天观察到关节炎。从第14天开始,可以如下所述(关节炎的评估)评估动物的关节炎发展。从二次攻击时开始,且对于规定的时间(通常为2至3周)和给药频率每日(QD)或每日两次(BID),以预防性方式向动物给药候选治疗剂。使用评分系统对爪和四肢关节发展的炎症进行定量,该评分系统涉及按照上述标准评估4个爪。在第0天进行评估,以进行基线测量,并在第一个体征或每周肿胀多达3次时再次开始评估,直到实验结束。通过将各个爪的四个得分相加,得出每只动物的最高得分16,获得每只小鼠的关节炎指数。
生物学实施例10:大鼠体内哮喘模型
每周一次持续三周(第0、7和14天)用0.2ml明矾中的100μg的OA(卵清蛋白)i.p.对雄性Bro、wn-Norway大鼠进行致敏。在第21天(最后一次致敏后一周),在OA气雾剂攻击(1%OA达45分钟)前用媒介物或化合物配制剂对大鼠q.d.皮下给药0.5小时并在攻击后4或24小时终止。处死时,从所有动物收集血清和血浆分别用于血清学和PK。插入气管套管,并用PBS灌洗肺3次。分析BAL液的总白细胞数和差异白细胞计数。由Coulter计数器确定等份细胞(20-100μl)中的总白细胞数。对于差异白细胞计数,将50-200μL的样品在Cytospin中离心,并将载玻片用Diff-Quik染色。使用标准形态学标准在光学显微术下计数单核细胞、嗜酸性粒细胞、嗜中性粒细胞和淋巴细胞的比例,并以百分比表示。与对照水平相比,代表性的Btk抑制剂在OA致敏和攻击的大鼠的BAL中显示总白细胞计数降低。
Claims (14)
1.式(III)的化合物或其药学上可接受的盐:
其中
X是C(Ra)或N;
R1各自独立是H、D、C1-C10烷基、C2-C10烯基、C2-C10炔基、3至6元环烷基、5至8元杂环烷基、卤素、硝基、氰基、ORa、SRa、C1-C10烷基-Ra,其中所述3至6元环烷基、5至8元杂环烷基任选地用一个或多个Rd取代;
R2是H或C1-C4烷基;
R3是H、卤素、C1-C4烷基、卤代C1-C4烷基、或羟基C1-C4烷基;
R4是H、卤素、或C1-C4烷基;
Ra和Rd各自独立是H、D、C1-C10烷基、C2-C10烯基、C2-C10炔基、卤素、氰基、硝基、羟基、=O、C1-C10烷氧基、卤代C1-C10烷基、羟基C1-C10烷基、氨基C1-C10烷基、3至6元环烷基、5至8元杂环烷基,其中所述C1-C10烷基、3至6元环烷基、5至8元杂环烷基任选地用一个或多个Re取代;
Re是H、D、C1-C10烷基、卤素、氰基、羟基、C1-C10烷氧基、3至6元环烷基、5至8元杂环烷基;
m是0、1、2、3或4;
k是0,1或2;
s是0,1,2或3;且
r是0,1,2或3。
2.根据权利要求1的化合物或其药学上可接受的盐,其中所述化合物以式(IV)表示,其中:
其中
k是1或2;并且
r是1或2。
3.根据权利要求1的化合物或其药学上可接受的盐,其中所述化合物是
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(2-(4-(4,4-二氟环己基)-2-甲基哌嗪-1-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-吗啉代哌啶-1-基)苯基)丙烯酰胺、
N-(2-(4,4-二氟-[1,4'-联哌啶]-1'-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-甲基-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-氟-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)-3-(三氟甲基)苯基)丙烯酰胺、
(S)-N-(3-氰基-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-3-(异丙基磺酰基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺、
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)-3-((三氟甲基)磺酰基)苯基)丙烯酰胺、
N-(2-((2'S)-4,4-二氟-2'-甲基-[1,4'-联哌啶]-1'-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺、或
N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺。
4.根据权利要求1的化合物或其药学上可接受的盐,其中所述化合物选自下组:
(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺,
(S)-N-(2-(4-(4,4-二氟环己基)-2-甲基哌嗪-1-基)-5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺,和
(R)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(3-(二甲基氨基)吡咯烷-1-基)苯基)丙烯酰胺。
5.根据权利要求1的化合物或其药学上可接受的盐,其中所述化合物是N-(3-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)苯基)丙烯酰胺。
6.根据权利要求3的化合物或其药学上可接受的盐,其中所述化合物是(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(四氢-2H-吡喃-4-基)哌嗪-1-基)苯基)丙烯酰胺。
7.根据权利要求3的化合物或其药学上可接受的盐,其中所述化合物是(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-(羟基甲基)吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺。
8.根据权利要求3的化合物或其药学上可接受的盐,其中所述化合物是(S)-N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-(2-甲基-4-(氧杂环丁烷-3-基)哌嗪-1-基)苯基)丙烯酰胺。
9.根据权利要求3的化合物或其药学上可接受的盐,其中所述化合物是N-(5-((6-(2-(7,7-二甲基-1-氧代-1,3,4,6,7,8-六氢-2H-环戊二烯并[4,5]吡咯并[1,2-a]吡嗪-2-基)-3-甲基吡啶-4-基)-4-甲基-3-氧代-3,4-二氢吡嗪-2-基)氨基)-2-((2S)-2-甲基-4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺。
10.药物组合物,其包含如权利要求1中所定义的式(III)的化合物或其药学上可接受的盐和药学上可接受的稀释剂或载体。
11.如权利要求1中限定的式(III)的化合物或其药学上可接受的盐在制备药物中的用途,所述药物用于治疗新生物性疾病、自身免疫性疾病或炎性病症。
12.权利要求11的用途,其中所述自身免疫性疾病或炎性病症是寻常型天疱疮、类风湿关节炎、哮喘、多发性硬化、系统性红斑狼疮或变态反应。
13.权利要求11的用途,其中所述新生物性疾病是B细胞恶性肿瘤或实体瘤。
14.权利要求11的用途,其中所述新生物性疾病是慢性淋巴细胞性白血病、小淋巴细胞性淋巴瘤、套细胞淋巴瘤和弥漫性大B细胞淋巴瘤或多发性骨髓瘤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311008387.0A CN117209502A (zh) | 2018-02-19 | 2019-02-15 | Btk及其突变体的抑制剂 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862631945P | 2018-02-19 | 2018-02-19 | |
US62/631,945 | 2018-02-19 | ||
PCT/US2019/018139 WO2019161152A1 (en) | 2018-02-19 | 2019-02-15 | Inhibitors of btk and mutants thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311008387.0A Division CN117209502A (zh) | 2018-02-19 | 2019-02-15 | Btk及其突变体的抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111741959A CN111741959A (zh) | 2020-10-02 |
CN111741959B true CN111741959B (zh) | 2023-09-05 |
Family
ID=65685969
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311008387.0A Pending CN117209502A (zh) | 2018-02-19 | 2019-02-15 | Btk及其突变体的抑制剂 |
CN201980013997.5A Active CN111741959B (zh) | 2018-02-19 | 2019-02-15 | Btk的抑制剂及其突变体 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311008387.0A Pending CN117209502A (zh) | 2018-02-19 | 2019-02-15 | Btk及其突变体的抑制剂 |
Country Status (12)
Country | Link |
---|---|
US (4) | US11100492B2 (zh) |
EP (1) | EP3755702A1 (zh) |
JP (1) | JP2021514390A (zh) |
KR (1) | KR20200122348A (zh) |
CN (2) | CN117209502A (zh) |
AU (1) | AU2019222475A1 (zh) |
CA (1) | CA3088796A1 (zh) |
IL (1) | IL276575B2 (zh) |
MA (1) | MA51899A (zh) |
MX (1) | MX2020008627A (zh) |
SG (1) | SG11202006274XA (zh) |
WO (1) | WO2019161152A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11100492B2 (en) * | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
EP3930717A1 (en) * | 2019-02-25 | 2022-01-05 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitor of btk and mutants thereof |
WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
US20220363689A1 (en) * | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
US11416840B1 (en) * | 2019-12-31 | 2022-08-16 | American Express Travel Related Services Company, Inc. | Computer-based systems utilizing cards with cellular capabilities and methods of use thereof |
WO2021164735A1 (en) | 2020-02-20 | 2021-08-26 | Hutchison Medipharma Limited | Heteroaryl heterocyclic compounds and uses thereof |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
MX2023001865A (es) | 2020-08-14 | 2023-05-09 | Guangzhou Lupeng Pharmaceutical Company Ltd | Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. |
TW202220998A (zh) | 2020-09-21 | 2022-06-01 | 大陸商和記黃埔醫藥(上海)有限公司 | 雜芳基雜環化合物及其用途 |
CA3202745A1 (en) * | 2020-12-20 | 2022-06-23 | Yi Chen | Btk degrader |
US20230267444A1 (en) * | 2022-02-18 | 2023-08-24 | Bank Of America Corporation | Proximity-based device pairing system via acoustic communication for secure resource transfer |
US20230376945A1 (en) * | 2022-05-23 | 2023-11-23 | American Express Travel Related Services Company, Inc. | Virtualized transaction instruments using processing aliases |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103038233A (zh) * | 2010-05-07 | 2013-04-10 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
CN104125959A (zh) * | 2011-11-03 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
WO2015050703A1 (en) * | 2013-10-04 | 2015-04-09 | Yi Chen | Inhibitors of bruton's tyrosine kinase |
WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
CN110446710A (zh) * | 2016-12-15 | 2019-11-12 | 豪夫迈·罗氏有限公司 | 制备btk抑制剂的方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5590038A (en) * | 1994-06-20 | 1996-12-31 | Pitroda; Satyan G. | Universal electronic transaction card including receipt storage and system and methods of conducting electronic transactions |
DE19940695B4 (de) * | 1999-08-27 | 2008-03-27 | ITT Manufacturing Enterprises, Inc., Wilmington | Elektronisches Mediagerät |
AUPQ583600A0 (en) * | 2000-02-24 | 2000-03-16 | Cds Worldwide Pty Ltd | Vehicle parking system |
US20020134837A1 (en) * | 2001-01-23 | 2002-09-26 | Jakob Kishon | Method and apparatus for electronically exchanging data |
US20030085288A1 (en) * | 2001-11-06 | 2003-05-08 | Luu Deniel V.H. | Contactless SIM card carrier with detachable antenna and carrier therefore |
US6899276B2 (en) * | 2002-02-15 | 2005-05-31 | Axalto Sa | Wrapped-card assembly and method of manufacturing the same |
EP1365353A3 (en) * | 2002-05-20 | 2004-03-03 | Quadnovation, Inc. | Contactless transaction card and adapter therefor |
US20030222152A1 (en) * | 2002-05-28 | 2003-12-04 | Boley George E.S. | Pre-paid debit & credit card |
US7280847B2 (en) * | 2002-07-26 | 2007-10-09 | Way Systems Inc | System and method for mobile transactions using the bearer independent protocol |
US7336973B2 (en) * | 2002-10-30 | 2008-02-26 | Way Systems, Inc | Mobile communication device equipped with a magnetic stripe reader |
US6776332B2 (en) * | 2002-12-26 | 2004-08-17 | Micropin Technologies Inc. | System and method for validating and operating an access card |
US7440771B2 (en) * | 2003-02-28 | 2008-10-21 | American Express Travel Related Services Company, Inc. | Transaction card providing displayed information |
WO2005119607A2 (en) * | 2004-06-03 | 2005-12-15 | Tyfone, Inc. | System and method for securing financial transactions |
US7097108B2 (en) * | 2004-10-28 | 2006-08-29 | Bellsouth Intellectual Property Corporation | Multiple function electronic cards |
US20060287004A1 (en) * | 2005-06-17 | 2006-12-21 | Fuqua Walter B | SIM card cash transactions |
US8762263B2 (en) * | 2005-09-06 | 2014-06-24 | Visa U.S.A. Inc. | System and method for secured account numbers in proximity devices |
US7568631B2 (en) * | 2005-11-21 | 2009-08-04 | Sony Corporation | System, apparatus and method for obtaining one-time credit card numbers using a smart card |
US20070131759A1 (en) * | 2005-12-14 | 2007-06-14 | Cox Mark A | Smartcard and magnetic stripe emulator with biometric authentication |
US7784692B1 (en) * | 2005-12-29 | 2010-08-31 | United Services Automobile Association (Usaa) | Single access vehicle |
US7828204B2 (en) * | 2006-02-01 | 2010-11-09 | Mastercard International Incorporated | Techniques for authorization of usage of a payment device |
US20070185820A1 (en) * | 2006-02-08 | 2007-08-09 | Talker Albert I | Multi-account security verification system with a virtual account and linked multiple real accounts |
US7949373B2 (en) * | 2007-01-16 | 2011-05-24 | Jonathan Merrill Whiting | Combined telephone and credit transaction enabler |
US8827164B2 (en) * | 2007-01-26 | 2014-09-09 | Lg Electronics Inc. | Contactless interface within a terminal to support a contactless service |
SG10202107066WA (en) | 2007-03-28 | 2021-07-29 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
WO2009137076A2 (en) * | 2008-05-07 | 2009-11-12 | Yinzi Cai | A one card system |
ES2711249T3 (es) | 2008-06-27 | 2019-04-30 | Celgene Car Llc | Compuestos de heteroarilo y usos de los mismos |
CN102160061B (zh) * | 2008-08-20 | 2014-04-09 | X卡控股有限公司 | 安全智能卡系统 |
US8083141B1 (en) * | 2009-07-17 | 2011-12-27 | United Services Automobile Association (Usaa) | Systems and methods for transactions with a headless automated teller machine or point of sale device |
US9691059B1 (en) * | 2009-07-17 | 2017-06-27 | United Services Automobile Association (Usaa) | Systems and methods for transactions using an ATM/credit/debit card and a second communications channel to an account holder's bank |
US8671055B2 (en) * | 2010-03-02 | 2014-03-11 | Digital Life Technologies, Llc | Portable E-wallet and universal card |
US20120123868A1 (en) * | 2010-11-17 | 2012-05-17 | David Brudnicki | System and Method for Physical-World Based Dynamic Contactless Data Emulation in a Portable Communication Device |
US10586227B2 (en) * | 2011-02-16 | 2020-03-10 | Visa International Service Association | Snap mobile payment apparatuses, methods and systems |
US10026078B1 (en) * | 2011-04-26 | 2018-07-17 | Jpmorgan Chase Bank, N.A. | System and method for accessing multiple accounts |
US8538845B2 (en) * | 2011-06-03 | 2013-09-17 | Mozido, Llc | Monetary transaction system |
US8977569B2 (en) * | 2011-09-29 | 2015-03-10 | Raj Rao | System and method for providing smart electronic wallet and reconfigurable transaction card thereof |
US8600863B2 (en) * | 2012-01-16 | 2013-12-03 | International Business Machines Corporation | Financial services card that provides visual indicator according to available balance defined policies |
US9009069B2 (en) * | 2012-02-10 | 2015-04-14 | Target Brands, Inc. | Phased debit activation system and method |
US20150348018A1 (en) * | 2012-02-15 | 2015-12-03 | Blackhawk Network, Inc. | System and Method of Registering Stored-Value Cards into Electronic Wallets |
US9063737B2 (en) * | 2012-07-02 | 2015-06-23 | Square, Inc. | Wireless card reader with one or more card interfaces |
US8820649B2 (en) * | 2012-11-20 | 2014-09-02 | Omne Mobile Payments, Inc. | Electronic card with a programmable magnetic stripe |
US8825532B1 (en) * | 2013-02-21 | 2014-09-02 | Kamfu Wong | Payment system and method using a mobile telephone network for charging and settlement |
MX2015010983A (es) | 2013-03-05 | 2015-10-26 | Hoffmann La Roche | Inhibidores de tirosina-cinasa de bruton. |
US20140279476A1 (en) * | 2013-03-15 | 2014-09-18 | Visa International Service Association | Multiple Account Dynamic Card Apparatuses, Methods and Systems |
KR102273997B1 (ko) | 2013-06-26 | 2021-07-08 | 애브비 인코포레이티드 | Btk 억제제로서 1급 카복스아미드 |
US20150069126A1 (en) * | 2013-09-09 | 2015-03-12 | Omne Mobile Payments, Inc. | Method and apparatus for enabling communication between two devices using magnetic field generator and magnetic field detector |
WO2015073888A2 (en) * | 2013-11-14 | 2015-05-21 | Protean Payment, Inc. | Method for remotely controlling a reprogrammable payment card |
KR101598371B1 (ko) * | 2014-07-14 | 2016-02-29 | 브릴리언츠 주식회사 | 스마트멀티카드 |
US10614450B1 (en) * | 2014-08-08 | 2020-04-07 | Squre, Inc. | Controlled emulation of payment cards |
US20180189527A1 (en) * | 2017-01-03 | 2018-07-05 | Soo Hyang KANG | Method for activating multi-function device card |
KR20180092075A (ko) * | 2017-02-08 | 2018-08-17 | 삼성전자주식회사 | 카드 정보를 처리하기 위한 방법 및 그 전자 장치 |
US11157908B2 (en) * | 2017-07-14 | 2021-10-26 | The Toronto-Dominion Bank | Smart chip card with fraud alert and biometric reset |
AU2019210748B2 (en) | 2018-01-29 | 2021-08-05 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
US11100492B2 (en) * | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
US10755533B2 (en) * | 2018-05-02 | 2020-08-25 | International Business Machines Corporation | Secure anti-skimmer technology for use with magnetic cards |
US20200005269A1 (en) * | 2018-06-27 | 2020-01-02 | Chi-Yuan Ou | General purpose reloadable card consolidating multiple transaction cards |
EP3930717A1 (en) | 2019-02-25 | 2022-01-05 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitor of btk and mutants thereof |
US10810570B1 (en) * | 2019-09-30 | 2020-10-20 | Square, Inc. | Point of sale device with cradle for mobile computing device |
US20220363689A1 (en) | 2019-10-05 | 2022-11-17 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
WO2021091575A1 (en) | 2019-11-08 | 2021-05-14 | Nurix Therapeutics, Inc. | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway |
-
2019
- 2019-01-20 US US16/252,685 patent/US11100492B2/en active Active
- 2019-02-15 WO PCT/US2019/018139 patent/WO2019161152A1/en unknown
- 2019-02-15 KR KR1020207026689A patent/KR20200122348A/ko not_active Application Discontinuation
- 2019-02-15 CA CA3088796A patent/CA3088796A1/en active Pending
- 2019-02-15 EP EP19709178.8A patent/EP3755702A1/en active Pending
- 2019-02-15 IL IL276575A patent/IL276575B2/en unknown
- 2019-02-15 JP JP2020566200A patent/JP2021514390A/ja active Pending
- 2019-02-15 SG SG11202006274XA patent/SG11202006274XA/en unknown
- 2019-02-15 AU AU2019222475A patent/AU2019222475A1/en active Pending
- 2019-02-15 MA MA051899A patent/MA51899A/fr unknown
- 2019-02-15 CN CN202311008387.0A patent/CN117209502A/zh active Pending
- 2019-02-15 CN CN201980013997.5A patent/CN111741959B/zh active Active
- 2019-02-15 MX MX2020008627A patent/MX2020008627A/es unknown
-
2020
- 2020-08-18 US US16/996,516 patent/US11501284B2/en active Active
-
2021
- 2021-06-15 US US17/348,510 patent/US20220076238A1/en active Pending
-
2022
- 2022-10-10 US US17/962,798 patent/US20230140433A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103038233A (zh) * | 2010-05-07 | 2013-04-10 | 吉利德康涅狄格有限公司 | 吡啶酮和氮杂吡啶酮化合物及使用方法 |
CN104125959A (zh) * | 2011-11-03 | 2014-10-29 | 霍夫曼-拉罗奇有限公司 | 作为btk活性的抑制剂的杂芳基吡啶酮和氮杂-吡啶酮化合物 |
WO2015050703A1 (en) * | 2013-10-04 | 2015-04-09 | Yi Chen | Inhibitors of bruton's tyrosine kinase |
WO2015082583A1 (en) * | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
CN110446710A (zh) * | 2016-12-15 | 2019-11-12 | 豪夫迈·罗氏有限公司 | 制备btk抑制剂的方法 |
Non-Patent Citations (1)
Title |
---|
Two-Step Synthesis of 3,4-Dihydropyrrolopyrazinones from Ketones and Piperazin-2-ones;Cosme Sandoval等;《Organic Letters》;20180206;第20卷(第4期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
SG11202006274XA (en) | 2020-07-29 |
US20200377478A1 (en) | 2020-12-03 |
US11100492B2 (en) | 2021-08-24 |
US20220076238A1 (en) | 2022-03-10 |
MX2020008627A (es) | 2020-09-21 |
CN111741959A (zh) | 2020-10-02 |
CN117209502A (zh) | 2023-12-12 |
US11501284B2 (en) | 2022-11-15 |
KR20200122348A (ko) | 2020-10-27 |
AU2019222475A1 (en) | 2020-07-30 |
EP3755702A1 (en) | 2020-12-30 |
MA51899A (fr) | 2020-12-30 |
WO2019161152A1 (en) | 2019-08-22 |
IL276575B1 (en) | 2024-01-01 |
JP2021514390A (ja) | 2021-06-10 |
US20230140433A1 (en) | 2023-05-04 |
CA3088796A1 (en) | 2019-08-22 |
IL276575A (en) | 2020-09-30 |
IL276575B2 (en) | 2024-05-01 |
US20200286074A1 (en) | 2020-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111741959B (zh) | Btk的抑制剂及其突变体 | |
US10377755B2 (en) | BCL-2 inhibitors | |
CN111511748B (zh) | Bcl-2抑制剂 | |
US10253029B2 (en) | Dual-warhead covalent inhibitors of FGFR-4 | |
US20220363689A1 (en) | Inhibitor of btk and mutants thereof | |
US20160214963A1 (en) | Inhibitors of bruton's tyrosine kinase | |
US20220135569A1 (en) | Inhibitor of btk and mutants thereof | |
WO2022271823A1 (en) | Mutant kras modulators and uses thereof | |
WO2023137223A1 (en) | Pan-kras inhibitors and uses thereof | |
WO2022094172A2 (en) | Inhibitors of btk | |
US10456397B2 (en) | Covalent inhibitors of CDK-7 | |
WO2023076167A1 (en) | Inhibitor of btk and mutants thereof | |
WO2023230059A1 (en) | Mdm2 degrader | |
WO2023283130A1 (en) | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210318 Address after: 322, 326, 336, 338, 356, 358, 301, building 4, No. 33, science Avenue, Lianhe street, Huangpu District, Guangzhou City, Guangdong Province (self declaration) Applicant after: Guangzhou Lupeng Pharmaceutical Co.,Ltd. Address before: California, USA Applicant before: Newave Pharmaceutical Inc. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |